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1 INTRODUCTION 
1.1 Chronic pancreatitis 
Chronic pancreatitis (CP) is a long-term progressive inflammatory disease of the 
pancreas characterized by repeated attacks of abdominal pain and irreversible morphological 
changes which leads to the impairment of the exocrine as well as the endocrine component of 
the gland and eventually result in maldigestion and diabetes. Alcohol consumption and 
tobacco smoking are strongly associated with CP in Western countries, but other factors such 
as genetic variations, pancreatic duct obstruction, congenital malformations, 
hypertriglyceridemia, hypercalcemia, and autoimmunity also have been implicated (1,2). In a 
minority of CP cases, no identifiable cause can be found and a diagnosis of idiopathic 
pancreatitis is made. Both basic and clinical scientists are actively investigating the 
pathogenic mechanisms of injury, to find new therapeutic targets to arrest this devastating 
illness. There is no deﬁnitive   medical   treatment for CP. Treatment options are limited to 
enzyme replacement therapy, pain relief and surgical interventions. These treatments are only 
capable to manage complications and provide pain relief.  
1.2 Hereditary chronic pancreatitis 
Hereditary pancreatitis (HP) is defined by the presence of a proteinase serine 1 gene 
PRSS1 mutation, encodes the cationic trypsinogen (genetic criterion) or by the presence of 
CP with a familial history of least two first-degree relatives or three or more second degree 
relatives, in two or more generations (genealogical and clinical criteria) (3). HP is an 
autosomal dominant disease with incomplete penetrance, characterized by early-onset 
recurrent attacks of acute pancreatitis and with frequent progression to CP. HP belongs to the 
inherited forms of pancreatitis and gives approximately 1% of all cases of pancreatitis. 
The first description of a family with inherited pancreatitis in 1952 provided 
indication towards a possible genetic component in the etiology of CP (4). Decades later, 
three independent groups confirmed the co-segregation between the disease and the long arm 
chromosome 7 (7q35) using genetic linkage analysis (5–7). In the same year, a PRSS1 
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mutation, namely c.365G>A leading to a substitution of arginine by histidine in codon 122 
(p.R122H), was identified as a cause of the disease (7). In the large majority of HP families, 
the causative PRSS1 mutation is either p.R122H (~70%) or p.N29I (~20%). Other less 
frequent PRSS1 mutations documented to cause pancreatitis with a family history include 
p.A16V, p.N29T, p.V39A, p.R116C and p.R122C (3,8–10). Interestingly, mutation p.A16V 
exhibits variable penetrance and was often found in sporadic cases as well (11,12). Over the 
past decade, worldwide screening of PRSS1 broadened the mutational spectrum. More than 
50 additional PRSS1 variants have been reported, the majority of which were found in 
patients with sporadic CP (for a complete list with references see www.pancreasgenetics.org) 
and often assigned by disease causing mutation despite the lack of phenotypic 
characterization. PRSS2 (13) andPRSS3 (14) do not contain genetic alterations that enhances 
the risk of CP, but a protective, loss-of-function variant in PRSS2 has been identified (13,15). 
1.3 Human trypsinogens 
The pancreas is an enzyme factory. Almost all enzymes which act in the small 
intestine are synthetized by the pancreas. Trypsinogen is the most abundant proenzyme 
produced by the gland; it has a pivotal role in the digestive enzyme cascade, as it activates all 
zymogens to their active form. The human pancreas produces the digestive proenzyme, 
trypsinogen in three highly similar isoforms, encoded by the proteinase, serine – PRSS1, 
PRSS2 and PRSS3 genes. According to their electrophoretic mobility, the three trypsinogen 
isoforms commonly referred to as cationic- (PRSS1) anionic- (PRSS2) and mesotrypsinogen 
(PRSS3). Cationic trypsinogen makes up approximately two thirds of total trypsinogen 
amount in the pancreatic juice, while anionic trypsinogen represents one-third (16–18). 
Mesotrypsinogen is a minor species that accounts for 2 to 10% of human trypsinogens 
(16,19). Trypsinogens are synthetized as prepro-enzymes containing a signal peptide of 15 
amino-acids, followed by the 8 amino acid long propeptide, the trypsinogen activation 
peptide. The signal peptide is cleaved upon the entry in the endoplasmic reticulum (ER) and 
then the proenzymes (zymogens) are packaged into zymogen granules and are secreted into 
the pancreatic juice. In the small intestine the brush-border serine protease, enteropeptidase 
activates trypsinogen which then catalyzes the activation of all pancreatic proenzymes. 
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1.4 Trypsin-central paradigm of pancreatitis 
More than a hundred years ago, a German pathologist, Hans Chiari observed at 
autopsies that the pancreas “had succumbed to its own digestive properties” and coined the 
term, that pancreatitis is a disease of autodigestion (20). However, the molecular mechanism 
leading to self-digestion was unknown for a long time. Trypsin was assigned to play the key 
role in initiating the disease by triggering an activation cascade of the digestive zymogens in 
the pancreas. This pathogenic concept was supported by gain-of function mutations found in 
the cationic trypsinogen (10). Consistently, loss-of-function variants in serine protease 
inhibitor, Kazal type 1 (SPINK1) gene (21,22), encoding a pancreatic trypsin inhibitor, and 
the trypsin-degrading enzyme chymotrypsin C (CTRC) (23) are strongly associated with 
idiopathic CP. On the other hand, a pathological increase in trypsin activity in the pancreas 
has been observed consistently in animal models of pancreatitis (24–27). How the 
prematurely activated trypsin could contribute to the pathogenesis of disease remains 
obscure. 
Protective mechanisms evolved to curtail premature activation of zymogens. One of 
the defense mechanisms might be the hypersecretion of the bicarbonate-rich, alkaline 
pancreatic juice. It has been found that under certain circumstances, fluid secretion increases 
in the pancreas (28–30). Besides neutralizing the acidic chyme entering the duodenum from 
the stomach, pancreatic fluid is responsible for flushing out digestive enzymes down the 
ductal tree and thereby preventing their early activation. In humans, pancreatic secretions 
may contain up to 140 mM NaHCO3, which is secreted mainly via the apical Cl-/HCO3- 
exchangers working in parallel with the cystic fibrosis transmembrane conductance regulator 
Cl- channel (CFTR) and partly via the calcium activated chloride channels (31,32). 
Notably, decreased pancreatic ductal fluid secretion as occurs in cystic fibrosis (CF), 
a genetic disease of CFTR, leads to impairment of the whole gland. Consistently, 
compromised ductal fluid secretion as a result of CFTR gene mutations (33–36) increases the 
risk of pancreatitis (37,38). This hypothesis is further supported by the fact that secretin, a 
major mediator of pancreatic ductal fluid secretion, has been shown to have a beneficial 
effect on cerulein-induced acute pancreatitis (39). The pancreatic juice has an alkaline pH, 
achieved by high concentration of bicarbonate secreted by the duct cells, that is considered 
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important for the prevention of trypsin activation in the ductal space. It has been suggested 
that the fall of intraductal pH may increase the risk of developing pancreatitis (38,40). 
1.5 Biochemical characterization of trypsinogens 
To elucidate the role of trypsin in the pathogenesis of pancreatitis and how trypsin 
mutations in cationic trypsinogen cause pancreatitis, comparative in vitro analysis of 
recombinantly expressed human trypsinogens has been performed. Pancreatic tissue and 
juice are not readily available in significant amounts from patients carrying PRSS1 
mutations. In addition to limited availability, isolation of mutant trypsinogen from the 
complex protein mixture represents another technical challenge. Therefore, heterologous 
recombinant expression has been the method of choice to generate human wild-type and 
mutant trypsinogen proteins for biochemical analysis.  
The mechanism of action of HP-associated mutations involves increased 
autoactivation of mutant trypsinogens resulting in elevated intrapancreatic trypsin activity 
levels (41). Recent studies uncovered that these PRSS1 mutations alter the regulation of 
activation and degradation of cationic trypsinogen by CTRC (42). The digestive enzyme 
CTRC stimulates trypsinogen activation by processing the activation peptide at the Phe18-
Asp19 peptide bond to a shorter form, which is easier cleaved by trypsin (43). Somewhat 
paradoxically, CTRC also promotes degradation of trypsinogen by cleaving the Leu81-Glu82 
peptide bond in the calcium binding loop (44). This cleavage in combination with a trypsin-
mediated autolytic cleavage of the Arg122-Val123 peptide bond results in inactivation of 
trypsinogen during autoactivation and lower trypsin levels attained.  
Pancreatitis-associated mutations render trypsinogen resistant to CTRC-dependent 
degradation and/or increase N-terminal processing by CTRC and thereby elevate trypsin 
levels generated through autoactivation (42) 
The unifying pathological mechanism described above does not seem to apply to 
some mutations that alter the number of cysteine residues in cationic trypsinogen. HP-
associated mutation p.R116C was shown to induce protein misfolding with intracellular 
retention and degradation, which may represent an alternative disease-causing mechanism 
unrelated to trypsinogen activation and trypsin activity (45). Variant p.C139S, which was 
reported in sporadic cases of CP, exhibits similar properties (45). Mutation-dependent 
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misfolding can elicit ER stress, which might be responsible for increased pancreatitis risk, 
although the mechanism remains unclear. 
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2 AIMS OF THE STUDY 
I. The secretion of the alkaline pancreatic juice is considered to prevent intraductal 
trypsin activation. Inhibition of fluid secretion, accompanied by a decrease in 
intraductal pH, was proposed to increase the risk of developing CP. Therefore, we 
investigated the effect of pH on the autoactivation of human cationic trypsinogen.  
Our specific aim was: 
 To investigate the autoactivation of human trypsinogen at different 
pH  
II. Numerous rare PRSS1 mutations with unknown clinical significance were identified 
in subjects with idiopathic CP. Despite lack of evidence, some of these variants 
have been described as pancreatitis-associated. To clarify the possible pathogenic 
role of these mutations, our aim was to functionally characterize 13 published 
trypsinogen variants: 
1. Our primary objective was to test whether these variants also exhibit increased 
activation in the presence of CTRC, as previously seen with disease-causing 
mutants in HP.  
Our specific aims were: 
 To examine the kinetic parameters of variants 
 To investigate their autoactivation 
 To determine the effect of the CTRC on their autoactivation  
 To examine their degradation by CTRC 
2. Mutation-induced changes in folding and secretion may be another disease 
relevant mechanism, therefore, our second objective was to assess whether 
mutation-induced misfolding is a more common phenotype of PRSS1 variants 
than previously appreciated. 
Our specific aim was: 
 To assess cellular secretion of the mutants 
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3 MATERIALS AND METHODS 
3.1 Nomenclature 
Nucleotide numbering reflects coding DNA numbering with +1 corresponding to the 
A of the ATG translation initiation codon in PRSS1. Amino acid residues are numbered 
starting with the initiator methionine of the primary translation product for human cationic 
trypsinogen. The abbreviations are in italics throughout the text when referring to genes 
encoding digestive zymogens. 
3.2 Mutagenesis and construction of expression plasmids 
The pTrapT7 intein-PRSS1, pcDNA3.1(-)-PRSS1and pcDNA3.1(-)-CTRC 10His 
expression plasmids harboring the human cationic trypsinogen gene and human 
chymotrypsin C gene, respectively, were constructed earlier in our laboratory (43,44,46). 
Mutations were introduced by oligonucleotide-directed overlap-extension PCR mutagenesis 
using mutagenic primers listed in Table 1. Typically, the polymerase chain reaction (PCR) 
mixture contained 200 µM dNTP, 2 µM of each primer, DNA template, 0.05 U/µL Taq DNA 
polymerase (Qiagen) and in a total volume of 50 µL. 35 cycles of 30 sec denaturation at 94 
ºC, 30 sec annealing at 55 ºC and 1 min extension at 72 ºC were performed. PCR products 
were analyzed by agarose gel electrophoresis and DNA sequencing. 
Name of the primer Primer sequence 
For pTrapT7 constructs 
p.P36R sense 5’-GAA GAG AAT TCT GTT CGC TAC C-3’ 
p.G83E sense 5’-GTC CTT GAG GAG AAT GAG CAG-3’ 
p.G83E antisense 5’-CTG CTC ATT CTC CTC AAG GAC-3’ 
p.I88N sense 5’-GAG CAG TTT AAC AAT GCT GCC-3’ 
p.I88N antisense 5’-GGC AGC ATT GTT AAA CTG CTC-3’ 
p.K92N sense 5’-AAT GCT GCC AAT ATC ATC AGG-3’ 
p.K92Nantisense 5’–CCT GAT GAT ATT GGC AGC ATT-3’ 
p.Q98K sense 5’-AGG CAT CCC AAA TAC GAT AGG-3’ 
p.Q98K antisense 5’-CCT ATC GTA TTT GGG ATG CCT-3’ 
p.D100H sense 5’-CCC CAA TAC CAT AGG AAG ACC-3’ 
  - 13 -  
 
p.D100H antisense 5’-GGT CTT CCT ATG GTA TTG GGG-3’ 
p.V123M sense 5'-AAT GCT CGA ATG TCC ACC ATC-3' 
p.V123M antisense 5'-GAT GGT GGA CATTCG AGC ATT-3’ 
p.S124F 5'-ATC AAT GCT CGA GTGTTC ACC ATC TCT-3' 
p.T137M sense 5’–GCT ACT GGC ATG AAG TGC CTC-3’ 
p.T137M antisense 5’-GAG GCA CTT CAT GCC AGT AGC-3’ 
p.C139F sense 5’–GGC ACC AAG TTC CTC ATC TCC-3’ 
p.C139F antisense 5’-GGA GAT GAG GAA CTT GGT GCC-3’ 
p.K170E sense 5’–AGC CAG GCT GAG TGT GAA GCC-3’ 
p.K170E antisense 5’-GGC TTC ACA CTC AGC CTG GCT-3’ 
p.S181G sense 5’–AAG ATT ACC GGC AAC ATG TTC 3’ 
p.S181G antisense 5’-GAA CAT GTT GCC GGT AAT CTT-3’ 
p.G208A sense 5’–GTC TGT AAT GCA CAG CTC CAA–3’ 
p.G208A antisense 5’-TTG GAG CTG TGC ATT ACA GAC-3’ 
For pcDNA 3.1(-) constructs 
p.P36R sense 5’–AAT TCT GTC CGC TAC CAG GTG–3’ 
p.P36R antisense -5’–CAC CTG GTA GCG GAC AGA ATT-3’ 
p.G83E 5’–GTC CTG GAG GAG AAT GAG CAG–3’ 
p.G83Eantisense 5’–CTG CTC ATT CTC CTC CAG GAC-3’ 
p.I88N sense 5’–GAG CAG TTC AAC AAT GCA GCC–3’ 
p.I88N antisense 5’–GGC TGC ATT GTT GAA CTG CTC - 3’ 
p.K92N 5’–AAT GCA GCC AAT ATC ATC CGC–3’ 
p.K92N antisense 5’–GCG GAT GAT ATT GGC TGC ATT - 3’ 
p.Q98K sense 5’–CGC CAC CCC AAA TAC GAC AGG–3’ 
p.Q98K antisense 5’–CCT GTC GTA TTT GGG GTG GCG - 3’ 
p.D100H sense 5’–CCC CAA TAC CAC AGG AAG ACT–3’ 
p.D100H antisense 5’–AGT CTT CCT GTG GTA TTG GGG - 3’ 
p.V123M sense 5’–AAC GCC CGC ATG TCC ACC ATC–3’ 
p.V123M antisense 5’–GAT GGT GGA CAT GCG GGC GTT-3’ 
p.S124F sense 5’–GCC CGC GTG TTC ACC ATC TCT–3’ 
p.S124F antisense -5’–AGA GAT GGT GAA CAC GCG GGC-3’ 
p.T137M sense 5’–GCC ACT GGC ATG AAG TGC CTC–3’ 
p.T137M antisense 5’ – GAG GCA CTT CAT GCC AGT GGC-3’ 
p.C139F sense 5’–GGC ACG AAG TTC CTC ATC TCT–3’ 
p.C139F antisense 5’–AGA GAT GAG GAA CTT CGT GCC-3’ 
p.K170E Same as used for the pTrapT7 construct 
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p.S181G sense 5’–AAG ATT ACC GGC AAC ATG TTC-3’ 
p.S181G antisense 5’–GAA CAT GTT GCC GGT AAT CTT-3’ 
p.G208A sense 5’–GTC TGC AAT GCA CAG CTC CAA–3’ 
3.3 Recombinant expression and purification of human cationic trypsinogen 
3.3.1 Expression of human cationic trypsinogen 
Trypsinogen variants were cloned in fusion with a 154 amino acid long mini-intein. 
This construct was expressed in an aminopeptidase P deficient E. coli strain (LG-3) (46) as 
inclusion bodies. After spontaneous self-cleavage, the fusion protein gives rise to cationic 
trypsinogen with a homogeneous, authentic N-terminal sequence.  
Plasmids were transformed by electroporation using 0.2 mm electroporation cuvettes 
and an electroporator setting of 2.5kV. Transformants were spread onto Luria-Bertani (LB) 
agar plates supplemented with 100 µg/mL ampicillin and 50 µg/mL kanamycin and 
incubated at 30ºC overnight. Starter cultures were established by inoculating 10 mL LB 
medium containing 100 µg/mL ampicillin and 50 µg/mL kanamycin with a streak of colonies 
and incubated at 30ºC overnight with shaking. Starter cultures were then inoculated in 50 mL 
LB  medium  with   100   µg/mL   ampicillin   and   50   µg/mL   kanamycin   and   grow   until   density  
reached an OD600 nm of 0.5. At this point protein expression was induced by shifting the 
incubation temperature to 42 ºC for 30 min which induced the expression of T7 RNA 
polymerase under the control of temperature-sensitive  λ  repressor. Adding1 mM isopropyl-1-
thio-β,D-galactopyranoside derepressed the lac operator which is positioned between the T7 
promoter and the intein-trypsinogen fusion gene in the pTrapT7 plasmid. After induction, 
cultures were incubated for an additional 5 hours. Bacteria were harvested by centrifugation 
and inclusion bodies were isolated by sonication and centrifugation.  
Table 1. Primers for mutagenesis in the pTrapT7-intein-PRSS1 and pcDNA3.1(-)-PRSS1 constructs. The 
mutated codon is underlined. Two different primer sets were used for constructs in the pcDNA 3.1(-) and 
pTrapT7 expression plasmids as their DNA sequence was not identical. pcDNA 3.1(-) constructs harbored the 
native cDNA sequence of human cationic trypsinogen, whereas in order to improve protein expression levels in 
E. coli, codons were optimalized in pTrapT7. 
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3.3.2 In vitro refolding of human cationic trypsinogen 
The inclusion body pellet was washed three times with 1 mL of 0.1 M Tris-HCl (pH 
8.0)5 mM K-EDTA and resuspended in 500 µL of 4 M guanidine-HCl /0.1 M Tris-HCl, pH 
8.0., contained 30mM dithiothreitol and trypsinogen was solubilized at 37 °C for 30 min. 
Insoluble material was removed by centrifugation and reduced trypsinogen was then diluted 
into 50 mL of refolding buffer (0.9 M guanidine-HCl, 0.1 M Tris-HCl (pH 8.0), 30 mM L-
cysteine, 30 mM L-cystine), slowly stirred under argon gas for 5 min at room temperature, 
and kept at 4 °C overnight before purification. 
3.3.3 Purification of human cationic trypsinogen with ecotin affinity 
chromatography 
Ecotin is a pan-serine inhibitor from E. coli which can bind the inactive zymogen 
forms of pancreatic serine proteases and this complex is stable at neutral pH (47). 
Purification of trypsinogens was carried out on a 2 mL ecotin column. The in vitro refolded 
trypsinogen solution was supplemented with 100 mM Tris-HCl (pH 8.0) and 200 mM NaCl 
to a final volume of 100 mL and the sample was loaded onto the ecotin column. After 
washing with 20 mM Tris-HCl (pH 8.0) / 0.2 M NaCl, trypsinogen was eluted with 50 mM 
HCl. Protein concentration of eluted trypsinogen was calculated from the UV absorbance at 
280 nm using the extinction coefficient 37,525 M-1cm-1. 
3.4 Expression and purification of human chymotrypsin C 
A deca-histidine (10His) affinity tag was engineered onto the C terminus of the 
human CTRC, and this construct was expressed in human embryonic kidney 293T cells 
(HEK 293T). Cells were cultured in DMEM supplemented with 10% fetal bovine serum 
(FBS), 4 mM glutamine,1% penicillin in 75 cm2 flasks to 95% confluence. Transfections 
were carried out in a total volume of 20 mL DMEM using 75 µL lipofectamine 2000 
(Invitrogen)  and  30  µg plasmid harboring human CTRC-10His. After overnight incubation, 
cells were washed with OptiMEM and the transfection medium was replaced with 20 mL 
OptiMEM. The conditioned media were harvested after 48 h incubation replaced with 
another 20 mL OptiMEM and then collected again at 96 h. Approximately 900 mL 
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conditioned medium was used for purification. Ni-NTA Superflow Cartridge (Qiagen) 
equilibrated with NPI-20 buffer [50 mM NaH2PO4, 300 mMNaCl, 20 mM imidazole (pH 
8.0)]. The medium was loaded onto the column at 4 mL/min flow rate using a loading pump 
and the column was washed with NPI-20 buffer [50mM NaH2PO4, 300 mMNaCl, and 20 
mM imidazole (pH 8.0)] until the absorbance at 280 nm returned to baseline. CTRC was 
eluted with NPI-250 buffer [50 mM NaH2PO4, 300 mMNaCl, 250 mM imidazole (pH 8.0)] at 
2 mL/min flow rate and 5 mL fractions were collected. Aliquots (100 µL) of the fractions 
were analyzed by 15% SDS-PAGE and Coomassie blue staining and peak fractions were 
pooled and dialyzed for 24 h against two changes of 5 liters of 50 mM NaH2PO4 (pH 8.0) 
buffer containing 300 mM NaCl. The dialyzed CTRC proenzyme solution was concentrated 
using a Vivaspin concentrator (10 kDa molecular weight cut off).  
Purified CTRC zymogen was activated with 20 nM human cationic trypsin in 100 
mM Tris-HCl (pH 8.0) and 1 mM CaCl2 (final concentrations) for 30 min at 37 °C. 
Concentration of active CTRC was determined using active site titration with ecotin (48). 
3.5 Active site titration of trypsin with ecotin 
The concentration of trypsin for enzyme kinetic measurements was determined by 
active-site titration against ecotin. The concentration of the ecotin batch, which served as a 
universal titrant for all studies, was determined previously using titration against active site-
titrated bovine trypsin (42). Trypsin at 25 nM estimated concentration (calculated from the 
ultraviolet absorbance at 280 nm, using the theoretical extinction coefficient 37,525 M-1cm-1 ) 
was added to 0-100 nM ecotin (two-fold serial dilution in 0.1 M Tris-HCl (pH 8.0) with 1 
mM CaCl2)   in  a   total  volume  of  100  µL.  After 1 hour incubation at room temperature free 
trypsin activity was measured as described below. Titrations were performed using protease 
concentrations at least 2 orders of magnitude above the KD values. Substrate was given in a 
5µL  volume  so  as  not  to  perturb  the  equilibrium. The measured trypsin activity values were 
plotted as a function of the total inhibitor concentration. The equivalence point was 
determined by extrapolation of the linear portion of the curve to the x axis. This represents 
the inhibitor concentration equal to the trypsin concentration.  
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3.6 Measurements of enzyme activities and kinetic parameters of trypsin 
Trypsin activity was measured   by   adding   150   µL   200   µM  N-CBZ-Gly-Pro-Arg-p-
nitroanilide substrate and following the release of the yellow p-nitroaniline at 405 nm in a 
SpectraMax plus384 microplate reader (Molecular Devices,Sunnyvale, CA) for 1 min. 
Reaction rates were calculated from fits to the initial linear portions of the curves. The 
trypsin substrate was dissolved in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2 and 0.05% Tween-
20. To obtain kinetic parameters, activity measurements were performed at varying substrate 
concentrations (0-180µM) and initial rates were plotted as a function of substrate 
concentration. Kinetic parameters (Vmax, KM) were determined from hyperbolic fits to the 
Michaelis-Menten equation. 
3.7 Trypsinogen autoactivation in the presence and absence of 
chymotrypsin C 
Trypsinogen   at   1   µM   concentration   was   incubated   with   or   without   5   nM   human  
CTRC and with 10 nM cationic trypsin in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2and 0.05% 
Tween-20 (final concentrations) at 37 ºC.  At  given  times,  2  µL  aliquots  were  withdrawn  and  
mixed with 48  µL  assay  buffer  containing  0.1  M  Tris-HCl (pH 8.0), 1mM CaCl2, and 0.05% 
Tween-20. Trypsin activity was measured as described above.  
For autoactivation experiments at varying pH ranging from 6 to 8.5, a polybuffer 
system (100 mM MES, 100 mM HEPES and 100 mM Tris) was used. The pH of the 
polybuffer was adjusted to given values with HCl (pH 6.0 and 6.5) or NaOH (pH 7.0, 7.5, 8.0 
and 8.5). Reactions also contained 1 mM or 0.1 mM CaCl2 and 100 mM NaCl, as indicated. 
3.8 Cell culture and transfection for secretion measurements 
HEK 293T cells were cultured in DMEM supplemented with 10% fetal bovine serum, 
4mM glutamine and 1% penicillin/streptomycin solution in a 37 °C, 5% CO2 humidified 
incubator. A day before transfection approximately 1.5x106 cells were seeded in a six-well 
tissue   culture   plate.   Transfections   were   carried   out   using   1µg   pcDNA3.1(-) plasmid 
harboring the wild-type  or  mutant  trypsinogen  gene  and  2.5µL Lipofectamine 2000 in 2mL 
DMEM according to the manufacturer’s protocol. After overnight incubation cells were 
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washed and the transfection medium was replaced with 2 mL OptiMEM containing 1 mM 
benzamidine to inhibit autoactivation of secreted trypsinogen. After 24 hours from the media 
replacement, conditioned media were harvested for activity measurement and western blot 
analysis.  
3.9 Trypsin activity measurement in the conditioned media 
Aliquots  (50  µL)  of  conditioned  media  were  supplemented  with  5  µL  1  M  Tris-HCl 
(pH:8.0)  and  1  µL  0.5  M  CaCl2 and trypsinogens were activated by adding 1 µL 1.4 µg/mL 
human enteropeptidase (R&D Systems, Minneapolis, MN). After incubation for 1 h at 37 °C, 
50   µL   aliquot   was   removed   and   mixed   with   150   µL   200   µM   N-CBZ-Gly-Pro-Arg-p-
nitroanilide substrate. Trypsin activity was determined as described above. 
3.10 Assay of trypsinogen content by SDS-PAGE and Western blot  
Five   µL conditioned media were mixed with 20 µL Laemmli sample buffer 
containing 100 mM dithiothreitol, heat-denatured at 95 °C for 5 min and run on a 15% SDS-
polyacrylamide gel. Proteins were transferred onto an Immobilon-P (Milliore Corporation, 
Bedford, MA, USA) membrane at 300 mA for 1.5 hours. The membrane was blocked with 
5% milk powder in phosphate buffer saline (PBS) supplemented with 0.1% Tween-20 at 4 °C 
overnight. Trypsinogen was detected with a sheep polyclonal antibody (R&D Systems, 
#AF3848) used at a dilution of 1:5000 followed by Horseradhish-peroxidase (HRP)-
conjugated donkey polyclonal anti-sheep IgG (R&D Systems, #HAF016) used at 1:2000 
dilution. HRP was detected using the SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific). Incubations with primary and secondary antibodies were performed at 
room temperature for 1 hour.  
Quantitation of bands was carried out with Image Lab 3.0 software (Bio-Rad). 
Rectangles were drawn around each band of interest, and an identical rectangle was used in 
each lane for background subtraction. 
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4 RESULTS 
4.1 Autoactivation of human cationic trypsinogen is pH dependent 
Etiologic factors of pancreatitis, such as bile acids (49,50) or smoking (51,52), can 
inhibit pancreatic ductal bicarbonate secretion, which leads to the acidification of the 
intraductal space and slows down the washout of the digestive zymogens. 
To assess the effect of a decrease in intraductal pH on trypsinogen autoactivation, we 
examined the autoactivation of human cationic trypsinogen in vitro at pH values ranging 
from 6.0 to 8.5. The rate at which cationic trypsinogen autoactivates was increased when the 
pH was reduced from 8.5 to 7.0 (Figure.1A ) in the presence of 1 mM CaCl2  and in the 
absence of NaCl. However, decreasing the pH from 7.0 to 6.0 had a slight effect only 
(Figure.1A). 
To exclude that the differences observed in autoactivation were due to the different 
ionic strength of the buffers used, we performed the experiments in the presence of higher 
concentration of sodium (100mM NaCl, Figure.1B) or lower concentration of calcium (0.1 
mM CaCl2, Figure. 1C). Although the overall autoactivation rates were much slower in the 
presence of 100mM NaCl, the pH profile of autoactivation was essentially identical to that 
observed in the absence of added salt (Figure.1A). The pH dependent changes in the 
autoactivation of trypsinogen were still detectable when the experiments were performed 
using a low calcium buffer (Figure.1C).  
\ 
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A 
B 
C 
Figure 1. Autoactivation of human cationic trypsinogen at pH values ranging from 6.0 to 8.5. A) 
Trypsinogen   at   2µM   concentration   was   incubated   with   40   nM   trypsin   at   37  
oC in 0.1M Tris+HEPES+MES 
buffer mixture containing 1 mM CaCl2 in 100 µL  final  volume.  B) The same protocol was used in high NaCl 
buffer solution (the above described buffer was supplemented with 100 mM NaCl). C) The same protocol was 
used in low (0.1 mM CaCl2) Ca2+ solution. 
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4.2 PRSS1 missense variants are exceedingly rare in the general 
population 
We surveyed the functional properties of 13 rare PRSS1 missense mutations found in 
patients with sporadic CP. The 13 PRSS1 variants were found in patients with idiopathic CP 
without family history (Table 2). The variants were detected in the heterozygous state, with 
the exception of p.G208A, which was also identified in a homozygous individual. As 
indicated, the variants were found only in one to three cases each, therefore, the genetic 
information was insufficient to determine whether these variants are pathogenic or neutral. 
Note that variants p.T137M and p.G208A were from subjects of Asian origin, whereas all 
other variants were from subjects of European origin. 
To get an estimate of the prevalence of missense PRSS1 variants in healthy 
individuals, we sequenced exon-3 of the PRSS1 gene in 1000 German subjects without any 
pancreatic disease. Exon-3 was selected because most of the studied variants (9 of 13) were 
found in this region. With the exception of a novel c.367G>T (p.V123L) variant found in one 
subject, no other alterations were identified. 
We consulted the NHLBI Exome Sequencing ProjectExome Variant Server 
(http://evs.gs.washington.edu) which lists aggregate exome-sequencing data for 
approximately 4300 European-American and 2200 African-American individuals. We found 
PRSS1 variants p.V123M and p.T137M in one European-American subject each and variant 
p.S181G in one African-American subject. However, interpretation of these findings is 
difficult, because the database also lists the disease-causing mutation p.R122C found in two 
European-American individuals, suggesting that the studied cohort may have contained 
pancreatitis patients. We also surveyed published sequencing data, which showing the 
absence of these 13 PRSS1 variants in 200 French (53), 82 German (54), 420 Chinese (55,56) 
and 28 Korean (57) control subject. 
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Region Nucleotide change 
Amino acid 
change 
Carriers 
reported 
Clinical and genetic 
information Citations 
Exon 2 c.107C>G p.P36R 2 French m and fm, ICP (53)# 
Exon 3 c.248G>A p.G83E 1 Italian, ICP (53)# 
 c.263T>A p.I88N 1 18 y white fm, CP no SPINK1 or CFTR mut (58) 
 c.276G>T p.K92N 1 Italian, ICP (53)# 
 c.292C>A p.Q98K 1 
55 y French m, CP 
no SPINK1, CTRC or 
CFTRmut 
(9)* 
 c.298G>C p.D100H 1 German m, ICP (59) 
 c.367G>A p.V123M 1 French fm, ICP (53)# 
 c.371C>T p.S124F 1 
46 y German fm, ICP 
no SPINK1, CTRC or 
CFTRmut 
(60) 
 c.410C>T p.T137M 3 13 y Asian fm, AP no SPINK1 or CFTRmut (55) 
    Chinese, late onset ICP no SPINK1mut (55) 
    28 y Chinese, pancreatic cancer 
also carried p.T135A PRSS1
(56) 
 c.416G>T p.C139F 2 14 y German m, RAP unaffected mother carrier (54) 
    8 y fm, CP with chronic painno SPINK1 or CFTRmut (61) 
Exon 4 c.508A>G p.K170E 1 
30 y Indian m, CP 
no SPINK1, CTRC or 
CFTRmut 
(9)* 
 c.541A>G p.S181G 1 
6 y Italian m, RAP 
p.F508del CFTR 
unaffected mother carrier 
(62) 
Exon 5 c.623G>C p.G208A 3 
12 y Asian m, pancreatitis, hm 
p.F508del and p.Q1352H 
CFTR 
(58) 
    Korean child, RAP no SPINK1 mut (57) 
    7 y Korean, necrotizing AP (57) 
Table 2. Rare PRSS1 variants in pancreatitis. AP, acute pancreatitis, CP, chronic pancreatitis; ICP, idiopathic 
chronic pancreatitis, RAP, recurrent acute pancreatitis; m, male; fm, female; hm, homozygous, y, year, mut, mutation. 
Unless indicated otherwise, mutations are heterozygous. The age indicates the time of diagnosis. *Vinciane Rebours, 
personal communication. #Jian-Min Chen, personal communication. 
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4.3 Enzyme kinetic parameters of trypsin and autoactivation of 
trypsinogens 
First, trypsinogen variants were characterized for catalytic activity and their ability to 
autoactivate in the absence of CTRC. We measured catalytic activity of the activated trypsin 
variants with the synthetic peptide substrate N-CBZ-Gly-Pro-Arg-p-nitroanilide. Enzyme 
kinetic parameters of trypsin variants were comparable to those of wild-type cationic trypsin 
(Table 3). This finding is in accordance with previous observations that natural PRSS1 
variants almost never affect catalytic function of trypsin. 
 Note that mutant p.C139F could not be purified in sufficient quantities due to 
misfolding, therefore it was not tested in the autoactivation and catalytic activity assays. 
 kcat(s-1) KM (µM) kcat/KM (s-1·M-1) 
wild type 95.3 17.6 5.4 
p.P36R 86.6 19.1 4.5 
p.G83E 92.8 14.7 6.3 
p.I88N 80.8 16.2 5.0 
p.K92N 99.7 16.9 5.9 
p.Q98K 95.4 16.3 5.8 
p.D100H 77.6 15.8 4.9 
p.V123M 90.9 17.4 5.2 
p.S124F 91.6 16.1 5.7 
p.T137M 102.3 17.1 6.0 
p.K170E 107.8 14.4 7.5 
p.S181G 103.7 18.4 5.6 
p.G208A 89.7 17.5 5.1 
Table 3. Kinetic parameters of wild-type and mutant human cationic trypsin on the synthetic substrate N-
CBZ-Gly-Pro-Arg-p-nitroanilide, measured in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2 and 0.05% Tween 20, at 
22 oC. 
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Figure 2. Autoactivation of cationic trypsinogen variants in the absence of chymotrypsin C. Trypsinogen 
was incubated at 1 µM concentration with 10 nM initial trypsin in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2 and 
0.05% Tween-20 (final concentrations) at 37° C. At the indicated times, 2 µL aliquots were removed and 
trypsin activity was measured as described in Materials and Methods. Trypsin activity was expressed as percent 
of the maximal wild-type activity in the absence of CTRC. A) mutant with increased rate of autoactivation, B) 
mutants with unchanged autoactivation; C) mutants with decreased rates of autoactivation but normal final 
trypsin levels; D) mutants with decreased rates of autoactivation and reduced final trypsin levels. 
We measured the autoactivation rates of wild type and mutants in 0.1 M Tris/HCl (pH 
8.0), at 37 oC, at a physiologically relevant pH (8.0) and Ca2+ concentration (1 mM). Only 
one mutant, p.D100H, exhibited increased autoactivation, which was about 2.5-fold faster 
relative to wild type (Figure 2A). Five mutants (p.Q98K, p.T137M, p.K170E, p.S181G, and 
p.G208A) autoactivated comparable to wild-type trypsinogen (Figure 2B), while two 
(p.K92N and p.S124F) exhibited a decreased autoactivation rate, although they reached the 
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same activity level (Figure 2C). In contrast four of the investigated mutants (p.P36R, 
p.G83E, p.I88N, and p.V123M) exhibited decreased rates of autoactivation with reduced 
final level, suggesting that these variants may become partially degraded during 
autoactivation (Figure 2D). 
4.4 Autoactivation of wild-type and mutant trypsinogens in the presence 
of chymotrypsin C 
Cationic trypsinogen and trypsin are under the regulation of CTRC. CTRC promotes 
proteolytic degradation of trypsinogen and trypsin (44) and also stimulates trypsinogen 
autoactivation. To determine the effect of CTRC on trypsinogen variants, we measured 
autoactivation in the presence of CTRC. 
When trypsinogen at 1 µM concentration was incubated with 10 nM trypsin at 37 oC, 
at pH 8.0, in the presence of 1mM Ca2+, conversion to trypsin was essentially complete 
within 50 min (Figure 3) and final trypsin activity remained stable (black squares). As 
previously described (42), addition of human CTRC to this reaction (white triangles) resulted 
in a slightly increased rate of autoactivation with reduced final trypsin level slowly decreased 
over time from their peak value. In the experiments presented, wild-type cationic trypsinogen 
reached about 50% activity level in the presence of CTRC, relative to trypsin levels observed 
in the absence of CTRC (Figure 3). 
 
Figure 3. Activation of wild-type 
trypsinogen in the presence and 
absence of chymotrypsin C. 
 Trypsinogens was incubated at 1 µM 
concentration with 10 nM initial trypsin 
in 0.1 M Tris-HCl (pH 8.0), 1 mM 
CaCl2 and 0.05% Tween-20 (final 
concentrations) at 37 oC in the absence 
or presence of 5nM CTRC. At the 
indicated times, 2 µL aliquots were 
removed and trypsin activity was 
measured as described in Materials and 
Methods. 
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Under these conditions, both increases and decreases in autoactivation are readily 
detectable. To determine the effect of CTRC on the trypsinogen variants, we measured 
autoactivation in the presence of 5 nM concentration of human CTRC. 
Only one of the 12 variants tested, p.D100H exhibited increased activation in the 
presence of CTRC (Figure 4A). A similar phenotype was observed with this mutant when 
autoactivation was performed in the absence of CTRC (see above), indicating that the 
mutation increases autoactivation independent of CTRC. Consistent with this interpretation, 
degradation of p.D100H mutant trypsinogen and trypsin by CTRC was unchanged (not 
shown). Six mutants (p.K92N, p.Q98K, p.T137M, p.K170E, p.S181G, and p.G208A) 
autoactivated in the presence of CTRC in a manner that was comparable to wild type (Figure 
4B). Surprisingly, however, five mutants (p.P36R, p.G83E, p.I88N, p.V123M and p.S124F) 
reached markedly reduced trypsin activity levels during autoactivation, suggesting increased 
susceptibility to CTRC-dependent degradation (Figure 4C). This notion was confirmed by 
direct degradation experiments which demonstrated that these five mutants were degraded by 
CTRC at increased rates (Figure 5). 
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Figure 4. Autoactivation of cationic trypsinogen in the presence of CTRC:Trypsinogens were incubated at 1 
µM concentration with 10 nM initial trypsin in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2 and 0.05% Tween-20 
(final concentrations) at 37 oC in the presence of CTRC at 5 nM concentrations. At the indicated times, 2 µL 
aliquots were removed and trypsin activity was measured as described in Materials and Methods. Trypsin 
activity was expressed as percent of the maximal wild type activity in the absence of CTRC. Panel A) mutant 
with increased rate of autoactivation, B) mutants with unchanged autoactivation; C) mutants with decreased 
rates of autoactivation but normal final trypsin levels; D) mutants with decreased rates of autoactivation and 
reduced final trypsin levels. 
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4.5 Degradation of wild type and mutant trypsinogens/trypsins by 
chymotrypsin C 
Five mutants (p.P36R, p.G83E, p.I88N, p.V123M and p.S124F) reached markedly 
reduced trypsin activity levels during autoactivation in the presence of CTRC, suggesting 
increased susceptibility to CTRC-dependent degradation (Figure 4C). We performed direct 
degradation experiments to confirm this notion. First we tested degradation of trypsin by 
CTRC (Figure 5). Figure 4 and 5 demonstrate that indeed these five mutants exhibited an 
increased trypsin (Figure 5) as well as trypsinogen (Figure 6) degradation by CTRC. 
 
 
Figure 5. Degradation of cationic trypsins by chymotrypsin C: Wildtype and mutant trypsinogens were 
activated  at  1µM  concentration  with  enterokinase  for  30  min  at  37 oC in the presence of 1 mM Ca at pH 8.0. 
Degradation of trypsins was then followed after adding human CTRC at 25 nM concentration. 
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Figure 6. Degradation of cationic trypsinogen variants by chymotrypsin C. Trypsinogens at 2 µM 
concentration were incubated with 25 nM CTRC in 0.1 M Tris-HCl (pH 8.0) (final concentrations) at 37° C. At 
the indicated times, the reactions were precipitated with 10% trichloroacetic acid (final concentration) and 
analyzed by SDS-PAGE and Coomassie blue staining. Representative gels of two experiments are shown. The 
graph indicates densitometric evaluation of the intensity of the trypsinogen bands. Average of two experiments 
was plotted with error bars omitted for clarity. The errors were within 12% of the mean. 
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4.6 Secretion of PRSS1 variants from HEK 293T cells 
To identify trypsinogen variants defective in folding, we evaluated their secretion 
from transiently transfectedHEK293T cells. We evaluated their secretion using SDS-
PAGE,western blot analysis and trypsin activity measurements after activation with 
enteropeptidase from the conditioned media. 
Six of 13 mutants tested (p.P36R, p.G83E, p.Q98K, p.V123M, p.T137M, and 
p.S181G) showed trypsinogen secretion close to wild-type levels(~70-120%) (Figure 7, black 
bars). Severe secretion defects (~20% of wild type) were observed with mutants p.D100H 
and p.C139F. Moderate reduction in secretion (~40-50% of wild type) was noted in case of 
three mutants (p.K92N, p.S124F and p.G208A). Two mutants (p.I88N and p.K170E) showed 
increased secretion levels, 170% and 140% of wild type, respectively. Although increased 
secretion of variant p.I88N may represent a gain of function, the rapid degradation of this 
variant by CTRC (see above) would cancel out this effect and result in a loss-of-function 
phenotype. The higher secretion of mutant p.I88N was due to the appearance of a second 
trypsinogen band which represents an aberrantly glycosylated trypsinogen form (Figure 7A, 
7B). This band is also observed in a much fainter form with all other trypsinogen variants 
and may be an artifact of the heterologous cell line used. 
For the majority of the variants, the trypsin activity levels in the conditioned medium 
correlated well with the protein levels secreted (Figure 7B, gray bars). Four variants (p.P36R, 
p.G83E, p.K92N, and p.C139F) had considerably lower enzyme activity relative to their 
protein levels. Variant p.C139F may be misfolded and catalytically defective, which explains 
its lower activity. The other three variants exhibited normal catalytic activity in enzymatic 
tests (see above); suggesting that degradation or incomplete activation may underlie their 
lower activity. 
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Figure 7. Secretion of wild-type and mutant trypsinogens from transfected HEK 293T. Cells were 
transiently transfected and conditioned media were collected after 24 h. Trypsinogen protein levels were 
qualitatively analyzed on Coomassie Blue stained SDS-polyacrylamide gels (A) and then quantitatively 
determined by Western blots (B) and densitometry (C, black bars). Trypsin activity was measured after fully 
activation with enteropeptidase (C, gray bars). See in Materials and Methods section for details. Representative 
gels and blots of four independent experiments are shown. Average of four experiments with SD was plotted. 
Trypsinogen protein and trypsin activity levels were expressed as percent of wildtype values. 
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5 DISCUSSION 
A growing body of evidence supports the hypothesis that elevated intrapancreatic 
trypsin activity is highly significant in the pathogenesis of pancreatitis. However, the 
mechanism how activated trypsin acts still remains sketchy. There are protective 
mechanisms, such as the continuous ductal fluid secretion, responsible for the arrest of early 
trypsin activation. Impairment of bicarbonate secretion leads to the increase in the transit 
time of zymogens down the ductal tree and also decreases luminal pH (pHL). pHL can be 
elevated from 7.2 to 8.5 by stimulation with secretin or forskolin and this effect is strictly 
dependent on the presence of bicarbonate (63–65). Also, inhibition of ductal bicarbonate 
secretion with the anion-transport inhibitor H2DIDS can decrease the pHL to below 8.0 (64). 
In light of these results, we tested whether trypsinogen autoactivation was affected by pH 
over the range 6.0 to 8.5. Autoactivation of trypsinogen was relatively slow at pH 8.5, but 
decreasing the pH from 8.5 to 7 stimulated autoactivation. These results suggest that under 
physiological conditions bicarbonate secretion by pancreatic ductal epithelial cells is not only 
important for elevating the pH in the duodenum, but also for keeping digestive enzymes in an 
inactive state. On the other hand, our results indicate that not only the increased time but the 
decreased pHL will contribute to the early trypsin activation. Prematurely activated trypsin in 
the ductal tree inhibits bicarbonate transport (66) leading to a vicious cycle generating a 
further decrease in pHL and enhanced trypsinogen activation, which will favour development 
of pancreatitis. 
We investigated the functional properties of 13 rare PRSS1 variants detected in 
patients with CP. The clinical significance of such variants has been a contentious issue 
because their very low frequency did not allow statistical determination of genetic 
association with the disease phenotype (8). Segregation with pancreatitis within families 
could not be observed either, because these variants were found in cases with no family 
history. Nonetheless, investigators have often assigned clinical relevance to novel PRSS1 
variants found in subjects with CP, purely on the basis of a mistaken analogy with true 
disease-causing mutations. In a recent publication, we cautioned against this practice by 
demonstrating that the p.A121T variant had no functional effect on cationic trypsinogen even 
though it lies next to the amino-acid affected by the p.R122H causative mutation(8). In this 
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work, we used functional analysis as a tool to identify phenotypic similarities between rare 
variants and well-characterized known disease-causing PRSS1 mutations. The common 
biochemical phenotype of PRSS1 mutations associated with HP is the generation of greatly 
increased trypsin levels during autoactivation in the presence of CTRC (42). This 
phenomenon is due to increased sensitivity of trypsinogen mutants to CTRC-mediated 
stimulation of autoactivation and/or resistance to CTRC-dependent trypsinogen degradation 
(Figure 8). Simply put, if a rare variant exhibits similar properties as HP associated 
mutations, then this variant is very likely pathogenic (Table 4). Conversely, phenotypically 
neutral variants are likely to be clinically irrelevant (Table 4).  
PRSS1 mutations
Increased autoactivation
Pancreatitis risk
Increased 
trypsinogen levels
Decreased 
degradation by CTRC
Increased 
processing by CTRC
ER stress
Misfolding
 
 
 
 
 
Figure 8. Pathological pathways associated with PRSS1 mutations in hereditary and sporadic 
chronic pancreatitis. Mutations in PRSS1 can increase autoactivation of cationic trypsinogen by 
different mechanism: increased trypsinogen expression or secretion; inhibition of  chymotrypsin C 
(CTRC)-dependent trypsinogen degradation, stimulation of N-terminal processing of the trypsinogen 
activation peptide by CTRC; and direct stimulation of autoactivation. Alternatively PRSS1 mutations 
can cause misfolding and endoplasmic reticulum stress reticulum stress. See text for further details 
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Unexpectedly, we observed that only one (p.D100H) of 13 mutants had a gain-of-
function phenotype, which might contribute to the development of pancreatitis. However, 
this variant also exhibits a severe secretion defect and is therefore less likely to reach 
significant intrapancreatic trypsin activity. Contrariwise, half of the trypsinogen variants 
showed an increased propensity to CTRC degradation, resulting in lower trypsin levels 
during autoactivation relative to wild-type trypsinogen. This biochemical phenotype is 
inconsistent with the trypsin-dependent model of HP and suggests that these variants are not 
pathogenic (Table 4).This loss of function is particularly surprising for the mutant p.V123M, 
which is located next to the autolytic site Arg122, and was previously postulated to increase 
trypsin stability (53,67). This similar to mutant p.A121T, which has also been classified as 
HP associated mutation without functional analysis (67,68). However, uncertainties in the 
classification of cationic trypsinogen variants as disease associated mutations were already 
highlighted by Szmola et al. That study demonstrated that p.A121T variant is functionally 
innocuous and shows no association with HP (8). 
ER-stress is proposed to represent a different pathomechanism leading to pancreatitis 
(69) (Figure 8). Mutation-induced protein misfolding can cause ER-stress, especially if the 
protein is made in huge amounts, as it is the case of digestive enzymes in the pancreatic 
acinar cells. Misfolding and ER-stress can be assumed in vivo if the mutation exhibits a 
secretion defect in certain cell culture models (45,70,71). Furthermore, it can be hypothesized 
that the threshold of pathological ER-stress correlates with the abundance of each protein 
made. As cationic trypsinogen is the most abundant protease secreted from the pancreatic 
acinar cell, misfolding might have a significant impact. Although, most mutants investigated 
in this study did not cause a pancreatitis-associated gain-of-function phenotype, secretion 
defect, likely caused by mutation-induced misfolding, was observed in the present study for 
variants p.D100H and p.C139F and, to a smaller extent, variants p.K92N, p.S124F and 
p.G208A, suggesting that these variants are pathogenic (Table 4).  
Increased secretion of mutant trypsinogens may result in higher trypsinogen levels in 
the pancreatic juice with consequently increased risk for autoactivation (Figure 8). Copy 
number mutations in trypsinogen genes may exert their pathogenic effect via this mechanism 
(72,73). Conversely, decreased trypsinogen expression due to the c.1-408C>T  
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polymorphism in the 5’ region is associated with decreased pancreatitis risk (74). In 
this study, we observed slightly increased secretion with two mutants, p.I88N and p.K170E. 
While the rapid degradation of mutant p.I88N by CTRC would counteract the effect of 
higher trypsinogen concentrations, the phenotype of mutant p.K170E may indicate a true 
gain of function with potentially elevated risk of pancreatitis (Table 4). Finally, three 
trypsinogen variants (p.Q98K, p.T137M and p.S181G) proved functionally neutral in this 
study, indicating that PRSS1variants of no clinical significance may be incidental findings 
when subjects with CP are screened for underlying genetic defects (Table 4). 
 Taken together, our experimental results indicate that most of the investigated rare 
PRSS1 variants do not phenocopy the disease causing HP-associated PRSS1 mutations 
Region Nucleotide change Amino acid change Relevant phenotype 
Pathogenic variants, strong 
Exon 3 c.298G>C p.D100H severe secretion defect 
Exon 3 c.416G>T p.C139F severe secretion defect 
Pathogenic variants, mild 
Exon 3 c.276G>T p.K92N moderate secretion defect 
Exon 3 c.371C>T p.S124F moderate secretion defect 
Exon 4 c.508A>G p.K170E moderate secretion increase 
Exon 5 c.623G>C p.G208A moderate secretion defect 
Non-pathogenic variants, functionally neutral 
Exon 3 c.292C>A p.Q98K none 
Exon 3 c.410C>T p.T137M none 
Exon 4 c.541A>G p.S181G none 
Non-pathogenic variants, loss of function 
Exon 2 c.107C>G p.P36R degradation by CTRC 
Exon 3 c.248G>A p.G83E degradation by CTRC 
Exon 3 c.263T>A p.I88N degradation by CTRC 
Exon 3 c.367G>A p.V123M degradation by CTRC 
Table 4. Clinical relevance of PRSS1 variants classified on the basis of functional phenotype. 
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(p.R122H, p.R122C, p.N29I.). Instead, loss-of-function characteristics related to increased 
degradation or reduced secretion were observed mostly. Variants with decreased secretion 
may increase pancreatitis risk through an alternative pathological pathway related to 
mutation-induced misfolding and consequent ER stress. 
Considerable research effort has been made to identify the underlying mechanism leading 
to the development of CP. However, aspects of CP inflammation still need to be elucidated, 
including the mechanisms that turn acute inflammation into a chronic, destructive process 
which may eventually lead to pancreatic cancer. In the last decades increasing number of 
studies have been published concerning the important role of ion transport mechanisms in the 
development of inflammatory disorders (75–78). Supressed transporter activites, resulting in 
decreased ductal fluid secretion is associated with development of pancreatitis (49,66). These 
data suggest that the impairment of ion transport mechanisms might be a universal 
component for inflammatory diseases, such as pancreatitis and inflammatory bowel diseases. 
In the light of this view, we looked further ion transport mechanisms in different cell types of 
the gastrointestinal tract as it might imply novel mechanism to consider in the inflammation 
process. Our group found that in patients with ulcerative colitis the sodium hidrogen 
exchanger isoform 1 (NHE1), which has been shown to promote immun response (79) 
upregulated, whereas both sodium and chloride absorption is damaged, which may play a 
role in the pathogenesis of diarrhea in colitis (80). The same transporter (NHE1) was found 
to have a great impact on the cell function (migration and proliferation) of gastric 
myofibroblasts (81), contributors of the tumour genesis (82). The insight in other 
pathomechanistic processes, like inflammatory bowel diseases or cancer genesis might 
provide us new points to focus in the research of pancreatitis.  
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6 SUMMARY 
Introduction: Pancreatitis is caused by the premature activation of trypsinogen, 
followed by the activation of other digestive zymogenes. To prevent early activation, 
defensive mechanisms have evolved, such as the hypersecretion of pancreatic fluid during 
pancreatitis. Suppressed fluid secretion accompanied by the fall of intraductal pH found to 
have a deleterious effect on the whole gland. Hereditary CP is caused by mutations in human 
cationic trypsinogen (PRSS1) which lead to elevated intrapancreatic trypsin activity by 
altering the chymotrypsin C (CTRC)-dependent regulation of trypsinogen activation and 
degradation. To date, a large number of rare PRSS1 mutations have been found and reported 
in patients with pancreatitis. Despite lack of evidence, some of these variants have been 
described as pancreatitis-associated merely on the analogy of the disease-causing mutation. 
The aims of this work were to understand the effect of decreased intraductal pH on 
autoactivation of wild-type cationic trypsinogen and to establish possible clinical relevance 
of published rare PRSS1 mutations on the basis of their phenotypic characteristics. Design: 
We investigated the autoactivation of wild-type trypsinogen at different pH and performed 
functional analysis of 13 published PRSS1 variants with respect to autoactivation in the 
presence of CTRC and cellular secretion. To estimate PRSS1 variant frequency in healthy 
controls, we sequenced exon-3 in 1000 German subjects without pancreatic disease. Results: 
The autoactivation of human wild-type trypsinogen was increased when the pH was reduced 
from 8.5 to 7.0. However, decreasing the pH from 7.0 to 6.0 had a slight effect only. Only 
one mutation (p.D100H) increased trypsinogen autoactivation, but this gain on function was 
offset by marked reduction in secretion. Surprisingly, seven mutants showed a loss-of-
function phenotype, which was related to increased degradation by CTRC (p.P36R, p.G83E, 
p.I88N, p.V123M, p.S124F) or to markedly reduced secretion (p.C139F, p.D100H). In 
addition, moderately decreased secretion was observed with three mutants (p.K92N, 
p.S124F, p.G208A). One mutant showed slightly increased secretion and three mutants had 
no phenotypic alterations when compared to wild-type trypsinogen. DNA sequencing of 
exon-3 in healthy controls identified a novel p.V123L variant in one subject but no other 
variants. Conclusions: Increased autoactivation of cationic trypsinogen at decreased pH 
indicates that not only impaired washout but also decreased intraductal pH will contribute to 
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early trypsin activation, when fluid secretion is suppressed. Rare cationic trypsinogen 
variants found in subjects with sporadic CP do not exhibit a gain of function typical of 
hereditary pancreatitis. Instead, decreased secretion or increased degradation by CTRC is 
observed frequently. Impaired secretion is likely due to misfolding which may represent an 
alternative mechanism for pancreatitis risk unrelated to trypsin activity. These results 
emphasize that classification of novel PRSS1 variants should be based on functional 
evidence. 
  - 39 -  
 
7 ACKNOWLEDGEMENTS 
I would like to express my sincere appreciation to my supervisors at the University of 
Szeged, professor Péter Hegyi and associate professor Zoltán Rakonczay Jr. for the 
continuous support and guidance during my Ph.D. and undergraduate studies. To 
witness how they have built up a successful and continuously growing research group 
has been one of the best learning experiences of my budding career. 
I owe a debt of gratitude to my supervisor at Boston University, 
professor Miklós Sahin-Tóth, who is the true embodiment of a mentor. I am deeply 
grateful for introducing me the fascinating field of protease biochemistry, for the 
continuous encouragement, constructive criticism and prompt responses to all my 
queries. 
I wish to thank professors János Lonovics and Tibor Wittmann, past and present chairs of 
the First Department of Medicine, University of Szeged, for the possibility to pursue my 
Ph.D. studies in their department. 
I wish to thank my colleagues at Boston University, Dr. Sebastian Beer, Dr. András 
Szabó, Andrea Geisz, Dr. Melinda Bence and Vera Sahin-Tóth for teaching me the 
research techniques in biochemistry, for the numerous stimulating scientific discussions 
and for providing a cheerful environment. 
I owe warm thanks to all of my colleagues at the University of Szeged for all the emotional 
support, their kindness and for having had the opportunity to work with them. 
This work was supported by the National Development Agency grants (TÁMOP-4.2.2.A-
11/1/KONV-2012-0035, TÁMOP-4.2.2.A-11/1/KONV-2012-0073, TÁMOP-4.2.2-
11/1/KONV-2012-0052) by NIH grants (R01DK058088, R01DK082412, 
R01DK082412-S2, R01DK095753) and a scholarship from the Rosztoczy Foundation. 
My deepest gratitude goes to my dear father who taught me the value of hard work and 
education and supported me in every possible way. I dedicate this thesis to him. 
  - 40 -  
 
 
8 REFERENCES 
1.  Ahmed SA, Wray C, Rilo HLR, Choe KA, Gelrud A, Howington JA, et al. Chronic 
pancreatitis: recent advances and ongoing challenges. Curr Probl Surg. 2006 
;43(3):127–238.  
2.  Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new 
genetic developments. Gastroenterology. 2001;120(3):682–707.  
3.  Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, et al. Clinical and 
genetic characteristics of hereditary pancreatitis in Europe. Clin. Gastroenterol. Hepatol. 
2004;2(3):252–61.  
4.  Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing 
pancreatitis. Gastroenterology. 1952;21(1):54–63.  
5.  Le Bodic L, Schnee M, Georgelin T, Soulard F, Ferec C, Bignon JD, et al. An 
exceptional genealogy for hereditary chronic pancreatitis. Dig. Dis. Sci. 1996 
;41(7):1504–10.  
6.  Pandya A, Blanton SH, Landa B, Javaheri R, Melvin E, Nance WE, et al. Linkage 
studies in a large kindred with hereditary pancreatitis confirms mapping of the gene to a 
16-cM region on 7q. Genomics. 1996;38(2):227–30.  
7.  Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. 
Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat. 
Genet. 1996;14(2):141–5.  
8.  Szmola R, Sahin-Tóth M. Uncertainties in the classification of human cationic 
trypsinogen (PRSS1) variants as hereditary pancreatitis-associated mutations. J. Med. 
Genet. 2010;47(5):348–50.  
9.  Rebours V, Boutron-Ruault M-C, Schnee M, Férec C, Le Maréchal C, Hentic O, et al. 
The natural history of hereditary pancreatitis: a national series. Gut. 2009;58(1):97–103.  
10.  Teich N, Rosendahl J, Tóth M, Mössner J, Sahin-Tóth M. Mutations of human cationic 
trypsinogen (PRSS1) and chronic pancreatitis. Hum. Mutat. 2006;27(8):721–30.  
11.  Grocock CJ, Rebours V, Delhaye MN, Andrén-Sandberg A, Weiss FU, Mountford R, et 
al. The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in 
pancreatitis families. Gut. 2010;59(3):357–63.  
12.  Witt H, Luck W, Becker M. A signal peptide cleavage site mutation in the cationic 
trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology. 
1999;117(1):7–10.  
  - 41 -  
 
13.  Witt H, Sahin-Tóth M, Landt O, Chen J-M, Kähne T, Drenth JP, et al. A degradation-
sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat. 
Genet. 2006;38(6):668–73.  
14.  Rosendahl J, Teich N, Kovacs P, Szmola R, Blüher M, Gress TM, et al. Complete 
analysis of the human mesotrypsinogen gene (PRSS3) in patients with chronic 
pancreatitis. Pancreatology. 2010;10(2-3):243–9.  
15.  Kume K, Masamune A, Takagi Y, Kikuta K, Watanabe T, Satoh K, et al. A loss-of-
function p.G191R variant in the anionic trypsinogen (PRSS2) gene in Japanese patients 
with pancreatic disorders. Gut. 2009;58(6):820–4.  
16.  Guy O, Lombardo D, Bartelt DC, Amic J, Figarella C. Two human trypsinogens. 
Purification, molecular properties, and N-terminal sequences. Biochemistry. 
1978;17(9):1669–75.  
17.  Rinderknecht H, Renner IG, Carmack C. Trypsinogen variants in pancreatic juice of 
healthy volunteers, chronic alcoholics, and patients with pancreatitis and cancer of the 
pancreas. Gut. 1979;20(10):886–91.  
18.  Rinderknecht H, Stace NH, Renner IG. Effects of chronic alcohol abuse on exocrine 
pancreatic secretion in man. Dig. Dis. Sci. 1985;30(1):65–71.  
19.  Rinderknecht H, Renner IG, Abramson SB, Carmack C. Mesotrypsin: a new inhibitor-
resistant protease from a zymogen in human pancreatic tissue and fluid. 
Gastroenterology. 1984;86(4):681–92.  
20.  Chiari H. Über selbstverdauung des menschlichen pancreas. Zeitschrift für Heilkunde. 
1896;(17):69–96.  
21.  Pfützer RH, Barmada MM, Brunskill AP, Finch R, Hart PS, Neoptolemos J, et al. 
SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic 
chronic pancreatitis. Gastroenterology. 2000;119(3):615–23.  
22.  Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, et al. Mutations in the gene 
encoding the serine protease inhibitor, Kazal type 1 are associated with chronic 
pancreatitis. Nat. Genet. 2000;25(2):213–6.  
23.  Rosendahl J, Witt H, Szmola R, Bhatia E, Ozsvári B, Landt O, et al. Chymotrypsin C 
(CTRC) variants that diminish activity or secretion are associated with chronic 
pancreatitis. Nat. Genet. 2008;40(1):78–82.  
24.  Saluja AK, Lerch MM, Phillips PA, Dudeja V. Why does pancreatic overstimulation 
cause pancreatitis? Annu. Rev. Physiol. 2007;69:249–69.  
25.  Lerch MM, Gorelick FS. Early trypsinogen activation in acute pancreatitis. Med. Clin. 
North Am. 2000;84(3):549–563  
  - 42 -  
 
26.  Hofbauer B, Saluja AK, Lerch MM, Bhagat L, Bhatia M, Lee HS, et al. Intra-acinar cell 
activation of trypsinogen during caerulein-induced pancreatitis in rats. Am. J. Physiol. 
1998;275(2 Pt 1):G352–362.  
27.  Thrower EC, Gorelick FS, Husain SZ. Molecular and cellular mechanisms of pancreatic 
injury. Curr. Opin. Gastroenterol. 2010;26(5):484–9.  
28.  Czakó L, Yamamoto M, Otsuki M. Pancreatic fluid hypersecretion in rats after acute 
pancreatitis. Dig. Dis. Sci. 1997;42(2):265–72.  
29.  Yamamoto A, Ishiguro H, Ko SBH, Suzuki A, Wang Y, Hamada H, et al. Ethanol 
induces fluid hypersecretion from guinea-pig pancreatic duct cells. J Physiol. 
2003;551(3):917–26.  
30.  Yamamoto M, Shirohara H, Otsuki M. CCK-, secretin-, and cholinergic-independent 
pancreatic fluid hypersecretion in protease inhibitor-treated rats. Am. J. Physiol. 1998 
;274(2 Pt 1):G406–412.  
31.  Ishiguro H, Steward MC, Sohma Y, Kubota T, Kitagawa M, Kondo T, et al. Membrane 
potential and bicarbonate secretion in isolated interlobular ducts from guinea-pig 
pancreas. J. Gen. Physiol. 2002;120(5):617–28.  
32.  Sohma Y, Gray MA, Imai Y, Argent BE. HCO3- transport in a mathematical model of 
the pancreatic ductal epithelium. J. Membr. Biol. 2000;176(1):77–100.  
33.  Weiss FU, Simon P, Bogdanova N, Shcheynikov N, Muallem S, Lerch MM. Functional 
characterisation of the CFTR mutations M348V and A1087P from patients with 
pancreatitis suggests functional interaction between CFTR monomers. Gut. 
2009;58(5):733–4.  
34.  Chen J-M, Férec C. Genetics and pathogenesis of chronic pancreatitis: the 2012 update. 
Clin Res Hepatol Gastroenterol. 2012;36(4):334–40.  
35.  LaRusch J, Whitcomb DC. Genetics of pancreatitis. Curr. Opin. Gastroenterol. 2011 
;27(5):467–74.  
36.  Schneider A, Larusch J, Sun X, Aloe A, Lamb J, Hawes R, et al. Combined bicarbonate 
conductance-impairing variants in CFTR and SPINK1 variants are associated with 
chronic pancreatitis in patients without cystic fibrosis. Gastroenterology. 2011 
;140(1):162–71.  
37.  Cavestro GM, Zuppardo RA, Bertolini S, Sereni G, Frulloni L, Okolicsanyi S, et al. 
Connections between genetics and clinical data: Role of MCP-1, CFTR, and SPINK-1 
in the setting of acute, acute recurrent, and chronic pancreatitis. Am. J. Gastroenterol. 
2010;105(1):199–206.  
  - 43 -  
 
38.  Hegyi P, Rakonczay Z. Insufficiency of electrolyte and fluid secretion by pancreatic 
ductal cells leads to increased patient risk for pancreatitis. Am. J. Gastroenterol. 2010 
;105(9):2119–20.  
39.  Renner IG, Wisner JR Jr, Rinderknecht H. Protective effects of exogenous secretin on 
ceruletide-induced acute pancreatitis in the rat. J. Clin. Invest. 1983;72(3):1081–92.  
40.  Hegyi P, Pandol S, Venglovecz V, Rakonczay Z Jr. The acinar-ductal tango in the 
pathogenesis of acute pancreatitis. Gut. 2011;60(4):544–52.  
41.  Sahin-Tóth M, Tóth M. Gain-of-function mutations associated with hereditary 
pancreatitis enhance autoactivation of human cationic trypsinogen. Biochem. Biophys. 
Res. Commun. 2000;278(2):286–9.  
42.  Szabó A, Sahin-Tóth M. Increased Activation of Hereditary Pancreatitis-associated 
Human Cationic Trypsinogen Mutants in Presence of Chymotrypsin C. J. Biol. Chem. 
2012;287(24):20701–10.  
43.  Nemoda Z, Sahin-Tóth M. Chymotrypsin C (caldecrin) stimulates autoactivation of 
human cationic trypsinogen. J. Biol. Chem. 2006;281(17):11879–86.  
44.  Szmola R, Sahin-Tóth M. Chymotrypsin C (caldecrin) promotes degradation of human 
cationic trypsin: identity with Rinderknecht’s enzyme Y. Proc. Natl. Acad. Sci. U.S.A. 
2007;104(27):11227–32.  
45.  Kereszturi E, Szmola R, Kukor Z, Simon P, Weiss FU, Lerch MM, et al. Hereditary 
pancreatitis caused by mutation-induced misfolding of human cationic trypsinogen: a 
novel disease mechanism. Hum. Mutat. 2009;30(4):575–82.  
46.  Király O, Guan L, Sahin-Tóth M. Expression of recombinant proteins with uniform N-
termini. Methods Mol. Biol. 2011;705:175–94.  
47.  Lengyel Z, Pál G, Sahin-Tóth M. Affinity purification of recombinant trypsinogen using 
immobilized ecotin. Protein Expr. Purif. 1998;12(2):291–4.  
48.  Szabó A, Héja D, Szakács D, Zboray K, Kékesi KA, Radisky ES, et al. High affinity 
small protein inhibitors of human chymotrypsin C (CTRC) selected by phage display 
reveal unusual preference for P4’ acidic residues. J. Biol. Chem. 2011;286(25):22535–
45.  
49.  Venglovecz V, Rakonczay Z Jr, Ozsvári B, Takács T, Lonovics J, Varró A, et al. 
Effects of bile acids on pancreatic ductal bicarbonate secretion in guinea pig. Gut. 2008 
;57(8):1102–12.  
50.  Maléth J, Venglovecz V, Rázga Z, Tiszlavicz L, Rakonczay Z Jr, Hegyi P. Non-
conjugated chenodeoxycholate induces severe mitochondrial damage and inhibits 
bicarbonate transport in pancreatic duct cells. Gut. 2011;60(1):136–8.  
  - 44 -  
 
51.  Bynum TE, Solomon TE, Johnson LR, Jacobson ED. Inhibition of pancreatic secretion 
in man by cigarette smoking. Gut. 1972;13(5):361–5.  
52.  Kadiyala V, Lee LS, Banks PA, Suleiman S, Paulo JA, Wang W, et al. Cigarette 
smoking impairs pancreatic duct cell bicarbonate secretion. JOP. 2013;14(1):31–8.  
53.  Chen JM, Piepoli Bis A, Le Bodic L, Ruszniewski P, Robaszkiewicz M, Deprez PH, et 
al. Mutational screening of the cationic trypsinogen gene in a large cohort of subjects 
with idiopathic chronic pancreatitis. Clin. Genet. 2001;59(3):189–93.  
54.  Teich N, Bauer N, Mössner J, Keim V. Mutational screening of patients with 
nonalcoholic chronic pancreatitis: identification of further trypsinogen variants. Am. J. 
Gastroenterol. 2002;97(2):341–6.  
55.  Chang Y-T, Wei S-C, L P-C, Tien Y-W, Jan I-S, Su Y-N, et al. Association and 
differential role of PRSS1 and SPINK1 mutation in early-onset and late-onset idiopathic 
chronic pancreatitis in Chinese subjects. Gut. 2009;58(6):885.  
56.  Zeng K, Liu Q, Lin J, Lin X, Zhuang Z, Gao F, et al. Novel mutations of PRSS1 gene in 
patients with pancreatic cancer among Han population. Chin. Med. J. 
2011;124(13):2065–7.  
57.  Lee YJ, Kim KM, Choi JH, Lee BH, Kim G-H, Yoo H-W. High incidence of PRSS1 
and SPINK1 mutations in Korean children with acute recurrent and chronic pancreatitis. 
J. Pediatr. Gastroenterol. Nutr. 2011;52(4):478–81.  
58.  Keiles S, Kammesheidt A. Identification of CFTR, PRSS1, and SPINK1 mutations in 
381 patients with pancreatitis. Pancreas. 2006;33(3):221–7.  
59.  Tautermann G, Ruebsamen H, Beck M, Dertinger S, Drexel H, Lohse P. R116C 
mutation of cationic trypsinogen in a Turkish family with recurrent pancreatitis 
illustrates genetic microheterogeneity of hereditary pancreatitis. Digestion. 
2001;64(4):226–32.  
60.  Rosendahl J, Landt O, Bernadova J, Kovacs P, Teich N, Bödeker H, et al. CFTR, 
SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated 
CFTR overestimated? Gut [Internet]. 2012 [epub ahead of print]; 
61.  Sultan M, Werlin S, Venkatasubramani N. Genetic prevalence and characteristics in 
children with recurrent pancreatitis. J. Pediatr. Gastroenterol. Nutr. 2012;54(5):645–50.  
62.  Corleto VD, Gambardella S, Gullotta F, D’Apice MR, Piciucchi M, Galli E, et al. New 
PRSS1 and common CFTR mutations in a child with acute recurrent pancreatitis, could 
be considered an “Hereditary” form of pancreatitis  ?  BMC  Gastroenterol.  2010;;10:119.  
63.  Ishiguro H, Steward MC, Wilson RW, Case RM. Bicarbonate secretion in interlobular 
ducts from guinea-pig pancreas. J. Physiol. (Lond.). 1996;495 ( Pt 1):179–91.  
  - 45 -  
 
64.  Ishiguro H, Naruse S, Steward MC, Kitagawa M, Ko SB, Hayakawa T, et al. Fluid 
secretion in interlobular ducts isolated from guinea-pig pancreas. J. Physiol. (Lond.). 
1998;511 ( Pt 2):407–22.  
65.  Ishiguro H, Naruse S, Kitagawa M, Hayakawa T, Case RM, Steward MC. Luminal ATP 
stimulates fluid and HCO3- secretion in guinea-pig pancreatic duct. J. Physiol. (Lond.). 
1999;519 Pt 2:551–8.  
66.  Pallagi P, Venglovecz V, Rakonczay Z Jr, Borka K, Korompay A, Ozsvári B, et al. 
Trypsin reduces pancreatic ductal bicarbonate secretion by inhibiting CFTR Cl− 
channels and luminal anion exchangers. Gastroenterology. 2011;141(6):2228–2239.e6.  
67.  Felderbauer P, Schnekenburger J, Lebert R, Bulut K, Parry M, Meister T, et al. A novel 
A121T mutation in human cationic trypsinogen associated with hereditary pancreatitis: 
functional data indicating a loss-of-function mutation influencing the R122 trypsin 
cleavage site. J. Med. Genet. 2008 Aug;45(8):507–12.  
68.  Liu Q, Gao F, Ou Q, Zhuang Z, Lin S, Yang B, et al. Novel mutation and 
polymorphism of PRSS1 gene in the Chinese patients with hereditary pancreatitis and 
chronic pancreatitis. Chin. Med. J. 2008;121(2):108–11.  
69.  Kubisch CH, Logsdon CD. Endoplasmic reticulum stress and the pancreatic acinar cell. 
Expert Rev Gastroenterol Hepatol. 2008;2(2):249–60.  
70.  Szmola R, Sahin-Tóth M. Pancreatitis-associated chymotrypsinogen C (CTRC) mutant 
elicits endoplasmic reticulum stress in pancreatic acinar cells. Gut. 2010;59(3):365–72.  
71.  Beer S, Zhou J, Szabó A, Keiles S, Chandak GR, Witt H, et al. Comprehensive 
functional analysis of chymotrypsin C (CTRC) variants reveals distinct loss-of-function 
mechanisms associated with pancreatitis risk. Gut. 2012;  
72.  Chen JM, Masson E, Le Maréchal C, Férec C. Copy number variations in chronic 
pancreatitis. Cytogenet. Genome Res. 2008;123(1-4):102–7.  
73.  Le Maréchal C, Masson E, Chen J-M, Morel F, Ruszniewski P, Levy P, et al. 
Hereditary pancreatitis caused by triplication of the trypsinogen locus. Nat. Genet. 2006 
;38(12):1372–4.  
74.  Whitcomb DC, LaRusch J, Krasinskas AM, Klei L, Smith JP, Brand RE, et al. Common 
genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and 
sporadic pancreatitis. Nat. Genet. 2012;44(12):1349–54.  
75.  Németh ZH, Mabley JG, Deitch EA, Szabó C, Haskó G. Inhibition of the Na(+)/H(+) 
antiporter suppresses IL-12 p40 production by mouse macrophages. Biochim. Biophys. 
Acta. 2001; 20;1539(3):233–42.  
  - 46 -  
 
76.  Németh ZH, Deitch EA, Szabó C, Mabley JG, Pacher P, Fekete Z, et al. Na+/H+ 
exchanger blockade inhibits enterocyte inflammatory response and protects against 
colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2002;283(1):G122–132.  
77.  Rolfe MW, Kunkel SL, Rowens B, Standiford TJ, Cragoe EJ Jr, Strieter RM. 
Suppression of human alveolar macrophage-derived cytokines by amiloride. Am. J. 
Respir. Cell Mol. Biol. 1992;6(6):576–82.  
78.  Shi Y, Kim D, Caldwell M, Sun D. The role of Na(+)/h (+) exchanger isoform 1 in 
inflammatory responses: maintaining H(+) homeostasis of immune cells. Adv. Exp. 
Med. Biol. 2013;961:411–8.  
79.  De Vito P. The sodium/hydrogen exchanger: a possible mediator of immunity. Cell. 
Immunol. 2006;240(2):69–85.  
80.  Farkas K, Yeruva S, Rakonczay Z Jr, Ludolph L, Molnár T, Nagy F, et al. New 
therapeutic targets in ulcerative colitis: the importance of ion transporters in the human 
colon. Inflamm. Bowel Dis. 2011;17(4):884–98.  
81.  Czepán M, Rakonczay Z Jr, Varró A, Steele I, Dimaline R, Lertkowit N, et al. NHE1 
activity contributes to migration and is necessary for proliferation of human gastric 
myofibroblasts. Pflugers Arch. 2012;463(3):459–75.  
82.  Desmoulière A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player 
in the control of tumor cell behavior. Int. J. Dev. Biol. 2004;48(5-6):509–17.  
 
  
 
 
 
 
 
 
 
Articles closely related to the subject of the thesis and cited in the thesis 
 
  
 
 
 
 
 
 
 
I. 
 
 
ORIGINAL ARTICLE
Functional effects of 13 rare PRSS1 variants
presumed to cause chronic pancreatitis
Andrea Schnúr,1,2 Sebastian Beer,1 Heiko Witt,3,4 Péter Hegyi,2 Miklós Sahin-Tóth1
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
gutjnl-2012-304331).
1Department of Molecular and
Cell Biology, Henry
M. Goldman School of Dental
Medicine, Boston University,
Boston, Massachusetts, USA
2First Department of Medicine,
University of Szeged, Szeged,
Hungary
3Else Kröner-Fresenius-Zentrum
für Ernährungsmedizin (EKFZ) &
Zentralinstitut für Ernährungs-
und Lebensmittelforschung
(ZIEL), Technische Universität
München (TUM), Freising,
Germany
4Department of Pediatrics,
Klinikum rechts der Isar (MRI),
Technische Universität
München (TUM), Munich,
Germany
Correspondence to
Dr Miklós Sahin-Tóth,
Department of Molecular and
Cell Biology, Henry
M. Goldman School of Dental
Medicine, Boston University,
72 East Concord Street,
Evans-433; Boston,
MA 02118, USA;
miklos@bu.edu
Received 13 December 2012
Revised 3 February 2013
Accepted 5 February 2013
To cite: Schnúr A, Beer S,
Witt H, et al. Gut Published
Online First: [please include
Day Month Year]
doi:10.1136/gutjnl-2012-
304331
ABSTRACT
Objective Hereditary pancreatitis is caused by
mutations in human cationic trypsinogen (PRSS1) which
lead to increased autoactivation by altering chymotrypsin
C (CTRC)-dependent trypsinogen activation and
degradation. Exceptions are some cysteine mutations
which cause misfolding, intracellular retention and
endoplasmic reticulum stress. Clinical relevance of many
PRSS1 variants found in patients with sporadic chronic
pancreatitis is unknown but often assumed by analogy
with known disease-causing mutations. Functional
comparison of PRSS1 variants found in sporadic and
hereditary cases is needed to resolve this dilemma.
Design Here, we investigated the functional phenotype
of 13 published PRSS1 variants with respect to
autoactivation in the presence of CTRC and cellular
secretion.
Results Only mutation p.D100H increased trypsinogen
autoactivation, but this gain in function was offset by a
marked reduction in secretion. Five mutants (p.P36R,
p.G83E, p.I88N, p.V123M, p.S124F) showed decreased
autoactivation due to increased degradation by CTRC.
Five mutants exhibited strongly (p.D100H, p.C139F) or
moderately (p.K92N, p.S124F, p.G208A) reduced
secretion, whereas mutant p.K170E showed slightly
increased secretion. Mutant p.I88N was also secreted to
higher levels but was rapidly degraded by CTRC. Finally,
three mutants (p.Q98K, p.T137M, p.S181G) had no
phenotypic alterations relative to wild-type trypsinogen.
Conclusions Rare PRSS1 variants found in sporadic
chronic pancreatitis do not stimulate autoactivation but
may cause increased degradation, impaired secretion or
no functional change. Variants with reduced secretion
are likely pathogenic due to mutation-induced misfolding
and consequent endoplasmic reticulum stress.
INTRODUCTION
Hereditary pancreatitis is an autosomal dominant
disorder caused by mutations in the serine protease
1 (PRSS1) gene that codes for cationic trypsinogen.1
Causative mutations are p.R122H (∼65%), p.N29I
(∼25%) and less frequently p.A16V, p.D22G,
p.K23R, p.K23_I24insIDK, p.N29T, p.V39A,
p.R116C and p.R122C.1–5 To date, 21 additional
rare missense PRSS1 variants have been reported,
the majority of which were found in patients with
sporadic chronic pancreatitis with no family history5
(http://www.pancreasgenetics.org). The mechanism
of action of hereditary pancreatitis-associated muta-
tions involves increased autoactivation of mutant
trypsinogens resulting in elevated intrapancreatic
trypsin activity levels6 (ﬁgure 1). Recent studies
uncovered that PRSS1 mutations alter the regulation
of activation and degradation of cationic trypsino-
gen by chymotrypsin C (CTRC). The digestive
enzyme CTRC stimulates trypsinogen activation by
processing the activation peptide to a shorter form,
which is easier cleaved by trypsin.7 Somewhat para-
doxically, CTRC also promotes degradation of tryp-
sinogen by cleaving the calcium binding loop.6 8
This cleavage in combination with a trypsin-
mediated autolytic cleavage results in inactivation of
trypsinogen during autoactivation and lower trypsin
levels attained. Pancreatitis-associated mutations
render trypsinogen resistant to CTRC-dependent
degradation and/or increase N-terminal processing
by CTRC and thereby elevate trypsin levels gener-
ated through autoactivation6 (ﬁgure 1).
The unifying pathological mechanism described
above does not seem to apply to some mutations
that alter the number of cysteine residues in
cationic trypsinogen. Hereditary pancreatitis-
associated mutation p.R116C was shown to induce
protein misfolding with intracellular retention and
degradation, which may represent an alternative
Signiﬁcance of this study
What is already known on this subject?
▸ Hereditary pancreatitis is caused by mutations
in human cationic trypsinogen (PRSS1) that
increase autoactivation.
▸ Some pathogenic PRSS1 variants misfold, suffer
intracellular retention and cause endoplasmic
reticulum stress.
▸ Clinical relevance of rare PRSS1 variants found
in subjects with sporadic chronic pancreatitis is
uncertain but frequently assumed.
What are the new ﬁndings?
▸ Rare PRSS1 variants found in sporadic chronic
pancreatitis do not increase trypsinogen
activation.
▸ Rather, they cause increased degradation, loss
of secretion or no functional change.
▸ Reduced secretion is indicative of misfolding
that may increase pancreatitis risk through
endoplasmic reticulum stress.
How might it impact on clinical practice in
the foreseeable future?
▸ Functional classiﬁcation of PRSS1 variants
found in patients with chronic pancreatitis is
required for determination of clinical relevance.
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disease-causing mechanism unrelated to trypsinogen activation
and trypsin activity.9 Mutation p.C139S, which was reported in
sporadic cases of chronic pancreatitis, exhibits similar proper-
ties.9 Mutation-dependent misfolding can elicit endoplasmic
reticulum (ER) stress, which might be responsible for increased
pancreatitis risk, although the mechanism remains unclear
(ﬁgure 1).
In the present study, we surveyed the functional properties of
13 rare missense PRSS1 variants found in patients with sporadic
chronic pancreatitis. Our primary objective was to test whether
these variants also exhibit increased activation in the presence of
CTRC as previously seen with disease-causing mutants in her-
editary pancreatitis. A second objective of the study was to
assess cellular secretion of the mutants to determine whether
mutation-induced changes in folding and secretion may be a
more common phenotype of PRSS1 variants than previously
appreciated.
EXPERIMENTAL PROCEDURES
Nomenclature
Amino acid residues in human cationic trypsinogen (serine pro-
tease 1, PRSS1) are numbered starting with the initiator methio-
nine of the primary translation product in accordance with the
recommendations of the Human Genome Variation Society.
Plasmid construction and mutagenesis
The pTrapT7 intein-PRSS1, pcDNA3.1(-) PRSS1 and pcDNA3.1(-)
CTRC 10His expression plasmids were constructed previ-
ously.7 8 10 Missense mutations were introduced by overlap
extension PCR mutagenesis, cloned into the expression plasmids
and veriﬁed by DNA sequencing.
Expression and puriﬁcation of trypsinogen
Wild-type and mutant trypsinogens were expressed in the ami-
nopeptidase P deﬁcient LG-3 Escherichia coli strain as fusions
with a self-splicing mini-intein, as described in.10 11 This expres-
sion system was developed to produce recombinant trypsinogen
with uniform, authentic N-termini. Isolation of cytoplasmic
inclusion bodies, in vitro refolding and puriﬁcation with ecotin
afﬁnity chromatography were carried out according to published
protocols.10 11 Mutant p.C139F could not be puriﬁed by
this method, as it misfolded during in vitro refolding.
Concentrations of trypsinogen preparations were calculated
from their ultraviolet absorbance at 280 nm using the extinction
coefﬁcient 37 525 M−1 cm−1.
Cell culture and transfection
Human embryonic kidney 293T (HEK 293T) cells were cul-
tured and transfected as described previously.12 Transfections
were performed using 1 mg expression plasmid and 2.5 ml
Lipofectamine 2000 (Invitrogen, Carlsbad, California, USA) in
2 ml Dulbecco’s Modiﬁed Eagle Medium. After overnight incu-
bation, cells were washed and the transfection medium was
replaced with 2 ml OPTI-MEM I Reduced Serum Medium
(Invitrogen) containing 1 mM benzamidine (ﬁnal concentration)
to inhibit autoactivation of secreted trypsinogen. Conditioned
media were harvested 24 h after addition of OPTI-MEM.
Expression and puriﬁcation of human CTRC
Large-scale expression of human CTRC in HEK 293T cells and
puriﬁcation from the conditioned medium using nickel-afﬁnity
chromatography were performed as reported previously.6 CTRC
was activated with human cationic trypsin and active CTRC
concentrations were determined by active site titration with
ecotin, as described.13
Trypsinogen autoactivation in the presence of CTRC
Trypsinogen at 1 mM concentration was incubated with 5 nM
human CTRC and 10 nM cationic trypsin in 0.1 M Tris-HCl
(pH 8.0), 1 mM CaCl2 and 0.05% Tween-20 (ﬁnal concentra-
tions) at 37°C. At given times, 2 ml aliquots were withdrawn and
mixed with 48 ml assay buffer containing 0.1 M Tris-HCl (pH
8.0), 1 mM CaCl2 and 0.05% Tween-20. Trypsin activity was
measured by adding 150 ml 200 mM N-CBZ-Gly-Pro-
Arg-p-nitroanilide substrate and following the release of the
yellow p-nitroanilin at 405 nm in a SpectraMax plus384 micro-
plate reader (Molecular Devices, Sunnyvale, California, USA) for
1 min. Reaction rates were calculated from ﬁts to the initial linear
portions of the curves. The trypsin substrate was dissolved in
0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2 and 0.05% Tween-20.
Measurement of trypsin activity in conditioned media
Aliquots (50 ml) of conditioned media were supplemented with
5 ml 1 M Tris-HCl (pH 8.0) and 1 ml 0.5 M CaCl2 and trypsi-
nogens were activated by adding 1 μl 1.4 μg/ml human entero-
peptidase (R&D Systems, Minneapolis, Minnesota, USA). After
incubation for 1 h at 37°C, a 50 ml aliqout was removed and
mixed with 150 ml 200 mM N-CBZ-Gly-Pro-Arg-p-nitroanilide
substrate. Activity was determined as described above.
Sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) and
western blotting
Conditioned media (200 ml) was precipitated with 10% tri-
chloroacetic acid (ﬁnal concentration), resuspended in 20 μl
Laemmli sample buffer containing 100 mM dithiothreitol,
Figure 1 Pathological pathways associated with PRSS1 mutations in
hereditary and sporadic chronic pancreatitis. Mutations in PRSS1 can
increase autoactivation of cationic trypsinogen by different
mechanisms: increased trypsinogen expression or secretion; inhibition
of chymotrypsin C (CTRC)-dependent trypsinogen degradation,
stimulation of N-terminal processing of the trypsinogen activation
peptide by CTRC; and direct stimulation of autoactivation. Alternatively,
PRSS1 mutations can cause misfolding and endoplasmic reticulum (ER)
stress. See text for further details.
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heat-denatured at 95°C for 5 min and run on 15%
SDS-polyacrylamide gels. The gels were stained with Coomassie
Blue R-250. For western blotting, 5 ml conditioned media were
directly mixed with sample buffer and electrophoresed as
described above. Proteins were transferred onto an Immobilon-P
membrane (Millipore Corporation, Bedford, Massachusetts,
USA) at 300 mA for 1.5 h. The membrane was blocked with 5%
milk powder dissolved in phosphate-buffered saline supplemen-
ted with 0.1% Tween-20 (ﬁnal concentration), at 4°C overnight.
Trypsinogen was detected with a sheep polyclonal antibody
(R&D Systems, #AF3848) used at a dilution of 1:5000 fol-
lowed by horse-radish peroxidase (HRP)-conjugated donkey
polyclonal antisheep IgG (R&D Systems, #HAF016) used at
1:2000 dilution. Incubations with primary and secondary anti-
bodies were performed at room temperature for 1 h each. HRP
was detected using the SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientiﬁc). Quantitation of bands was carried
out with the Image Lab 3.0 (Bio-Rad) software.
RESULTS
PRSS1 variants found in subjects with sporadic
chronic pancreatitis
We studied here 13 missense PRSS1 variants found in patients
with idiopathic chronic pancreatitis or recurrent acute pancrea-
titis with no family history (table 1). The variants were detected
in the heterozygous state, with the exception of p.G208A,
which was also identiﬁed in a homozygous individual. As indi-
cated, the variants were found only in one to three cases each;
therefore, the genetic information was insufﬁcient to determine
whether these variants are pathogenic or neutral. Unaffected
carrier parent was reported in two cases, for variant p.C139F
and p.S181G. Note that variants p.T137M, p.K170E and
p.G208A were from subjects of Asian origin, whereas all other
variants were from subjects of European origin.
To determine whether these 13 variants are prevalent in the
general population, we consulted the NHLBI Exome Sequencing
Project Exome Variant Server (http://evs.gs.washington.edu) which
lists aggregate exome-sequencing data for approximately 4300
European-American and 2200 African-American individuals. We
found PRSS1 variants p.V123M and p.T137M in one
European-American subject each and variant p.S181G in one
African-American subject. However, interpretation of these ﬁnd-
ings is difﬁcult, because the database also lists the disease-causing
mutation p.R122C found in two European-American individuals,
suggesting that the studied cohort may have contained pancreatitis
patients. Therefore, we sequenced exon-3 of the PRSS1 gene in
1000 German subjects without any pancreatic disease. Exon-3 was
selected because most of the studied variants (nine of 13) were in
this region. With the exception of a novel c.367G>T (p.V123L)
variant found in one subject, no other alterations were identiﬁed.
Table 1 Rare PRSS1 variants in pancreatitis
Region Nucleotide change Amino acid change Carriers reported Clinical and genetic information Citations
Exon 2 c.107C>G p.P36R 2 French m and fm, ICP 14*
Exon 3 c.248G>A p.G83E 1 Italian, ICP 14*
Exon 3 c.263T>A p.I88N 1 18 years white fm, CP
No SPINK1 or CFTR mut
23
Exon 3 c.276G>T p.K92N 1 Italian, ICP 14*
Exon 3 c.292C>A p.Q98K 1 55 years French m, CP
No SPINK1, CTRC or CFTR mut
4†
Exon 3 c.298G>C p.D100H 1 German m, ICP 24
Exon 3 c.367G>A p.V123M 1 French fm, ICP 14*
Exon 3 c.371C>T p.S124F 1 46 years German fm, ICP
No SPINK1, CTRC or CFTR mut
25
Exon 3 c.410C>T p.T137M 3 13 years Asian fm, AP
No SPINK1 or CFTR mut
23
Chinese, late onset ICP
No SPINK1 mut
16
28 years Chinese, pancreatic cancer
Also carried p.T135A PRSS1
17
Exon 3 c.416G>T p.C139F 2 14 years German m, RAP
Unaffected mother carrier
15
8 years fm, CP with chronic pain
No SPINK1 or CFTR mut
26
Exon 4 c.508A>G p.K170E 1 30 years Indian m, CP
No SPINK1, CTRC or CFTR mut
4†
Exon 4 c.541A>G p.S181G 1 6 years Italian m, RAP
p.F508del CFTR
Unaffected mother carrier
27
Exon 5 c.623G>C p.G208A 3 12 years Asian m, pancreatitis, hm
p.F508del and p.Q1352H CFTR
23
Korean child, RAP
No SPINK1 mut
18
7 years Korean, necrotising AP 18
Unless indicated otherwise, mutations are heterozygous. The age indicates the time of diagnosis.
*Jian-Min Chen, personal communication.
†Vinciane Rebours, personal communication.
AP, acute pancreatitis; CP, chronic pancreatitis; CTRC, chymotrypsin C; fm, female; hm, homozygous; ICP, idiopathic chronic pancreatitis; m, male; mut, mutation; RAP, recurrent acute
pancreatitis.
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This observation is in agreement with published sequencing data
showing the absence of these 13 PRSS1 variants in 200 French,14
82 German,15 420 Chinese16 17 and 28 Korean18 control subjects.
We conclude that the 13 PRSS1 variants presumed to cause
chronic pancreatitis (table 1) are not generally found in a healthy
population.
Autoactivation and catalytic activity of PRSS1 variants
First, trypsinogen variants were characterised for their ability to
autoactivate in the absence of CTRC. When measured at
pH 8.0, in 1 mM Ca2+, only one mutant, p.D100H, exhibited
increased autoactivation, which was about 2.5-fold faster than
wild type (see online supplementary ﬁgure S1A). Five mutants
(p.Q98K, p.T137M, p.K170E, p.S181G and p.G208A) autoac-
tivated as well as wild-type cationic trypsinogen (see online
supplementary ﬁgure S1B). Mutants p.K92N and p.S124F auto-
activated at a decreased rate but reached essentially the same
ﬁnal trypsin levels as wild-type trypsinogen (see online
supplementary ﬁgure S1C). In contrast, four mutants exhibited
decreased rates of autoactivation (p.P36R, p.G83E, p.I88N and
p.V123M) with reduced ﬁnal trypsin levels, suggesting that
these mutants may become partially degraded during autoactiva-
tion (see online supplementary ﬁgure S1D).
Catalytic activity of the activated trypsin variants was mea-
sured with the synthetic peptide substrate N-CBZ-Gly-Pro-Arg-
p-nitroanilide. As shown in online supplementary table S1,
enzyme kinetic parameters of trypsin variants were comparable
with those of wild-type cationic trypsin. This ﬁnding is consist-
ent with previous observations that natural PRSS1 variants
almost never affect catalytic function of trypsin.
Note that mutant p.C139F could not be puriﬁed in sufﬁcient
quantities due to misfolding; therefore, it was not tested in the
autoactivation and catalytic activity assays.
Autoactivation of PRSS1 variants in the presence of CTRC
To determine the effect of CTRC on the trypsinogen variants,
we measured autoactivation in the presence of 5 nM human
CTRC. This low CTRC concentration slightly stimulates the
rate of autoactivation but causes a reduction in ﬁnal active
trypsin levels due to trypsinogen degradation during activation.6
In the experiments presented, wild-type cationic trypsinogen
reached about 50% activity in the presence of CTRC, relative to
trypsin activity observed in the absence of CTRC (not shown,
also see ﬁgure 1A in6). Under these conditions, both increases
and decreases in autoactivation are readily detectable.
Only one of the 12 variants tested, p.D100H, exhibited
increased activation in the presence of CTRC (ﬁgure 2A). A
similar phenotype was observed with this mutant when autoacti-
vation was performed in the absence of CTRC (see above), indi-
cating that the mutation increases autoactivation independent of
CTRC. Consistent with this interpretation, degradation of
p.D100H mutant trypsinogen and trypsin by CTRC was
unchanged (not shown). Six mutants (p.K92N, p.Q98K,
p.T137M, p.K170E, p.S181G and p.G208A) autoactivated in
the presence of CTRC in a manner that was comparable with
wild type (ﬁgure 2B). Surprisingly, however, ﬁve mutants
(p.P36R, p.G83E, p.I88N, p.V123M and p.S124F) reached
markedly reduced trypsin activity levels during autoactivation,
suggesting increased susceptibility to CTRC-dependent degrad-
ation (ﬁgure 2C). This notion was conﬁrmed by direct
degradation experiments which demonstrated that these ﬁve
Figure 2 Autoactivation of cationic trypsinogen variants in the
presence of chymotrypsin C (CTRC). Trypsinogen was incubated at
1 μM concentration with 5 nM CTRC and 10 nM initial trypsin in
0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2 and 0.05% Tween-20 (ﬁnal
concentrations) at 37°C. At the indicated times, 2 μl aliquots were
removed and trypsin activity was measured as described in
Experimental procedures section. Trypsin activity was expressed as per
cent of the maximal wild-type activity in the absence of CTRC.
(A) Mutant with increased autoactivation. (B) Mutants with unchanged
autoactivation. (C) Mutants with decreased autoactivation.
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mutants were degraded by CTRC at increased rates (see online
supplementary ﬁgure S2).
Secretion of PRSS1 variants from HEK 293T cells
To identify trypsinogen variants defective in folding, we evalu-
ated their secretion from transfected cells to the conditioned
medium using SDS-PAGE with Coomassie Blue staining,
western blot analysis and trypsin activity measurements after
activation with enteropeptidase. The use of HEK 293T cells for
cellular secretion studies is a compromise, as efﬁcient transfec-
tion of pancreatic acinar cells is not feasible. Despite its constitu-
tive secretion, this cell line remains a good model to study ER
related disturbances such as misfolding, retention and degrad-
ation of secretory proteins.
Six of 13 mutants tested (p.P36R, p.G83E, p.Q98K,
p.V123M, p.T137M and p.S181G) showed trypsinogen secre-
tion close to wild-type levels (∼70%–85%) (ﬁgure 3A–C, black
bars). Severe secretion defects (∼20% of wild type) were
observed with mutants p.D100H and p.C139F. Moderate reduc-
tion in secretion (∼40%–50% of wild type) was noted with
three mutants (p.K92N, p.S124F and p.G208A). Two mutants
(p.I88N and p.K170E) showed increased secretion levels, 140%
and 130% of wild type, respectively. The higher secretion of
mutant p.I88N was due to the appearance of a second trypsino-
gen band which represents an aberrantly glycosylated trypsino-
gen form (ﬁgure 3A,B). This band was also observed in a much
fainter form with wild-type trypsinogen and all other variants
and may be an artefact of the heterologous cell line used.
Figure 3 Secretion of cationic trypsinogen variants from HEK 293T cells. Cells were transiently transfected and conditioned media were collected
after 24 h. Trypsinogen protein levels were qualitatively analysed on Coomassie Blue stained SDS-polyacrylamide gels (A) and then quantitatively
determined by western blots (B) and densitometry (C, black bars). Trypsin activity was measured after activation with enteropeptidase (C, grey bars).
See Experimental procedures section for details. Representative gels and blots of four independent experiments are shown. Average of four
experiments with SD was plotted. Trypsinogen protein and trypsin activity levels were expressed as per cent of wild-type values.
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Although increased secretion of variant p.I88N may represent a
gain of function, the rapid degradation of this variant by CTRC
(see above) would cancel out this effect and result in a
loss-of-function phenotype. On the other hand, it seems prob-
able that the slightly more efﬁcient secretion of mutant
p.K170E may confer an increased risk for pancreatitis.
For the majority of the variants, trypsin activity levels in the
conditioned medium correlated well with the protein levels
secreted (ﬁgure 3C, grey bars). Four variants (p.P36R, p.G83E,
p.K92N and p.C139F) had considerably lower enzyme activity
relative to their protein levels. Variant p.C139F may be mis-
folded and catalytically defective, which explains its lower activ-
ity, whereas mutants p.P36R and p.G83E suffer some
degradation during activation, as seen in the autoactivation
experiments in online supplementary ﬁgure S1D. The lower
activity of mutant p.K92N is unexplained and may be related to
increased sensitivity to some inhibitory component in the cell
culture medium, because when this mutant was puriﬁed either
from E coli or from the conditioned medium of transfected
HEK 293T cells, wild-type trypsin activity levels were reached
after activation with enteropeptidase.
DISCUSSION
In this study, we investigated the functional properties of 13
rare PRSS1 variants detected in patients with sporadic chronic
pancreatitis. The common biochemical phenotype of PRSS1
mutations associated with hereditary pancreatitis is the gener-
ation of greatly increased trypsin levels during autoactivation in
the presence of CTRC.6 This phenomenon is due to increased
sensitivity of trypsinogen mutants to CTRC-mediated stimula-
tion of autoactivation and/or resistance to CTRC-dependent
trypsinogen degradation (ﬁgure 1). Unexpectedly, only one of
the investigated 13 mutants exhibited a similar phenotype when
autoactivation was tested in the presence of CTRC. Mutant
p.D100H autoactivated at a faster rate and reached higher
trypsin levels than wild-type trypsinogen; however, this was
independent of CTRC as the same phenotype was observed in
its absence. More importantly, further studies, discussed below,
demonstrated that mutant p.D100H was poorly secreted, which
would completely negate any increased propensity for autoacti-
vation and result in diminished trypsin levels upon activation.
Five mutants were degraded by CTRC at an increased rate
resulting in lower trypsin levels during autoactivation, relative to
wild-type trypsinogen. This biochemical phenotype is inconsist-
ent with the trypsin-dependent model of hereditary pancreatitis
and suggests that these variants are not pathogenic (table 2).
Previous studies found that PRSS1 mutations p.R116C and
p.C139S resulted in reduced trypsinogen secretion.9 These
mutations alter the number of Cys residues and thus may inter-
fere with correct disulﬁde formation during folding, which
results in intracellular retention and degradation. A similar
secretion defect, likely caused by mutation-induced misfolding,
was observed in the present study for variants p.D100H and
p.C139F and, to a smaller extent, variants p.K92N, p.S124F
and p.G208A, suggesting that these variants are pathogenic
(table 2). Trypsinogen misfolding underlying the reduced secre-
tion may elicit ER stress and thereby increase the risk for pan-
creatitis, as previously shown for mutants p.R116C and
p.C139S9 (ﬁgure 1). Secretion defect and ER stress was also
observed for a subset of CTRC mutants associated with chronic
pancreatitis.12 19 Increased secretion of mutant trypsinogens
may result in higher trypsinogen levels in the pancreatic juice
with consequently increased risk for autoactivation (ﬁgure 1).
Copy number mutations in trypsinogen genes may exert their
pathogenic effect via this mechanism.20 21 Conversely, decreased
trypsinogen expression due to the c.1-408C>T polymorphism
in the 50 region is associated with decreased pancreatitis risk.22
In this study, we observed slightly increased secretion with two
mutants, p.I88N and p.K170E. While the rapid degradation of
mutant p.I88N by CTRC would counteract the effect of higher
trypsinogen concentrations, the phenotype of mutant p.K170E
may indicate a true gain of function with potentially elevated
risk of pancreatitis (table 2). Finally, three trypsinogen variants
(p.Q98K, p.T137M and p.S181G) proved functionally neutral
in this study, indicating that PRSS1 variants of no clinical signiﬁ-
cance may be incidental ﬁndings when subjects with chronic
pancreatitis are screened for underlying genetic defects (table 2).
In summary, functional analysis of 13 PRSS1 variants found
in patients with chronic pancreatitis demonstrated that these
rare PRSS1 variants do not phenocopy the disease-causing her-
editary pancreatitis-associated PRSS1 mutations. Instead,
increased degradation or reduced secretion was observed mostly.
Variants with decreased secretion may increase pancreatitis risk
through an alternative pathological pathway related to
mutation-induced misfolding rather than trypsin activity.
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 Supplementary Table S1. Kinetic parameters of wild-type and mutant human cationic trypsin 
on the synthetic substrate N-CBZ-Gly-Pro-Arg-p-nitroanilide, measured in 0.1 M Tris-HCl (pH 
8.0), 1 mM CaCl2 and 0.05% Tween 20, at 22 oC. 
 
 kcat (s-1) KM (µM) kcat/KM (s-1·M-1) 
wild type 95.3 17.6 5.4 
p.P36R 86.6 19.1 4.5 
p.G83E 92.8 14.7 6.3 
p.I88N 80.8 16.2 5.0 
p.K92N 99.7 16.9 5.9 
p.Q98K 95.4 16.3 5.8 
p.D100H 77.6 15.8 4.9 
p.V123M 90.9 17.4 5.2 
p.S124F 91.6 16.1 5.7 
p.T137M 102.3 17.1 6.0 
p.K170E 107.8 14.4 7.5 
p.S181G 103.7 18.4 5.6 
p.G208A 89.7 17.5 5.1 
 
  
Supplementary Figure S1. Autoactivation of cationic trypsinogen variants in the absence of 
chymotrypsin C (CTRC). Trypsinogen (1 µM) was incubated with 10 nM initial trypsin in 0.1 M 
Tris-HCl (pH 8.0), 1 mM CaCl2 and 0.05% Tween-20 (final concentrations) at 37° C. At the 
indicated times, 2 µL aliquots were removed and trypsin activity was measured as described in 
Experimental Procedures. Trypsin activity was expressed as percent of the maximal wild-type 
activity. A, mutant with increased rate of autoactivation, B, mutants with unchanged 
autoactivation; C, mutants with decreased rates of autoactivation but normal final trypsin levels; 
D, mutants with decreased rates of autoactivation and reduced final trypsin levels. 
  
Supplementary Figure S2. Degradation of cationic trypsinogen variants by chymotrypsin C 
(CTRC). Trypsinogens at 2 µM concentration were incubated with 25 nM CTRC in 0.1 M Tris-
HCl (pH 8.0) (final concentrations) at 37° C. At the indicated times, reactions were precipitated 
with 10% trichloroacetic acid (final concentration) and analyzed by SDS-PAGE, and Coomassie 
blue staining. Representative gels of two experiments are shown. The graph indicates 
densitometric evaluation of the intensity of the trypsinogen bands. Average of two experiments 
was plotted with error bars omitted for clarity. The error was within 12% of the mean. 
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Trypsin Reduces Pancreatic Ductal Bicarbonate Secretion by Inhibiting
CFTR Cl! Channels and Luminal Anion Exchangers
PETRA PALLAGI,* VIKTÓRIA VENGLOVECZ,‡ ZOLTÁN RAKONCZAY Jr,* KATALIN BORKA,§ ANNA KOROMPAY,§
BÉLA ÓZSVÁRI,* LINDA JUDÁK,* MIKLÓS SAHIN–TÓTH,! ANDREA GEISZ,*,! ANDREA SCHNÚR,*,! JÓZSEF MALÉTH,*
TAMÁS TAKÁCS,* MIKE A. GRAY,¶ BARRY E. ARGENT,¶ JULIA MAYERLE,# MARKUS M. LERCH,# TIBOR WITTMANN,*
and PÉTER HEGYI*
*First Department of Medicine and ‡Department of Pharmacology, University of Szeged, Szeged, Hungary; §2nd Department of Pathology, Semmelweis University,
Budapest, Hungary; !Department of Molecular and Cell Biology, Henry M. Goldman School of Dental Medicine, Boston University, Boston, Massachusetts; ¶Institute
for Cell & Molecular Biosciences, Newcastle University, Newcastle upon Tyne, England; and #Department of Medicine A, Greifswald University Hospital, Greifswald,
Germany
BACKGROUND & AIMS: The effects of trypsin on pan-
creatic ductal epithelial cells (PDECs) vary among species
and depend on the localization of proteinase-activated
receptor 2 (PAR-2). We compared PAR-2 localization in
human and guinea-pig PDECs, and used isolated guinea
pig ducts to study the effects of trypsin and a PAR-2
agonist on bicarbonate secretion. METHODS: PAR-2 lo-
calization was analyzed by immunohistochemistry in
guinea pig and human pancreatic tissue samples (from 15
patients with chronic pancreatitis and 15 without pancre-
atic disease). Functionally, guinea pig PDECs were studied
by microperfusion of isolated ducts, measurements of
intracellular pH and intracellular Ca2! concentration, and
patch clamp analysis. The effect of pH on trypsinogen
autoactivation was assessed using recombinant human
cationic trypsinogen. RESULTS: PAR-2 localized to the
apical membrane of human and guinea pig PDECs. Tryp-
sin increased intracellular Ca2! concentration and intra-
cellular pH and inhibited secretion of bicarbonate by the
luminal anion exchanger and the cystic fibrosis trans-
membrane conductance regulator (CFTR) Cl" channel.
Autoactivation of human cationic trypsinogen accelerated
when the pH was reduced from 8.5 to 6.0. PAR-2 expres-
sion was strongly down-regulated, at transcriptional and
protein levels, in the ducts of patients with chronic pan-
creatitis, consistent with increased activity of intraductal
trypsin. Importantly, in PAR-2 knockout mice, the effects
of trypsin were markedly reduced. CONCLUSIONS:
Trypsin reduces pancreatic ductal bicarbonate secre-
tion via PAR-2–dependent inhibition of the apical
anion exchanger and the CFTR Cl! channel. This
could contribute to the development of chronic pan-
creatitis by decreasing luminal pH and promoting
premature activation of trypsinogen in the pancreatic
ducts.
Keywords: Acinar Cells; Ductal Epithelium; Animal Model;
Pancreatic Enzymes.
Trypsinogen is the most abundant digestive proteasein the pancreas. Under physiologic conditions,
trypsinogen is synthesized and secreted by acinar cells,
transferred to the duodenum via the pancreatic ducts, and
then activated by enteropeptidase in the small intestine.1
There is substantial evidence that early intra-acinar2,3 or
luminal4,5 activation of trypsinogen to trypsin is a key and
common event in the development of acute and chronic
pancreatitis. Importantly, almost all forms of acute pan-
creatitis are due to autodigestion of the gland by pancre-
atic enzymes.6
Several studies have shown that trypsin stimulates en-
zyme secretion from acinar cells via proteinase-activated
receptor 2 (PAR-2),7,8 whereas the effect of trypsin on
pancreatic ductal epithelial cells (PDECs) is somewhat
controversial. Trypsin activates ion channels in dog
PDECs9 and stimulates bicarbonate secretion in the CA-
PAN-1 human pancreatic adenocarcinoma cell line,10
whereas it dose-dependently inhibits bicarbonate efflux
from bovine PDECs.11 The effect of trypsin differs not
only among species, but also with respect to the localiza-
tion of PAR-2. When PAR-2 is localized to the basolateral
membrane and activated by trypsin, the result is stimula-
tion of bicarbonate secretion.9,10 In contrast, when the
receptor is localized to the luminal membrane, the effect
is inhibition.11 Interestingly, there are no data available
concerning the effects of trypsin on guinea pig PDECs
which, in terms of bicarbonate secretion, are an excellent
model of human PDECs.12
The human pancreatic ductal epithelium secretes an
alkaline fluid that may contain up to 140 mmol/L
NaHCO3.12,13 The first step in HCO3" secretion is the
accumulation of HCO3" inside the cell, which is driven by
basolateral Na!/HCO3" cotransporters, Na!/H! exchang-
ers, and H!-adenosine triphosphatases.12,13 Only 2 trans-
porters have been identified on the apical membrane of
Abbreviations used in this paper: BAPTA-AM, 1,2-bis(o-aminophe-
noxy)ethane-N,N,N=,N=-tetraacetic acid; CFTR, cystic fibrosis transmem-
brane conductance regulator Cl! channel; CFTRinh-172, CFTR inhibitor-
172; [Ca2"]i, intracellular Ca2" concentration; H2DIDS, dihydro-4,4=-
diisothiocyanostilbene-2,2=-disulfonic acid; PAR-2, proteinase-activated
receptor-2; PAR-2-AP, PAR-2 activating peptide; PAR-2-ANT, PAR-2 an-
tagonist; PDEC, pancreatic ductal epithelial cell; pHi, intracellular pH;
pHL, luminal pH; SBTI, soybean trypsin inhibitor; SLC26, solute carrier
family 26.
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cells in the proximal ducts that are the major sites of
HCO3" secretion: cystic fibrosis transmembrane conduc-
tance regulator (CFTR) and the solute carrier family 26
(SLC26) anion exchangers.12,13 How these transporters act
in concert to produce a high HCO3" secretion is contro-
versial.14 Most likely, HCO3" is secreted through the an-
ion exchanger until the luminal concentration reaches
about 70 mmol/L, after which the additional HCO3"
required to raise the luminal concentration to 140
mmol/L is transported via CFTR.15,16
The role of PAR-2 in experimental acute pancreatitis is
also controversial and highly dependent on the model of
pancreatitis studied. PAR-2 was found to be protective
in secretagogue-induced pancreatitis in mice7,17–19 and
rats.20 However, PAR-2 is clearly harmful when pancreati-
tis is evoked by the clinically more relevant luminal ad-
ministration of bile salts in mice.17
In this study, we show for the first time that (1) PAR-2
is localized to the apical membrane of the human proxi-
mal PDECs, (2) the localization of PAR-2 in the guinea pig
pancreas is identical to that in the human gland, (3)
trypsin markedly reduces bicarbonate efflux through a
dihydro-4,4=-diisothiocyanostilbene-2,2=-disulfonic acid
(H2DIDS)-sensitive apical SLC26 anion exchanger and
strongly inhibits CFTR, (4) a decrease in pH within the
ductal lumen will strongly accelerate the autoactivation of
trypsinogen, and (5) trypsin down-regulates PAR-2 expres-
sion at both transcriptional and protein levels in PDECs
of patients with chronic pancreatitis.
Materials and Methods
A brief outline of the materials and methods is given in
the following text. For further details, please see Supplementary
Materials and Methods.
Solutions
The compositions of the solutions used for microfluo-
rimetry are shown in Table 1.
Isolation of Pancreatic Ducts and Individual
Ductal Cells
Small intralobular proximal ducts and individual ductal
cells were isolated from guinea pigs or PAR-2 wild-type (PAR-
2!/!) and knockout (PAR-2"/") mice with a C57BL6 back-
ground by microdissection as described previously.21
Measurement of Intracellular pH and Ca2"
Concentration
Intracellular pH (pHi) and calcium concentration ([Ca2!]i)
were estimated by microfluorimetry using the pH- and Ca2!-sensi-
tive fluorescent dyes 2,7-bis-(2-carboxyethyl)-5-(and-6-)carboxyfluo-
rescein, acetoxymethyl ester (BCECF-AM) and 2-(6-(bis(carboxy-
methyl)amino)-5-(2-(2-(bis(carboxymethyl)amino)-5-methylphenoxy)-
ethoxy)-2-benzofuranyl)-5-oxazolecarboxylic acetoxymethyl ester
(FURA 2-AM), respectively.
Microperfusion of Intact Pancreatic Ducts
The luminal perfusion of the cultured ducts was per-
formed as described previously.22
Electrophysiology
CFTR Cl" channel activity was investigated by whole cell
patch clamp recordings on guinea pig single pancreatic ductal
cells.
Measuring Autoactivation of Trypsinogen
Autoactivation of human cationic trypsinogen was de-
termined in vitro at pH values ranging from 6.0 to 8.5. Experi-
mental details are described in Supplementary Materials and
Methods.
Immunohistochemistry
Five guinea pig, 2 PAR-2!/!, 2 PAR-2"/", and 30 human
pancreata were studied to analyze the expression pattern of
PAR-2 protein. Relative optical densitometry was used to quan-
tify the protein changes in the histologic sections. Patients’ data
and the full methods are described in Supplementary Supple-
mentary Materials and Methods.
Real-Time Reverse-Transcription Polymerase
Chain Reaction
RNA was isolated from 30 human pancreata. Following
reverse transcription, messenger RNA (mRNA) expression of
PAR-2 and !-actin was determined by real-time polymerase
chain reaction analysis.
Results
Expression of PAR-2 in Guinea Pig and
Human Pancreata
PAR-2 was highly expressed in the luminal mem-
brane of small intralobular and interlobular ducts (Figure
1A [i]; cuboidal epithelial cells forming the proximal pan-
creatic ducts) but was almost undetectable in the larger
interlobular ducts (Figure 1A [ii]; columnar epithelial cells
forming the distal pancreatic ducts). The localization of
PAR-2 in the human pancreas was identical to that in the
guinea pig gland (Figure 1A [iv–vi]). Measurements of
relative optical density confirmed the significant differ-
ences between the expression of PAR-2 in small intralob-
ular and interlobular ducts and the larger interlobular
ducts in both species (Figure 1C).
Table 1. Composition of Solutions for Microfluorimetry
Studies
Standard Standard Cl"-free Ca2!-free
HEPES HCO3" HCO3" HEPES
NaCl 130 115 132
KCl 5 5 5
MgCl2 1 1 1
CaCl2 1 1
Sodium HEPES 10 10
Glucose 10 10 10 10
NaHCO3 25 25
Sodium gluconate 115
Magnesium gluconate 1
Calcium gluconate 6
Potassium sulfate 2.5
NOTE. Values are concentrations in mmol/L.
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Luminal Administration of PAR-2-AP and
Trypsin Induces Dose-Dependent [Ca2"]i
Signals
Because PAR-2 expression was detected only on the
luminal membrane of intralobular duct cells, we used the
microperfusion technique to see whether these receptors
can be activated by PAR-2 agonists. First, the experiments
were performed at pH 7.4 to understand the effects of
trypsin and PAR-2 under quasi-physiologic conditions
(Figure 2). The fluorescent images in Figure 2A clearly
show that luminal administration of PAR-2 activating
peptide (PAR-2-AP) increased [Ca2!]i in perfused pancre-
atic ducts. The [Ca2!]i response was dose dependent and
consisted of a peak in [Ca2!]i that decayed in the contin-
ued presence of the agonist, possibly reflecting PAR-2
inactivation or depletion of intracellular Ca2! stores (Fig-
ure 2B). Pretreatment of PDECs with 10 "mol/L PAR-2
antagonist (PAR-2-ANT) for 10 minutes completely
blocked the effects of 10 "mol/L PAR-2-AP on [Ca2!]i
(Figure 2A and C). Removal of extracellular Ca2! had no
effect on the increase in [Ca2!]i evoked by luminal admin-
istration of 10 "mol/L PAR-2-AP; however, preloading
ducts with the calcium chelator 1,2-bis(o-aminophe-
noxy)ethane-N,N,N=,N=-tetraacetic acid (BAPTA-AM) at 40
"mol/L totally blocked the response (Figure 2A and C).
Trypsin also induced a dose-dependent elevation in
[Ca2!]i similar to that evoked by PAR-2-AP (Figure 2E and
F). Addition of 5 "mol/L soybean trypsin inhibitor
(SBTI), 10 "mol/L PAR-2-ANT, and 40 "mol/L
BAPTA-AM totally blocked the increase in [Ca2!]i (Figure
2D and F). These data show that trypsin activates PAR-2
on the luminal membrane of the duct cell, which leads to
release of Ca2! from intracellular stores and an elevation
of [Ca2!]i.
Because the pH of pancreatic juice can vary between
approximately 6.8 and 8.0,23,24 we also evaluated the ef-
fects of trypsin and PAR-2-AP on [Ca2!]i at these pH
values (Supplementary Figures 1 and 2, respectively). The
Figure 1. Localization of PAR-2 on human and guinea pig pancreatic ducts. Light micrographs of (A [i–iii]) guinea pig and (A [iv–vi]) human pancreas
are shown. (i) PAR-2 is localized to the luminal membrane of PDECs in small intralobular and interlobular ducts (original magnification 400#). (ii) Large
interlobular ducts do not express PAR-2 (original magnification 200#). (iii) No primary antiserum (original magnification 200#). (iv and v) Sections from
human pancreas exhibit a similar localization of PAR-2 compared with the guinea pig gland (original magnification 400# and 200#). (vi) No primary
antiserum (original magnification 200#). (B) Western blot analysis was used to determine the specificity of the PAR-2 antibody. Polyclonal anti–PAR-2
showed a single 44-kilodalton band. (C) Quantitative measurement of relative optical densities (RO-Density) of small intralobular and interlobular
ducts (A.i,iv), and large interlobular ducts (A.ii,v) is shown. n$ 12. *P% .05 vs A.ii or A.v, respectively. Scale bar$ 50 "m for A (i, iv) and 100 "m for
A (ii and iii) and A (v and vi).
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elevations of [Ca2!]i at pH 6.8 and 8.0 were generally very
similar to the changes observed at pH 7.4. However, the
increases in [Ca2!]i evoked by 1 "mol/L PAR-2-AP and 0.1
"mol/L trypsin were significantly lower at pH 6.8 com-
pared with either pH 7.4 or 8.0 (Supplementary Figure 3).
Luminal Exposure to PAR-2-AP and Trypsin
Evokes Intracellular Alkalosis in PDECs
Figure 3 shows pHi recordings from microperfused
pancreatic ducts. Luminal application of the CFTR inhib-
itor (CFTRinh) 172 (10 "mol/L) and the anion exchanger
inhibitor H2DIDS (500 "mol/L) induced intracellular al-
kalization in PDECs (Figure 3A [i]). These data indicate
that when bicarbonate efflux across the luminal mem-
brane of PDECs (ie, bicarbonate secretion) is blocked,
elevation of duct cell pHi occurs, presumably because the
basolateral transporters continue to move bicarbonate
ions into the duct cell. Note also that the increase in pHi
evoked by the inhibitors is not sustained and begins to
reverse before the inhibitors are withdrawn (Figure 3A [i]),
which might be explained by the regulation of pHi by
basolateral acid/base transporters.
Both luminal PAR-2-AP and trypsin induced a dose-depen-
dent elevation of pHi (Figure 3A [ii and iii]), suggesting that
activation of PAR-2 inhibits bicarbonate efflux across the apical
membrane of the duct cell. Preincubation of PDECswith either
10 "mol/L PAR-2-ANT or 5 "mol/L SBTI or 40 "mol/L
BAPTA-AM for 30 minutes totally blocked the effect of trypsin
on pHi (Figure 3A [iv]). The inhibitory effect of the calcium
chelator BAPTA-AM suggests that the actions of trypsin and
PAR-2-AP on pHi are mediated by the increase in [Ca2!]i that
they evoke (Figure 2). Therefore, in this case, the transient
nature of the pHi response may reflect the transient effect that
PAR-2 activators have on [Ca2!]i (Figure 2B and E), as well as
pHi regulation by basolateral acid/base transporters.
Next we tested the effects of trypsin on pHi in Cl"-free
conditions and during pharmacologic inhibition of the
Figure 2. Effects of PAR-2-AP and trypsin on [Ca2!]i in microperfused guinea pig pancreatic ducts at pH 7.4. (A) Light (1) and fluorescent ratio
images (2 and 3) of microperfused pancreatic ducts showing the effects of luminal administration of 10 "mol/L PAR-2-AP, 10 "mol/L PAR-2-ANT,
or 40 "mol/L BAPTA-AM on [Ca2!]i. Images were taken before (1 and 2) and after (3) exposure of the ducts to PAR-2-AP or trypsin. (B and C)
Representative experimental traces and summary data of the changes in [Ca2!]i. (D) The same protocol was used to evaluate the effects of trypsin.
Addition of 5 "mol/L SBTI was used to inhibit trypsin activity. (E and F) Representative experimental traces and summary data of the changes in
[Ca2!]i. n $ 5 for all groups. *P % .05 vs 1 "mol/L PAR-2-AP or 0.1 "mol/L trypsin, respectively. **P % .001 vs 10 "mol/L PAR-2-AP or 10 "mol/L
trypsin, respectively.
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Figure 3. Effects of PAR-2-AP and trypsin on pHi in microperfused guinea pig pancreatic ducts. (A) Representative pHi traces showing the effects
of luminal administration of different agents in microperfused pancreatic ducts. (i) A total of 10 "mol/L CFTRinh-172 and/or 500 "mol/L H2DIDS
caused alkalization of pHi. (ii) PAR-2-AP and (iii) trypsin induced a dose-dependent pHi elevation. (iv) Preincubation of ductal cells with 10 "mol/L
PAR-2-ANT or 5 "mol/L SBTI or 40 "mol/L BAPTA-AM totally blocked the alkalization caused by 10 "mol/L trypsin. (v) Removal of luminal Cl" or
(vi) administration of H2DIDS (500 "mol/L) decreased, but did not totally abolish, the effects of 10 "mol/L trypsin on pHi. (vii) Pretreatment with 10
"mol/L CFTRinh-172 also decreased the effects of trypsin (10"mol/L) on pHi. (viii) Simultaneous administration of H2DIDS andCFTRinh-172 strongly
inhibited the effect of 10 "mol/L trypsin. (B and C) Summary of the effects of PAR-2-AP and trypsin on changes in pHi. &pHmax was calculated from
the experiments shown in A. (D) Effects of Cl"-free conditions. Cl"-free conditions, H2DIDS, CFTRinh-172, and a combination of the inhibitors all
induced an intracellular alkalosis. Trypsin further increased the alkalinization of pHi, although the effect wasmarkedly reduced when both H2DIDS and
CFTRinh-172 were present. n $ 4–5 for all groups. (B) *P % .05 vs 0.1 "mol/L trypsin; **P % .001 vs 10 "mol/L trypsin. (C) *P % .05 vs 0.1 "mol/L
PAR-2-AP; **P % .001 vs 10 "mol/L PAR-2-AP. (D) *P % .05 vs the respective filled column.
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luminal anion exchangers and/or CFTR (Figure 3A [v–
viii]). Luminal Cl"-free conditions increased the pHi of
PDECs, presumably by driving HCO3" influx on the api-
cal anion exchangers (Figure 3A [v]). Note that luminal
administration of trypsin further elevated pHi in Cl"-free
conditions (Figure 3A [v]) and also in the presence of
H2DIDS (Figure 3A [vi]) and CFTRinh-172 (Figure 3A
[vii]). However, pretreatment of ducts with a combination
of H2DIDS and CFTRinh-172 markedly reduced the effect
of trypsin on pHi (Figure 3A [viii]).
Figure 3B–D is a summary of the pHi experiments.
Trypsin (Figure 3B) and PAR-2-AP (Figure 3C) both in-
duced statistically significant, dose-dependent increases in
pHi and these effects were blocked by PAR-2-ANT, SBTI,
and BAPTA-AM. Exposure of the ducts to luminal Cl"-
free conditions, H2DIDS, CFTRinh-172, or a combination
of the inhibitors also induced an intracellular alkalosis
(Figure 3D). Also shown in Figure 3D is the additional,
statistically significant increase in pHi caused by trypsin in
ducts exposed to Cl"-free conditions and the individual
inhibitors. However, when ducts were exposed to both
CFTRinh-172 and H2DIDS simultaneously, the effect of
trypsin on pHi was markedly reduced, although it re-
mained statistically significant (Figure 3D). We interpret
these results as indicating that trypsin inhibits both
Cl"-dependent (ie, anion exchanger mediated; revealed
when CFTR is blocked by CFTRinh-172) and Cl"-inde-
pendent (ie, CFTR mediated; revealed in Cl"-free con-
ditions and when the luminal exchangers are blocked
by H2DIDS) bicarbonate secretory mechanisms in
PDECs. Reduced bicarbonate secretion will lead to a
decrease in intraductal pH.
Trypsin and PAR-2-AP Inhibit CFTR
Exposure of guinea pig PDECs to 5 "mol/L fors-
kolin, which elevates intracellular adenosine 3=5=-cyclic
monophosphate levels, increased basal whole cell currents
(Figure 4A–D [i]) from 8.9 ' 2.3 to 91.2 ' 13.5 pA/pF
(Figure 4A–D [ii]) at !60 mV in 78% of cells (38/49). The
forskolin-activated currents were time- and voltage-inde-
pendent, with a near linear I/V relationship and a reversal
potential of "5.15 ' 1.12 mV (Figure 4A–D [iv]). These
biophysical characteristics indicate that the currents are
carried by CFTR.
Exposure of PDECs to 10 "mol/L trypsin did not affect
the basal currents; however, administration of either 10
"mol/L PAR-2-AP (Figure 4A [iii]) or 10 "mol/L trypsin
(Figure 4B [iii]) inhibited forskolin-stimulated CFTR cur-
rents by 51.7% ' 10.5% and 57.4% ' 4.0%, respectively. In
both cases, the inhibition was voltage independent and
irreversible. Pretreatment with either SBTI (10 "mol/L;
Figure 4C [iii]) or PAR-2-ANT (10 "mol/L; Figure 4D [iii])
completely prevented the inhibitory effect of trypsin on
the forskolin-stimulated CFTR currents. Figure 4E is a
summary of these data, which suggest that trypsin inhib-
its CFTR Cl" currents by activation of PAR-2.
Autoactivation of Trypsinogen Is pH
Dependent
Trypsinogen can undergo autocatalytic activation
during which trace amounts of trypsin are generated,
which, in turn, can further activate trypsinogen in a self-
amplifying reaction. Human trypsinogens are particularly
prone to autoactivation, and mutations that facilitate
autoactivation are associated with hereditary pancreatitis.
To assess the effect of a decrease in intraductal pH (caused
by reduced bicarbonate secretion) on trypsinogen activa-
tion, we measured autoactivation of human cationic
trypsinogen in vitro at pH values ranging from 6.0 to 8.5
using a mixture of various buffers. As shown in Figure 5A,
the rate at which cationic trypsinogen autoactivates was
markedly increased as the pH was reduced from 8.5 to 7.0
when the buffer solution contained 1 mmol/L CaCl2 and
no NaCl. However, a further reduction in pH, from 7.0 to
6.0, had little effect (Figure 5A [i]).
To rule out that the differences observed in autoacti-
vation were due to the different ionic strengths of the
buffers used, we repeated the experiments in the presence
of a higher concentration of sodium (100 mmol/L NaCl,
Figure 5A [ii]) or lower concentration of calcium (0.1
mmol/L CaCl2, Figure 5A [iii]). Although the overall au-
toactivation rates were much slower in the presence of
NaCl, the pH profile of autoactivation was essentially
identical to that observed in the absence of added salt
(Figure 5A [ii]). Also, pH-dependent changes in the auto-
activation of trypsinogen were still detectable when the
experiments were performed using a low calcium buffer
(Figure 5A [iii]).
PAR-2 Is Down-regulated in Patients With
Chronic Pancreatitis
It has been documented that there is activated
trypsin in the pancreatic ductal lumen in chronic pancre-
atitis in humans.25–28 If trypsin activity is elevated in the
duct lumen, PAR-2 down-regulation should occur, which
could be due to either (1) changes in PAR-2 mRNA tran-
scription and/or (2) receptor internalization and translo-
cation to the cytoplasm. Our data show a marked
reduction in membranous PAR-2 protein level but no
significant changes in cytoplasmic PAR-2 protein in
chronic pancreatitis (Figure 5B [i–iv] and C). Furthermore,
PAR-2 mRNA expression was markedly reduced in
chronic pancreatitis (Figure 5D), suggesting that reduced
PAR-2 mRNA transcription may cause PAR-2 down-regu-
lation in chronic pancreatitis.
Luminal Exposure to R122H Mutant Cationic
Trypsin Induces Elevation of [Ca2"]i and
Evokes Alkalosis in PDECs
It has been shown that mutations in cationic
trypsinogen increase the risk of chronic pancreatitis, most
likely because of the enhanced autoactivation exhibited
by the mutant trypsinogens.29 Here we tested whether
the commonest mutation in cationic trypsin, R122H, af-
fected the ability of the protease to interact with PAR-2.
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Figure 6A and B shows that 1 "m of R122H human
cationic trypsin causes comparable changes in pHi and
[Ca2!]i to 0.4 "mol/L wild-type bovine trypsin, suggesting
that a trypsin-mediated inhibition of bicarbonate secre-
tion could play a role in the pathogenesis of hereditary as
well as chronic pancreatitis.
Activation of PAR-2 Is Diminished in
PAR-2!/! Mice
Finally, we investigated the effects of both PAR-
2-AP and trypsin on PDECs isolated from PAR-2!/! and
PAR-2"/" mice (Figure 6C–E). First we confirmed using
Figure 4. Effects of trypsin and PAR-2-AP on CFTR Cl" currents of guinea pig pancreatic duct cells. Representative fast whole cell current
recordings from PDECs. (A–D) (i) Unstimulated currents, (ii) currents after stimulation with 5 "mol/L forskolin, and (iii) currents following 3-minute
exposure to (A) 10"mol/L PAR-2-AP, (B) 10 "mol/L trypsin, (C) 10 "mol/L trypsin/5 "mol/L SBTI, and (D) 10 "mol/L trypsin/10 "mol/L PAR-2-ANT.
(iv) I/V relationships. Diamonds represent unstimulated currents, squares represent forskolin-stimulated currents, and triangles represent forskolin-
stimulated currents in the presence of the tested agents (see previous text). (E) Summary of the current density (pA/pF) data obtained from A–D
measured at Erev' 60 mV. Exposing PDECs to either PAR-2-AP or trypsin blocked the forskolin-stimulated CFTR Cl" currents, while administration
of SBTI or PAR-2-ANT prevented the inhibitory effect of trypsin. n$ 6 for all groups. *P% .05 vs the unstimulated cells, **P% .05 vs forskolin. FORSK,
forskolin; TRYP, trypsin.
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immunohistochemistry that PAR-2!/! mice do, whereas
PAR-2"/" mice do not, express PAR-2 in their PDECs
(Figure 6C [i and iii]). Accordingly, our functional data
clearly show that the pHi and [Ca2!]i responses to luminal
administration of either trypsin or PAR-2-AP were mark-
edly diminished in PAR-2"/" PDECs (Figure 6D and E).
Discussion
The human pancreatic ductal epithelium secretes 1
to 2 L of alkaline fluid every 24 hours that may contain up
to 140 mmol/L NaHCO3.12,13 The physiologic function of
this alkaline secretion is to wash digestive enzymes down
the ductal tree and into the duodenum and to neutralize
acidic chyme entering the duodenum from the stomach.
There are important lines of evidence supporting the idea
that pancreatic ducts play a role in the pathogenesis of
pancreatitis: (1) ductal fluid and bicarbonate secretion are
compromised in acute and chronic pancreatitis,30,31 (2)
one of the main end points of chronic pancreatitis is the
destruction of the ductal system,32,33 (3) mutations in
CFTR may increase the risk of pancreatitis,30,31,34–36 and
(4) etiologic factors for pancreatitis, such as bile acids or
ethanol in high concentration, inhibit pancreatic ductal
bicarbonate secretion.37–39 Despite the previously men-
Figure 5. The effects of pH on trypsinogen activation and analyses of PAR-2 expression in human pancreatic samples. The autoactivation of human
cationic trypsinogen was determined in vitro at pH values ranging from 6.0 to 8.5. (A) (i) Trypsinogen at 2 "mol/L concentration was incubated with
40 nmol/L trypsin at 37oC in 0.1 mol/L Tris ! HEPES ! 2-(N-morpholino)ethanesulfonic acid2-(N-morpholino)ethanesulfonic acid buffer mixture
containing 1 mmol/L CaCl2. (ii) The same protocol was used in high (100 mmol/L) NaCl buffer solution. Autoactivation of cationic trypsinogen
significantly increased as the pH was reduced from 8.5 to 6.0. (iii) The same protocol was used in low (0.1 mmol/L) Ca2!-buffered solution buffer
solution. (B) (i–iv) PAR-2 expression. (i) Representative section of normal human pancreas. (ii) No primary antiserum. (iii) Representative section of
human pancreas from a patient with chronic pancreatitis (CP). (iv) No primary antiserum. (C) Relative optical density. n $ 15. *P % .05 vs CP
membrane. (D) Real-time reverse-transcription polymerase chain reaction analysis of PAR-2 mRNA expression of human pancreas. Data are given
in 2^dCT. n $ 15. *P % .05 vs CP.
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tioned data, the role of PDECs in the development of
pancreatitis has received relatively little attention.40
There are important species differences regarding the
localization of PAR-2 in pancreatic ducts and in the effect
of its activation on bicarbonate secretion. For example,
CAPAN-1 cells10 and dog PDECs9 express PAR-2 only on
the basolateral membrane, whereas bovine PDECs express
PAR-2 on the luminal membrane.11 Therefore, one of our
Figure 6. Experiments using R122H human
mutant cationic trypsin and PAR-2"/" mice.
Representative (A) pHi and (B) [Ca2!]i mea-
surements using luminal administration of
normal and R122H mutant cationic trypsin in
microperfused guinea pig pancreatic ducts.
n $ 5 for all experiments. (C) (i–iv) PAR-2–
expressing cells were visualized by immuno-
histochemistry as described in Figure 1. (i)
Representative section of the pancreas re-
moved from PAR-2!/!mice. (ii) Section with-
out primary antiserum. (iii) Pancreas removed
from PAR-2"/" mice. (iv) Section without pri-
mary antiserum. (D) pHi and (E) [Ca2!]i mea-
surements using luminal administration of
trypsin in microperfused pancreatic ducts
isolated from PAR-2 knockout (red curve)
and PAR-2 wild-type mice (black curve). n $
5 for all experiments. *P % .05 vs 10 "mol/L
trypsin PAR-2!/!, **P % .05 vs 10 "mol/L
PAR-2-AP PAR-2!/!.
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first aims was to determine which animal model best
mimics human PAR-2 expression and thus would be the
best for studying the effects of trypsin on PDEC function.
Our results showed that in the human pancreas PAR-2 is
localized to the luminal membrane of small proximal
pancreatic ducts, which are probably the major site of
bicarbonate and fluid secretion. Because CAPAN-1 cells
and dog PDECs express PAR-2 only on the basolateral
membrane, they do not mimic the human situation. Rats
or mice are also not good models for the human gland
because they secrete only 70 to 80 mmol/L bicarbon-
ate.41,42 However, the guinea pig pancreas secretes (140
mmol/L bicarbonate, as does the human gland, and the
regulation of bicarbonate secretion is similar in both
species.41,42 Because PAR-2 expression in the guinea pig
pancreas was localized to the luminal membrane of duct
cells, we performed our experiments on isolated guinea
pig ducts.
First we characterized the effects of PAR-2 activation by
trypsin and PAR-2-AP on PDECs. Previously, it has been
shown that activation of the G protein–coupled PAR-2 by
proteinases requires proteolytic cleavage of the receptor,
which is followed by an elevation of [Ca2!]i.43–45 As ex-
pected, luminal trypsin and PAR2-AP caused a dose-de-
pendent elevation of [Ca2!]i in guinea pig ducts. Impor-
tantly, the trypsin inhibitor SBTI, PAR-2-ANT, and the
intracellular calcium chelator BAPTA-AM all completely
blocked the elevation of [Ca2!]i, whereas removal of ex-
tracellular Ca2! had no effect. Acidosis (pH 6.8) also
slightly reduced the changes in [Ca2!]i evoked by trypsin,
most probably due to reduced cleavage activity of trypsin
at an acidic pH. Next we characterized the effects of PAR-2
activation on pHi. Luminal application of trypsin and
PAR-2-AP both caused a dose-dependent intracellular al-
kalosis in PDECs. This alkalosis is most likely explained
either by a reduction in the rate of bicarbonate efflux (ie,
secretion) across the apical membrane of PDECs or by an
increase in the rate of bicarbonate influx at the basolateral
side of the cell. We favor the former explanation because
luminal application of the anion exchange inhibitor
H2DIDS or the CFTR inhibitor CFTRinh-172 produced a
similar intracellular alkalization.22,46 Thus, PAR-2 activa-
tion inhibits bicarbonate secretion in PDECs by inhibit-
ing SLC26 anion exchangers and CFTR Cl" channels
expressed on the apical membrane of the duct cell. In
similarity with the [Ca2!]i signals, the effect of PAR-2
activation on pHi was blocked by SBTI, PAR-2-ANT, and
BAPTA-AM, with the action of BAPTA-AM suggesting
that the inhibition of bicarbonate secretion follows from
the increase in [Ca2!]i. Interestingly, an elevation of
[Ca2!]i is crucial for both stimulatory (eg, acetylcholine,13
low concentrations of bile acids,39 and ethanol38) and
inhibitory pathways (eg, basolateral adenosine triphos-
phate, arginine vasopressin, and high concentrations of
ethanol) that control bicarbonate secretion by PDECs.
Such marked differences in the outcome of [Ca2!]i signals
in PDECs probably reflect differences in the source of
Ca2! and/or in the intracellular compartmentalization of
[Ca2!]i signals generated by different secretory agonists
and antagonists.
Remarkably, trypsin was still able to evoke an elevation
of pHi when Cl" was removed from the duct lumen and
when PDECs were pretreated with H2DIDS, conditions
that should inhibit bicarbonate efflux on the exchanger.
These results suggested the involvement of CFTR, the
only other known bicarbonate efflux pathway on the api-
cal membrane, in the inhibitory effect of trypsin. This
hypothesis was confirmed by patch clamp experiments in
which trypsin decreased CFTR whole cell currents in iso-
lated guinea pig PDECs by 50% to 60%. Finally, the fact
that the trypsin-induced alkalinization was completely
blocked by a combination of CFTRinh-172 and H2DIDS
confirms the involvement of both CFTR and SLC26 anion
exchangers. Our conclusion from these pHi and patch
clamp data is that PAR-2 activation inhibits both the
SLC26 anion exchanger (probably SLC26A6 [PAT-1]47 be-
cause SLC26A3 [DRA] is only weakly inhibited by disul-
fonic stilbenes47,48) and CFTR Cl" channels expressed on
the apical membrane of the duct cell.
The pH of pancreatic juice (and therefore the luminal
pH [pHL] in the duct) can vary between approximately 6.8
and 8.0. It has recently been shown that protons core-
leased during exocytosis cause significant acidosis (up to 1
pH unit) in the lumen of the acini.23 However, Ishiguro et
al49 have clearly shown that the pHL in pancreatic ducts is
dependent on the level of bicarbonate secretion. pHL can
be elevated from 7.2 to 8.5 by stimulation with secretin or
forskolin, and this effect was strictly dependent on the
presence of bicarbonate.24,49,50 Also, inhibition of ductal
bicarbonate secretion with H2DIDS can decrease the pHL
to less than 8.0.49 In view of these results, we tested
whether trypsinogen autoactivation was affected by pH
over the range of 6.0 to 8.5. Autoactivation of trypsinogen
was relatively slow at pH 8.5, but decreasing the pH from
8.5 to 7 progressively stimulated autoactivation. These
results suggest that under physiologic conditions bicar-
bonate secretion by PDECs is not only important for
elevating the pH in the duodenum, but also for keeping
pancreatic enzymes in an inactive state in the ductal
system of the gland.
Receptor down-regulation is a phenomenon that occurs
in the continued presence of an agonist and leads to a
reduction in the sensitivity of the cell to the agonist.
Potentially, there are 2 mechanisms that could underlie
receptor down-regulation of PAR-2: (1) after proteolytic
activation, the PAR-2 is internalized by a clathrin-medi-
ated mechanism and then targeted to lysosomes45 and (2)
if trypsin is present for a longer time in the lumen, PAR-2
may be down-regulated at the transcriptional level. In this
study, we provide evidence that the second mechanism,
transcriptional down-regulation, explains the reduced ex-
pression of PAR-2 seen in chronic pancreatitis.
Conflicting data can be found in the literature concern-
ing the role of PAR-2 in acute pancreatitis. Singh et al7
showed that in secretagogue-induced experimental pan-
creatitis, PAR-2 deletion is associated with a more severe
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pancreatitis. Although Laukkarinen et al17 confirmed
these results in cerulein-induced pancreatitis, they also
clearly showed that in taurocholate-induced pancreatitis,
PAR-2 deletion markedly reduced the severity of the dis-
ease. There is no evidence to suggest that clinical pancreatitis
is evoked by supramaximal secretagogue stimulation; how-
ever, the taurocholate-induced pancreatitis model may
mimic the clinical situation. Therefore, Laukkarinen et al17
speculated that PAR-2 activation promotes the worsening of
clinical pancreatitis and our data are consistent with that
hypothesis.
Besides the clear pathophysiologic role of the tryp-
sin/PAR-2 interaction in chronic pancreatitis, there is
still a debate as to why PAR-2 are localized to the
luminal membrane of PDEC in small ducts close to the
acinar cells. What could the physiologic role of this
PAR-2 be? A number of agents have been shown to have
dual effects on PDECs at different concentrations. For
example, bile acids in low concentrations stimulate but
in high concentrations inhibit bicarbonate secretion.39
The same applies to ethanol.38 Under physiologic con-
ditions, trypsin inhibitors are coreleased from acinar
cells with trypsinogen and should block the activity of
any trypsin that is generated spontaneously. Therefore,
only very small amounts of active trypsin, if any, will be
present in the duct lumen under normal conditions.
However, there remains a possibility that very small
amounts of active trypsin (ie, concentrations less than
0.1 "mol/L that would not cause an elevation of [Ca2!]i
or change in pH) could bind to PAR-2 on the luminal
membrane of the ducts and augment other stimulatory
mechanisms so as to enhance flushing of digestive
enzymes down the ductal tree.
In conclusion, we suggest for the first time that one of
the physiologic roles of bicarbonate secretion by PDECs is
to curtail trypsinogen autoactivation within the pancre-
atic ductal system. However, if trypsin is present in the
duct lumen (as may occur during the early stages of
pancreatitis due to leakage from acinar cells), PAR-2 on
the duct cell will be activated, leading to Ca2! release from
intracellular stores and an increase in cytosolic Ca2! con-
centration. This causes inhibition of the luminal anion
exchangers and CFTR Cl" channels, reducing bicarbonate
secretion by the duct cell. The decrease in bicarbonate
secretion will increase the transit time of zymogens down
the duct tree and decrease pHL, both of which will pro-
mote the autoactivation of trypsinogen. The trypsin so
formed will further inhibit bicarbonate transport, leading
to a vicious cycle generating further decreases in pHL and
enhanced trypsinogen activation, which will favor devel-
opment of the pancreatitis (Supplementary Figure 4).
Finally, the R122H mutant cationic trypsin also elevated
[Ca2!]i and pHi in duct cells, suggesting that this mech-
anism may be particularly important in hereditary pan-
creatitis in which the mutant trypsinogens more readily
autoactivate.29
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2011.08.039.
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Supplementary Materials and Methods
Ethics
All experiments were conducted in compliance
with the Guide for the Care and Use of Laboratory
Animals (USA NIH publication No 85-23, revised 1985).
Animal experiments were approved by the Regional Eth-
ical Board at the University of Szeged, Hungary.
Solutions and Chemicals
HEPES-buffered solutions were gassed with 100%
O2, and their pH was set to 7.4 with HCl at 37oC. HCO3"-
buffered solutions were gassed with 95% O2/5% CO2 to set
pH to 7.4 at 37oC. For patch clamp studies, the standard
extracellular solution contained (in mmol/L): 145 NaCl,
4.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 5 glucose (pH
7.4 adjusted with NaOH). The osmolarity of the extra-
cellular solution was 300 mOsm/L. The standard pipette
solution for the patch clamp experiments contained (in
mmol/L): 120 CsCl, 2 MgCl2, 0.2 ethylene glycol-bis(!-
aminoethyl ether)-N,N,N=,N=-tetraacetic acid (EGTA), 10
HEPES, and 1 Na2ATP (pH 7.2 adjusted with NaOH).
Chromatographically pure collagenase was purchased
from Worthington (Lakewood, NJ). 2,7-Bis-(2-carboxy-
ethyl)-5-(and-6-)carboxyfluorescein, acetoxymethyl ester
(BCECF-AM), 2-(6-(bis(carboxymethyl)amino)-5-(2-(2-
(bis(carboxymethyl)amino)-5-methylphenoxy)ethoxy)-2-
benzofuranyl)-5-oxazolecarboxylic acetoxymethyl ester
(FURA 2-AM), dihydro-4,4=-diisothiocyanostilbene-
2,2=-disulfonic acid (H2DIDS), and 1,2-bis(o-amino-
phenoxy)ethane- N,N,N=,N=-tetraacetic acid (BAPTA-
AM) were from Invitrogen (Carlsbad, CA). PAR-2-ANT
(H-Phe-Ser-Leu-Leu-Arg-Tyr-NH2) and PAR-2-AP (H-
Ser-Leu-Ile-Gly-Arg-Leu-amid trifluoroacetate salt)
were from Peptides International (Louisville, KY). For-
skolin were from Tocris (Ellisville, MO). Rabbit PAR-2
polyclonal antibody was purchased from Santa Cruz
Biotechnology (Heidelberg, Germany). All other chem-
icals were obtained from Sigma-Aldrich (Budapest,
Hungary).
Isolation of Pancreatic Ducts and Individual
Ductal Cells
Male guinea pigs weighing between 150 and 250 g
or mice (PAR-2!/! and PAR-2"/") weighing between 18
and 21 g were humanely killed by cervical dislocation, the
pancreas was removed, and small intralobular proximal
ducts were isolated by microdissection as described pre-
viously.1 PAR-2"/" mice (B6.Cg-F2rl1tm1Mslb/J) were previ-
ously generated by Schmidlin et al1 and a kind gift from
Ashok Saluja.2 Isolated ducts were then cultured over-
night in a 37oC incubator gassed with 5% CO2/95% air.3
To obtain single pancreatic ductal cells, cultured ducts
were incubated for 50 minutes at 37°C in 50 U/mL
elastase dissolved in storage solution (Dulbecco’s modi-
fied Eagle medium containing 3% [wt/vol] bovine serum
albumin [pH 7.4 with NaOH]). Then the ducts were
transferred to a Ca2!/Mg2!-free HEPES-buffered solu-
tion and incubated for a further 10 minutes at 37°C.
After the incubation, the ducts were transferred to a
coverslip and teased apart using stainless steel needles.
The individual ductal cells were used for experiments
within 3 to 4 hours after isolation.
Measurement of pHi and Ca2" Concentration
Ducts were bathed in standard HEPES solution
and loaded with BCECF-AM (2 "mol/L) or FURA 2-AM
(5 "mol/L) for 30 to 60 minutes at room temperature.
Ducts were then transferred to a perfusion chamber
mounted on an IX71 inverted microscope (Olympus,
Budapest, Hungary) and perfused continuously with so-
lutions at 37oC both from the luminal and basolateral
side at a rate of 10 to 30 "L/min and 4 to 5 mL/min,
respectively. Four to 5 small areas (region of interests) of
5 to 10 cells in each intact duct were excited with light at
a given wavelength. Excitation of BCECF was at 495 and
440 nm, with emitted light monitored at 535 nm. Exci-
tation of FURA-2 was at 380 and 340 nm, with emitted
light monitored at 510 nm. The fluorescence emissions
were captured by a charge-coupled device camera and
digitized by a Cell imaging system (Olympus, Budapest,
Hungary). Ratio images were collected at 1-second inter-
vals. In situ calibration of pHi measured with BCECF was
performed using the high K!-nigericin technique.4,5
Electrophysiology
Guinea pig PDECs were isolated by an enzymatic
microdissection procedure as described previously. Using
a glass pipette, a few drops of cell suspension were placed
within a perfusion chamber mounted on the stage of an
inverted microscope (TMS; Nikon, Tokyo, Japan). The
ductal cells were allowed to settle and attach to
the bottom of the chamber for at least 30 minutes before
the perfusion was started.
Patch clamp micropipettes were fabricated from boro-
silicate glass capillaries (Clark, Reading, England) by us-
ing a P-97 Flaming/Brown micropipette puller (Sutter
Co, Novato, CA). These pipettes had resistances between
1.5 and 2.5 M). Membrane currents were recorded with
an Axopatch 1D amplifier (Axon Instruments, Union
City, CA) using the whole cell configuration of the patch
clamp technique at 37oC. After establishing a high-resis-
tance seal (1–10 G)) by gentle suction, the cell mem-
brane beneath the tip of the pipette was disrupted by
suction or by application of short electrical pulses. The
series resistance was typically 4 to 8 M) before compen-
sation (50%–80%, depending on the voltage protocol).
Current-voltage (I/V) relationships were obtained by
holding Vm at 0 mV and clamping to '100 mV in 20-mV
increments. Membrane currents were digitized by using a
333-kHz analog-to-digital converter (Digidata 1200;
Axon Instruments) under software control (pClamp 6;
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Axon Instruments). Analyses were performed by using
pClamp 6 software after low-pass filtering at 1 kHz.
Expression and Purification of Human
Trypsinogens
Wild-type and R122H mutant human cationic
trypsinogen was expressed in Escherichia coli and purified
by ecotin-affinity chromatography as reported previ-
ously.6
Measuring Autoactivation of Trypsinogen
Autoactivation of trypsinogen was measured at 2
"mol/L concentration at 37oC in a polybuffer system
(American Bioanalytical Inc, Natick, MA) containing 100
mmol/L 2-(N-morpholino)ethanesulfonic acid, 100
mmol/L HEPES, and 100 mmol/L Tris in 100 "L final
volume. The pH of the Polybuffer was adjusted to given
values with HCl (pH 6.0 and 6.5) or NaOH (pH 7.0, 7.5,
8.0, and 8.5). Reactions also contained 1 mmol/L or 0.1
mmol/L CaCl2 and 100 mmol/L NaCl, as indicated. At
given times, 2-"L aliquots were removed and trypsin
activity was determined using the N-CBZ-Gly-Pro-Arg-p-
nitroanilide substrate at 150 "mol/L final concentration.
Immunohistochemistry
Pancreatic tissue from 5 guinea pigs, 15 patient
samples without pancreatic disease near neuroendocrine
tumors (average age, 59.5; female/male, 7:8), and 15 pa-
tients (average age, 56.6; female/male, 4:11) who had
chronic pancreatitis (13 alcohol, 2 gallstone) were inves-
tigated. The human samples were obtained with the per-
mission of the Regional Ethical Committee of Semmel-
weis University (#172/2003).
The pancreatic tissues were fixed in 10% neutral buff-
ered formalin for 24 hours, followed by paraffin embed-
ding, and were then cut and stained with H&E to estab-
lish the diagnosis. Paraffin-embedded, 3- to 4-"m-thick
sections were used for immunohistochemistry to detect
PAR-2 expression. The slides were treated for 30 minutes
with target retrieval solution (Dako, Glostrup, Denmark)
in a microwave oven, followed by incubation with the
primary rabbit polyclonal antibody (Santa Cruz Biotech-
nology Inc, Heidelberg, Germany) in 1:100 dilution over-
night at 4°C. Signal detection was achieved by using
ImPRESS reagent with secondary anti-rabbit immuno-
globulin G antibody (20 minutes) (Vector Laboratories,
Burlingame, CA). Diaminobenzidine was used to visual-
ize immune complexes, and nuclear counterstaining was
performed with hematoxylin. For negative controls, the
appropriate antibody was omitted and either the anti-
body diluent alone or isotype-matched immunoglobulin
G serum was used. The negative controls exhibited no
signal. Normal skin epithelial cells were used as positive
controls to confirm correct immunohistochemical stain-
ing for PAR-2 (results not shown).
The immunohistochemical reactions were digitalized
with a Mirax MIDI slide scanner (3DHistech Ltd, Buda-
pest, Hungary). Relative optical (RO) density was calcu-
lated using ImageJ program (National Institutes of
Health, Bethesda, MD). Pixel values (PV) were normalized
to erythrocyte density (PVNorm $ PVMeasured – PVErythrocyte)
in all sections. RO-Density value was calculated from the
RO-Density$ log10(255/PVNorm) equation, assuming that
the brightest value in the image equals 255.
Western blot analysis was used to determine the spec-
ificity of the PAR-2 antibody. Proteins were extracted
from fresh-frozen guinea pig (n $ 3) and human (n $ 3)
pancreatic tissue stored at "80°C. Isolation was per-
formed by using lysis buffer (20 mmol/L Tris, pH 7.5, 150
mmol/L NaCl, 2 mmol/L EDTA, 1% Triton X-100 con-
taining protease inhibitor complex [Sigma Aldrich Co,
Budapest, Hungary]). Samples (50 mg) were homoge-
nized, followed by centrifugation at 13,200 rpm at 4°C
for 5 minutes. Measurements of protein concentration
were performed using Bradford analysis.7 A total of 30 "g
of protein samples were loaded in each lane, run on 10%
sodium dodecyl sulfate/polyacrylamide electrophoresis
at 200 V for 35 minutes, and then transferred to nitro-
cellulose membranes at 100 V, 4°C, for 75 minutes. For
aspecific protein blocking, nonfat dry milk (5%, phos-
phate-buffered saline) was used for 30 minutes. Blots
were incubated with polyclonal PAR-2 rabbit antibody
(1:300; Santa Cruz Biotechnology Inc, Heidelberg, Ger-
many) and anti-GAPDH antibody (1:5000; AbDSerotec,
Kidlington, England) at 4°C overnight. After washing in
0.1% Tris, the secondary antibodies as anti-mouse
GAPDH (1:2000; AbDSerotec, Düsseldorf, Germany) and
horseradish peroxidase–conjugated anti-rabbit antibody
(1:2000, Dako Cytomation, Ghostrup, Denmark) were
applied at room temperature for 90 minutes. Following 3
series of washings in Tris-buffered saline with Tween 20,
signals were visualized by enhanced chemiluminescent
detection.
Real-Time Reverse-Transcription Polymerase
Chain Reaction
RNA extraction. Fifteen formalin-fixed, paraffin-
embedded normal pancreatic tissue samples and 15 sam-
ples of chronic pancreatitis tissue were selected for real-
time reverse-transcription polymerase chain reaction
analysis. Total RNA was isolated from five 5- to 10-"m
macrodissected sections (connective tissue excluded) using
RNeasy FFPE Kit (Qiagen, Hilden, Germany) in accordance
with the manufacturer’s instructions. RNA concentrations
were obtained using a NanoDrop Spectrophotometer ND-
1000 (Thermo Fisher Scientific Inc, Waltham, MA).
Reverse transcription of RNA. Complementary
DNA samples were prepared from 1 "g total RNA using
a High Capacity RNA-to-cDNA Kit (Applied Biosystems,
Carlsbad, CA) as specified by the manufacturer.
Primer design. Gene-specific primers were de-
signed by AlleleID 6.01 primer design software (Premier
Biosoft International, Palo Alto, CA) for real-time reverse-
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transcription polymerase chain reaction. Isoform speci-
ficity and primer sizes were checked by BioEdit biological
sequence alignment editor software (Tom Hall Ibis Ther-
apeutics, Carlsbad, CA). Primer specificity was checked by
BiSearch software (Hungarian Academy of Sciences, In-
stitute of Enzymology, Budapest, Hungary). Primer spe-
cific amplification degree (58°C) was optimized by gradi-
ent polymerase chain reaction. The used primer sequences
are shown in Supplementary Table 1.
Reverse-transcription polymerase chain reac-
tion. Real-time reverse-transcription polymerase chain
reaction analysis was performed using SYBR Green tech-
nology on an ABI Prism 7000 Sequence Detection System
(Applied Biosystems, Foster City, CA), according to the
manufacturer’s instructions. !-actin was used as the in-
ternal control gene. Primer-specific amplification was
controlled by 2% agarose gel electrophoresis, as well as by
melting temperature analysis. The final 20 "L reaction
mixture contained Power SYBR Green PCR Master Mix
(Applied Biosystems), 10 pmol/L of forward and reverse
primers, and 100 ng complementary DNA as template.
Amplification conditions were as follows: incubation at
95°C for 10 minutes, followed by 45 cycles at 95°C for 15
seconds, 60°C for 60 seconds, and 72°C for 15 seconds,
with subsequent melting analysis, heating to 95°C for 20
seconds, cooling to 45°C for 10 seconds, and then re-
heating to 95°C.
Statistical Analysis
Data are expressed as means ' SEM. Significant
difference between groups was determined by analysis of
variance. Statistical analysis of the immunohistochemical
data was performed using the Mann–Whitney U test.
Probability values of P % .05 were accepted as being
significant.
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ORIGINAL ARTICLE
New Therapeutic Targets in Ulcerative Colitis: The Importance
of Ion Transporters in the Human Colon
Klaudia Farkas, MD,* Sunil Yeruva, MSc, PhD,† Zolta´n Rakonczay, Jr, MD, PhD,* Lisa Ludolph, MSc,†
Tama´s Molna´r, MD, PhD,* Ferenc Nagy, MD, PhD,* Zolta´n Szepes, MD, PhD,* Andrea Schnu´r, MSc,*
Tibor Wittmann, MD, PhD,* Jessica Hubricht, MD,† Brigitte Riederer, MSc, PhD,†
Vikto´ria Venglovecz, MSc, PhD,‡ Gyo¨rgy La´za´r, MD, PhD,§ Marianna Kira´ly, MSc,¶
A´kos Zsembery, MD, PhD,k Ga´bor Varga, MSc, PhD, DSc,¶ Ursula Seidler, XX,† and Pe´ter Hegyi, MD, PhD*
Background: The absorption of water and ions (especially Naþ
and Cl") is an important function of colonic epithelial cells in both
physiological and pathophysiological conditions. Despite the com-
prehensive animal studies, there are only scarce available data on the
ion transporter activities of the normal and inflamed human colon.
Methods: In this study, 128 healthy controls and 69 patients suffer-
ing from ulcerative colitis (UC) were involved. We investigated the
expressional and functional characteristics of the Naþ/Hþ exchangers
(NHE) 1–3, the epithelial sodium channel (ENaC), and the SLC26A3
Cl"/HCO"3 exchanger downregulated in adenoma (DRA) in primary
colonic crypts isolated from human biopsy and surgical samples
using microfluorometry, patch clamp, and real-time reverse-transcrip-
tion polymerase chain reaction (RT-PCR) techniques.
Results: Data collected from colonic crypts showed that the
activities of electroneutral (via NHE3) and the electrogenic Naþ
absorption (via ENaC) are in inverse ratio to each other in the
proximal and distal colon. We found no significant differences in
the activity of NHE2 in different segments of the colon. Surface
cell Cl"/HCO"3 exchange is more active in the distal part of the
colon. Importantly, both sodium and chloride absorptions are
damaged in UC, whereas NHE1, which has been shown to pro-
mote immune response, is upregulated by 6-fold.
Conclusions: These results open up new therapeutic targets in UC.
(Inflamm Bowel Dis 2011;17:884–898)
Key Words: ulcerative colitis, therapeutic targets, ion transporters
U lcerative colitis (UC), a form of inflammatory boweldisease (IBD), is a chronic, idiopathic inflamma-
tory disorder of the colorectum. Although the medical
treatment of IBD has advanced rapidly, complete
remission cannot be achieved in most of the compli-
cated cases.1 Therefore, studies focusing on the patho-
physiology of the disease that highlight new therapeu-
tic targets are crucially important. In the last decades
more and more animal studies have been published
concerning the role of ion transport mechanisms in in-
testinal epithelial cells (colonic crypts) in the pathoge-
nesis of UC.2–4 Although Teleky et al5 investigated the
regulation of intracellular pH (pHi) in freshly isolated
human colonocytes, a comprehensive functional charac-
terization of ion transporters of human colonic crypts
is still missing.
The ion transporters on the apical and basolateral
plasma membranes of polarized colonic epithelial cells deter-
mine the selectivity of the cells for the vectorial transport of
specific ions. Under physiological conditions, the mammalian
colon absorbs Naþ, Cl", and water and secretes Kþ and
HCO"3 .
6 Human colonic electroneutral sodium absorption is
probably mediated via parallel activity of Naþ/Hþ exchangers
(NHE) 2 and 3 and Cl"/HCO"3 exchangers in the proximal
and distal colon,6,7 whereas electrogenic sodium uptake is
mediated by the epithelial sodium channel (ENaC). Animal
studies suggested that colonic sodium chloride absorption
(including electroneutral Naþ/Hþ exchange, Cl"/HCO"3
exchange, and the electrogenic sodium uptake) differs signifi-
cantly in the proximal and distal segments of the large
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intestine.8–11 A limited number of human studies also showed
segmental heterogeneity of these transporters in the colon.12,13
Concerning the anion exchange mechanisms in the large
intestine, recent studies revealed that Cl"-dependent HCO"3
secretion and the mucosal surface pH is higher in the distal
than in the proximal colon in mouse.14 These data also suggest
that pHi regulation and the functional activities of the acid-
base transporters are different in the proximal and distal colon.
A recent study in rodent colon demonstrated strong segmental
differences in Slc26a3 (downregulated in adenoma (DRA))
expression, a Cl"/HCO"3 exchanger expressed in the luminal
membrane, towards the distal colon.11
In UC, Cl" uptake by the colon is significantly
reduced.15 It has been described that there is a higher level of
Cl" in the colon of patients with UC compared to controls,
suggesting that the normal luminal to mucosal exchange of
Cl" for bicarbonate is damaged.16 Excess bacterial fatty acids
have been implicated as the cause of acidic stools, especially
in infant diarrhea.17 However, it has been shown that the fail-
ure of bicarbonate secretion rather than excessive bacterial
fermentation is the cause of decreased luminal pH of the colon
with UC.15 Not only anion exchange, but also sodium uptake
is altered in UC. NHE3 and Naþ/Hþ exchanger regulatory
factor (NHERF) protein expression have been described to be
downregulated in IBD patients and in a mouse colitis model.16
Notably, NHE3-deficient mice spontaneously develop colitis
restricted to the distal colonic mucosa, suggesting a key role
of NHE3 in UC.3 In addition, UC is also associated with sub-
stantial decreases in the expression of the electrogenic ENaC
beta and gamma subunits.19
The regulation of NHE1 on the basolateral membrane
behaves opposite to the apical NHE3 in UC. NHE1 was
shown to be upregulated in mouse colitis.2 Supporting this ob-
servation, NHE1 is rapidly activated in response to a variety
of inflammatory signals, such as interleukin-1 (IL-1),20 tumor
necrosis factor alpha (TNF-a),21 interferon gamma,22 and li-
popolysaccharide.21,24 Furthermore, functional NHE1 activity
is required for both maximal nuclear factor-kappa B activation
and IL-8 production in colonic epithelial cells.2 The regulation
of intestinal inflammation by NHE is also operational in vivo,
because NHE inhibition dramatically attenuates disease activ-
ity in the mouse dextran sulfate model of IBD.2 In this study
we characterized the segmental differences of ion transport
mechanisms (NHE1-3, DRA, ENaC) in human colonic epithe-
lial cells for the first time; in addition, we also highlight cru-
cial differences between the activities of these transporters in
UC that may open up new therapeutic approaches.
MATERIALS AND METHODS
Humans Involved in the Study
Humans were divided into two groups. In all, 69
IBD patients with active distal UC and 128 age- and
sex-matched healthy controls with normal colonoscopic
findings were enrolled in the study. Informed consent
was obtained prior to endoscopy or surgery. Protocols of
the study were approved by the regional ethical commit-
tees (both at the University of Szeged, Szeged, Hungary,
and Hannover Medical School, Hannover, Germany). Six
colonic biopsies were obtained from each patient under-
going colonoscopy at the First Department of Medicine
or surgery at the Department of Surgery, University of
Szeged, and 2–3 biopsies from each patient in addition
to those needed for histological examination at the
Department of Gastroenterology, Hannover Medical
School.
In control patients neither macroscopic (by endos-
copy) nor microscopic (by histology) evaluation showed
any signs of inflammation in the colon. Patients with nor-
mal endoscopic findings were examined because of colo-
rectal cancer screening or different abdominal complaints.
IBD patients did not receive any steroid therapy.
All of the UC patients complained of diarrhea with
or without hematochezia. The diagnosis of UC was made
based on the colonoscopic findings that showed erythema
and friability of the mucosa, confluent superficial ulcera-
tion, and a decreased vascular pattern. Histological exami-
nation was performed in every case showing inflammatory
cell infiltration in the mucosa, cryptitis, and/or crypt ab-
scess. Patients having only mild or moderate UC with no
steroid therapy were involved in the study. Please note that
we also wanted to include patients with severe colitis as
well; however, only a small number of strongly damaged
colonic crypts could be isolated from the biopsy samples,
which were unsuitable for functional experiments.
Isolation of Colonic Crypts
Colonic crypts were isolated from six biopsy speci-
mens obtained from colonoscopy or surgical samples of
control and IBD patients. Samples were collected from
four different segments of the colon (cecum, transverse co-
lon, sigmoid colon or rectum). However, only one segment
of the colon was investigated in each patient. The tissue
samples were placed immediately in ice-cold NaHCO3 con-
taining Hank’s balanced salt solution (HBSS) and trans-
ferred to the laboratory. The samples were washed three
times with HBSS and cut into small pieces with a razor
blade and incubated in 1 mM dithiothreitol (DTT) in
HBSS for 15 minutes followed by 2 $ 30 minutes enzy-
matic digestion with 0.38 mg/mL collagenase A at 37%C
and continuously gassed with 5% CO2 / 95% O2. The small
fragments were mixed with a Pasteur pipette, the large
fragments were allowed to settle down to the bottom of the
flask under gravity for 35–40 seconds, and the supernatant
removed and viewed under a Nikon stereo microscope
(Jencons-PLS, Grinstead, UK). The crypts (200–300 crypts/
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isolation) were aspirated into a micropipette and transferred
to a Petri dish. For intracellular pH (pHi) measurements the
crypts were kept in a storage solution for 3 hours at 4%C
before the experiments. However, for patch clamp experi-
ments the crypts were incubated on 24-mm coverslips in
culture solution for 24 hours at 37%C with 5% CO2.
The culture solution contained Dulbecco’s Modified
Eagle’s Medium (DMEM), 10% fetal bovine serum (FBS;
Sigma-Aldrich, Budapest, Hungary), 2 mM L-glutamine,
100 U/mL penicillin, and 100 lg streptomycin.
Materials and Solutions for the Experiments
General laboratory chemicals were obtained from
Sigma-Aldrich. Collagenase A was obtained from Roche
Diagnostic (Mannheim, Germany), nigericin from Fluka
Biochemic (Munich, Germany). Nigericin was dissolved in
absolute ethanol. HOE-642 (4-isopropyl-3-methylsulpho-
nylbenzoyl-guanidin methanesulphonate) was kindly pro-
vided by Sanofi Aventis (Frankfurt, Germany) and was dis-
solved in dimethyl sulfoxide (DMSO).
BCECF-AM (20,70-biscarboxyethyl-5(6)-carboxyfluor-
escein-acetoxymethylester) was obtained from Invitrogen
(Eugene, OR); cell and tissue adhesive from Becton Dick-
inson Bioscience (Cell Tak, Bedford, MA). BCECF-AM
was dissolved in DMSO.
pHi Measurements
The compositions of the solutions used are shown in
Table 1. HEPES-buffered solutions were gassed with 100%
O2 and their pH was set to 7.4 with NaOH or HCl at 37
%C.
HCO"3 -buffered solutions were gassed with 95% O2/5%
CO2 to set the pH to 7.4 at 37
%C.
Colonic crypts were attached with Cell Tak to a
glass 24-mm diameter coverslips 3 hours after isolation
and placed in a perfusion chamber mounted on the stage
of an inverted fluorescent microscope linked to a cell
imaging system (Olympus, Budapest, Hungary). Colonic
crypts were bathed in standard HEPES solution at 37%C
and loaded with the pH-sensitive fluorescent dye
BCECF-AM for 20–30 minutes. Crypts were continu-
ously perfused with solutions at a rate of 4–5 mL/min.
Three different areas (base, medium, surface) in each
crypt were excited with light at wavelengths of 495 nm
and 440 nm and the 495/440 fluorescence emission ratio
was measured at 535 nm.24,25 In situ calibration of the
fluorescence signal was performed using the high Kþ-
nigericin technique.
Measurement of NHE Activities
The crypts were acid-loaded by exposure to a 5-mi-
nute pulse of 20 mM NH4Cl in HEPES solution followed
by a 10-minute exposure of Naþ-free HEPES solution. Due
to the blocked acid/base transporters (neither sodium nor
bicarbonate was present in the solution), the pHi was set to
a stable acidic level. NHE activity was switched on by
readdition of extracellular sodium and the activity of NHE
was determined by measuring the initial rate of pHi recov-
ery over the first 60 seconds (60 data points). The activities
of the different NHE isoforms were extracted using the iso-
form selective NHE inhibitor HOE-642. One lM HOE-642
inhibits NHE1, whereas 50 lM HOE-642 inhibits both
NHE1 and 2 but not NHE3.26,27 Although there are nine
different NHE isoforms in mammalian digestive tract,28
only NHE1–3 are localized to the membrane of the cells.29
TABLE 1. Composition of solutions. Values are concentrations in mM. NMDG: N-methyl-D-glucamine.
Standard HEPES High-Kþ HEPES NHþ4 in HEPES Na
þ-free HEPES Standard HCO"3 Cl
"-free HCO"3
NaCl 130 5 110 115
KCl 5 130 5 5 5
MgCl2 1 1 1 1 1
CaCl2 1 1 1 1 1
Na-HEPES 10 10 10
Glucose 10 10 10 10 10 10
NaHCO3 25 25
NH4Cl 20
HEPES 10
NMDG-Cl 140
Na-gluconate 115
Mg-gluconate 1
Ca-gluconate 6
K2-sulfate 2.5
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Therefore, the activities (A) of NHE isoforms can be calcu-
lated from the recoveries (R) as follows:
ANHE1 ¼ R0lM HOE"642 " R1lM HOE"642
ANHE2 ¼ R1lM HOE"642 " R50lMHOE"642
ANHE3 ¼ R50lM HOE"642
Measurement of Cl2/HCO"3 Exchange Activity
The Cl"/HCO"3 exchange activity of the cells was
determined using the Cl" withdrawal technique. Briefly,
removing Cl" from the standard HCO"3 /CO2 buffered solu-
tion causes alkalization due to the reverse activity of the
Cl"/HCO"3 exchanger. The activity of the exchanger was
determined by measuring the initial rate of alkalization
over the first 30 seconds (30 data points).
Measurement of ENaC Activity
Voltage-clamp recordings were performed using the
patch-clamp technique in whole-cell configuration at room
temperature with an Axopatch 200B amplifier (Axon
Instruments, Union City, CA). Micropipettes were fabri-
cated by a P-97 Flaming/Brown type micropipette puller
(Sutter Instrument, Novato, CA) from GC120F-10 glass
capillary tubes (Harvard Apparatus, Holliston, MA) and
had resistances of 5–10 MX when filled with pipette solu-
tion. Capacitative currents were compensated with analog
compensation. Linear leak currents were not compensated.
Series resistance was '8–15 MX, and series resistance
compensation (70%–80%) was used in whole-cell record-
ings if the current exceeded 1 nA. Currents were filtered at
2 kHz (four-pole Bessel filter) and sampled at 5 kHz. Pulse
generation, data acquisition, and analysis were performed
using pClamp 6.03 software (Axon Instruments). The pip-
ette solution contained (in mM): 95 K-gluconate, 5 Na-glu-
conate, 2 Mg-ATP, 10 HEPES, 2 EGTA-Na, 0.2 MgCl2,
40 CsOH, and 20 TEA-OH, with pH adjusted to 7.2 using
gluconic acid. Our standard bath solution contained (in
mM): 140 Na-gluconate, 5 K-gluconate, 1 CaCl2, 5 BaCl2,
1 MgCl2, 10 HEPES, and 5 glucose, with pH adjusted to
7.4 using Tris, supplemented when appropriate with 50 lg/
mL trypsin or 10 lM amiloride (final concentrations). In
some experiments, Naþ was substituted with N-methyl-d-
glucamine (NMDGþ) in the extracellular solution. Inward
currents (downward current deflections) are defined as neg-
ative currents, i.e., movement of positive charge from the
extracellular side to the cytoplasmic side. Starting from a
Vhold of "50 mV, voltage step protocols were performed
intermittently using consecutive 300-ms step changes to
potentials ranging from "100 up to þ100 mV in 20-mV
increments. The average current values reached during the
last 100 ms of the voltage steps were used for the I-V plots.
The changes in current amplitudes are expressed as
changes in current densities (pA/pF).
RNA Isolation and Real-time Reverse-transcription
Polymerase Chain Reaction (RT-PCR)
The biopsy samples were collected in RNA later
(Sigma-Aldrich, Steinheim, Germany) solution. RNA was
isolated from the biopsies using Nucleo spin kit (Machery
and Nagel, Du¨ren, Germany) as recommended by the man-
ufacturer. The RNA of each sample was tested for intact-
ness, and only such samples were used in which no RNA
breakdown was documented. One lg of RNA was reverse-
transcribed using MMLV superscript III reverse transcrip-
tase (Invitrogen, Karlsruhe, Germany). Real-time PCR was
performed using SYBR Green PCR mastermix (Applied
Biosystems, Darmstadt, Germany) exactly as previously
described.30 Primer sequences are given in Table 2.
Statistical Analysis
Values are means 6 SE. Statistical analyses were per-
formed using unpaired Student’s t-test or analysis of variance
(ANOVA) as appropriate. P ( 0.05 was accepted as signifi-
cant. N ¼ 10–15 colonic crypts isolated from 4–6 patients.
For the quantitative mRNA results, the number of biopsies
used for the experiments is indicated in the figure legends.
RESULTS
Determination of the Resting pHi of Human
Colonic Crypts in Different Parts of the Colon
In the first series of experiments, our aim was to deter-
mine the resting pHi of human colonic crypts (Fig. 1A,B). We
used the classical linear model24,25 to determine the resting
pHi, which proved to be significantly higher in the middle ver-
sus the surface or the base of the crypts (Fig. 1C) in all parts of
the colon. Importantly, the resting pHi was significantly higher
in the distal versus proximal part of the colon (Fig. 1D).
TABLE 2. Primer sequences for PCR experiments.
Gene Sequence
NHE1 For 50-TGAGGAGCTGAAGGGCAAAG-30
NHE1 Rev 50-CCTTGCTCCGCATCATGAT-30
NHE2 For 50- CTTCCACTTCAACCTCCCGAT-30
NHE2 Rev 50-GCTGCTATTGCCATCTGCAA-30
NHE3 For 50-AGAAGCGGAGAAACAGCAG-30
NHE3 Rev 50-TGGTGACACTAGCCAGGAAC-30
DRA For 50-AGCACAGGAGGCAAAACACAG-30
DRA Rev 50-GACTTTTGTAGAGGCGCCAGG-30
Villin For 50-CTATGCCAACACCAAGAGAC-30
Villin Rev 50-CCCAGACATCTAGTAGGAACAC-30
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Activities and Expression of NHE Isoforms in
Different Parts of the Normal Colon
Since the NHEs play a key role in the regulation of
pHi, we investigated the activity of different NHE iso-
forms in the normal human colon. Removal of Naþ from
the standard HEPES solution caused a rapid decrease in
the pHi, while adding back Na
þ led to a complete pHi re-
covery, confirming the presence of a Naþ-dependent Hþ
efflux in the epithelial cells of the colonic crypts (data
not shown). The NH4Cl pulse technique was used to mea-
sure the activity of NHE isoforms. Exposure of colonic
crypts to 20 mM NH4Cl induced an immediate rise in
FIGURE 1. Resting pHi of colonic epithelial cells. (A) Light and fluorescence microscopy. Isolated colonic crypts were fixed on
a coverglass. Three areas (ROIs) of each crypt were excited with light at wavelengths of 495 nm and 440 nm and the 495/
440 fluorescence emission ratio was measured at 535 nm. (B) Crypts were exposed to nigericin/high Kþ HEPES solutions of
pH 7.1 and 7.4. Resting pHi was calculated by linear regression analysis. Bar charts show the summary of resting pHi in dif-
ferent parts of the (C) crypts and (D) the colon. Significantly higher resting pHi was measured in the middle part of the
crypts. Significantly higher resting pHi was detected in the distal versus the proximal part of the normal colon. n ¼ 19 colo-
nic crypts isolated from seven patients. Data are presented as means 6 SEM. *Significant difference (P < 0.05) versus the re-
spective groups. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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pHi because of the rapid entry of the lipophilic base, NH3
into the cell. After the removal of NH4Cl, pHi rapidly
decreased (Fig. 2A). This acidification is caused by the
dissociation of intracellular NHþ4 to H
þ and NH3, fol-
lowed by the diffusion of NH3 out of the cell. After this
acidification, pHi starts to recover due to activation of
pHi regulatory mechanisms. In the absence of extracellu-
lar HCO"3 in the solution and due to the low activity of
Hþ efflux mechanisms from the cells, the recovery from
acidosis (in the presence of Naþ) reflects the activity of
NHE. Cariporide (HOE-642), the well-known isoform-spe-
cific NHE inhibitor,31 was used to test the activities of
NHE1, NHE2, and NHE3, as previously validated in mu-
rine colonic crypts of NHE knockout mice.26,27 The activ-
ities of NHE1 and 3 isoforms showed a decreasing pat-
tern from the proximal to the distal part of the colon,
whereas the activity of NHE2 did not change significantly
(Fig. 2B–D). The activities of all examined NHE isoforms
could be detected in the different parts of the colonic
crypts (surface, middle, base). Importantly, in the proxi-
mal colon NHE3 activity was significantly higher in the
surface of the crypt (Fig. 2D).
Next, we were interested in whether the alterations of
NHE1, NHE2, and NHE3 activities are associated with the
changes of mRNA levels of these transporters. RT-PCR
analyses revealed that mRNA expression of NHE3 was
clearly decreased in the distal part of the colon in relation
to villin, an epithelial marker (Fig. 3C), b-actin, and b2-
microglobulin, which are nonepithelial markers (data not
shown). However, there were no significant differences
between the NHE1 and 2 mRNA levels in the different
segments of the colon (Fig. 3A,B).
FIGURE 2. Determination of the Naþ/Hþ exchange activity in colonic epithelial cells. (A) Representative pHi trace. The crypts
were acid loaded by an exposure to a 5-minute pulse of 20 mM NH4Cl followed by a 10-minute exposure of Na
þ-free HEPES
solution. The activities of the different NHE isoforms were measured by the isoform selective NHE inhibitor HOE-642. One
lM HOE-642 inhibits the activity of NHE1, whereas 50 lM HOE-642 inhibits the activity of NHE2 and 3. The line charts (B–D)
show that the activities of NHE1 and 3 were significantly higher in the proximal versus the distal part of the colon. NHE3 ac-
tivity proved to be the highest at the surface of the isolated colonic crypts. n ¼ 26 colonic crypts isolated from 13 patients.
Data are presented as means 6 SEM. *Significant difference (P < 0.05) versus the respective groups. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Differences in Functional Na1 Channel Activity
Along the Large Intestine
In order to compare the Naþ channel activity in differ-
ent parts of the large intestine, we isolated colonocytes from
the cecum, transverse colon, and sigmoid colon/rectum of
individuals without UC. Colonic crypts were seeded on glass
coverslips covered by Matrigel, where they preserved the
original crypt structures and attached in a perpendicular ori-
entation (Fig. 4A). There is recent evidence that proteases
contribute to ENaC regulation by cleaving specific sites in
the extracellular loops of the a- and c-subunits but not the b-
subunit.32 Several studies indicate that trypsin activates
ENaC by interacting with its a and/or c subunits.33,34 This
interaction could alter the binding of amiloride to ENaC,
decreasing the potency of the inhibitor.35 Thus, trypsin was
chosen to stimulate Naþ channel activity. Figure 4B,C shows
that inward currents were activated by trypsin (50 lg/mL) in
colonocytes isolated from sigmoid colon/rectum. These
effects were abolished when extracellular Naþ was replaced
with NMDG (Fig. 4D). On the other hand, trypsin remained
ineffective if cells were perfused with NMDGþ-rich external
solution. Readministration of Naþ to the bath solution
restored the stimulatory effects of trypsin (data not shown).
In our hands, amiloride (10 lM) inhibited trypsin-induced
activation of the inward currents in only two cells out of 10
experiments. In contrast to colonic crypts isolated from sig-
moid colon/rectum, trypsin did not cause significant activa-
tion of inward currents in cells derived from the cecum or
transverse colon (Fig. 4E; Table 3). Following trypsin
administration, the reversal potential shifted towards more
positive values in cells isolated from both sigmoid colon/rec-
tum and transverse colon, suggesting the activation of inward
Naþ current (Fig. 4F).
Cl2/HCO"3 Exchange Activities in Different Parts
of the Normal Colon
To test the activity of the Cl"/HCO"3 exchange (AE)
mechanisms of colonic crypts we utilized the Cl" removal
FIGURE 3. mRNA expression of NHE 1, 2, and 3 in the noninflamed human biopsies collected from cecum to rectum. RNA
was isolated from human biopsies and real-time PCRs were conducted as mentioned in Materials and Methods. (A) NHE1, (B)
NHE2, and (C) NHE3 mRNA expression levels were normalized against villin (an epithelial marker). (D) An overview of all
three genes normalized against villin shows the differential expression of these genes from cecum to rectum. For each
region, RNA was isolated from several biopsies of 3–5 controls. Data are presented as means 6 SEM. *Significant difference
(P < 0.05) between the different parts of the colon. CT: The cycle number at the threshold level of log-based fluorescence.
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technique in the presence of HCO"3 ions. Cl
" removal
from the standard HCO"3 /CO2 solution caused a marked
alkalization in colonic crypts suggesting active anion
exchange. Notably, the alkalization was significantly higher
in the surface versus the middle and the base of the crypts
(Fig. 5A), suggesting that it may be predominantly caused
FIGURE 4. Differences in the functional Naþ channel activity along the large intestine. (A) Phase contrast image of a control rec-
tum-derived crypt adhered to a Matrigel-coated coverglass. Scale bar ¼ 100 lm. (B) Representative whole-cell current recording
measured on control rectum-derived colonic crypts. (C) Exposure to trypsin caused an increase in inward currents. (D) Inward cur-
rents were rapidly suppressed when Naþ was replaced with NMDG in the extracellular solution. (E) Average I/V plots obtained in
cells derived from cecum (n ¼ 12), transverse colon (n ¼ 12), and sigmoid colon/rectum (n ¼ 13) isolated from five control individ-
uals in each location. Trypsin significantly activated the Naþ channel activity in control sigmoid colon/rectum samples. (F) Trypsin
caused a significant shift of the reversal potentials towards more positive values in cells derived from transverse and sigmoid co-
lon/rectum samples of control individuals. Note that trypsin-induced changes in reversal potentials were significantly larger in sig-
moid colon or rectum derived cells than in cecum. Data represent mean 6 SEM (*P < 0.05). n ¼ 12–13 colonic crypts isolated
from five patients. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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by the surface-located Slc26a3 (DRA).34 In contrast to the
activities of apical NHE3, AE activity was significantly
higher in the distal versus the proximal part of the colon
(Fig. 5B). Since the SLC26A3 (DRA) is the dominant
anion exchanger on the apical side of colonic epithelial
cells,11,36 we also tested the expression level of this trans-
porter. RT-PCR experiments showed no significant differ-
ence between the mRNA expressions at the distal and
proximal parts of the colon (Fig. 5C).
Changes in the Activities of NHE1 and NHE3 in
Colonic Crypts of UC Patients
After the basic characterization of ion transport mecha-
nisms of the normal human colon, we examined the changes
of these ion transport mechanisms in patients suffering from
UC. Since UC always involves the rectum, and in many cases
sigmoidoscopy is enough for a control endoscopy, biopsy
samples were collected only from the sigma and rectum. The
resting pHi of epithelial cells of the crypts isolated from
patients with UC did not differ from the controls (Fig. 6A).
The activity of NHE1 in the colonic crypts isolated
from the inflamed region of the distal colon was approxi-
mately two times higher than in healthy colonic crypts iso-
lated from the same region (Fig. 6B). However, not only
the activity, but also the expression of NHE1 was highly
elevated. NHE1 was strongly upregulated in UC patients
versus controls (Fig. 6D).
The activities of NHE3 significantly decreased in the
middle and in the surface of the crypts in UC patients versus
controls. As it was predictable, no changes were observed in
the base of the colonic crypts (Fig. 6C). Quantitative RT-
PCR revealed no significant changes in the UC versus the
control group, suggesting that the defect of NHE3 activity is
functional, rather than due to a downregulation of NHE3
expression (Fig. 6E). The activity of NHE2 showed no sig-
nificant differences in UC versus controls (data not shown).
Impaired Activity of ENaC in UC
Since the effects of trypsin on ENaC activity were more
pronounced in colonic crypts isolated from sigmoid colon/rec-
tum biopsies and the disease always involves this region, we
decided to compare Naþ channel activity in this part of the
large intestine in subjects with and without UC. Contrary to the
control cells, in UC colonocytes trypsin did not elicit significant
increase in Naþ current (Fig. 7A; Table 4). Although we
detected a moderate positive shift in reversal potential follow-
ing administration of trypsin, the difference did not reach the
level of significance (Fig. 7B). These data suggest that besides
alterations of other ion transport mechanisms and accumulation
of local inflammatory mediators, disorders of Naþ transport
also contribute to the development of diarrhea in UC.
TABLE 3. Whole cell current recordings in samples
isolated from coecum, transverse colon, and sigmoid
colon/rectum of control individuals, prior and after
trypsin administration. Currents are expressed as current
densities (pA/pF), negative values represent inward
currents. Data represent mean 6 SE (*p < 0.05). Number
of cells is shown in parentheses.
coecum (12) basal
ENaC activities
coecum (12)
trypsin-induced
ENaC activities
"100 mV "6,57 6 4,44 "6,94 6 4,14
"80 mV "5,23 6 3,70 "5,42 6 3,22
"60 mV "3,96 6 2,93 "4,04 6 2,33
"40 mV "2,58 6 2,17 "3,14 6 2,19
"20 mV "1,40 6 1,46 "1,27 6 0,37
0 mV "0,06 6 0,96 "0,09 6 0,31
þ20 mV 1,28 6 1,05 1,31 6 1,13
þ40 mV 3,03 6 1,58 2,37 6 1,68
þ60 mV 4,51 6 2,32 4,02 6 2,90
þ80 mV 5,96 6 3,01 5,53 6 3,66
þ100 mV 7,49 6 3,60 7,40 6 5,15
transverse colon
(12) basal ENaC
activities
transverse colon
(12) trypsin-induced
ENaC activities
"100 mV "6,83 6 5,07 "8,36 6 5,74
"80 mV "5,46 6 3,95 "6,87 6 4,78
"60 mV "4,25 6 3,02 "5,29 6 3,88
"40 mV "2,87 6 2,09 "3,63 6 2,97
"20 mV "1,48 6 1,53 "2,16 6 2,41
0 mV 0,05 6 1,52 "0,61 6 2,09
þ20 mV 1,67 6 2,29 1,10 6 2,34
þ40 mV 3,33 6 3,20 2,71 6 2,91
þ60 mV 4,73 6 3,61 3,90 6 3,78
þ80 mV 5,65 6 4,09 5,12 6 4,67
þ100 mV 6,65 6 4,70 6,15 6 5,62
signioid colon/rectum
(13) basal ENaC
activities
sigrnoid colon/rectum
(13) trypsin-induced
ENaC activities
"100 mV "10,03 6 6,94 "21,15 6 13,02*
"80 mV "8,25 6 6,16 "17,82 6 11,11*
"60 mV "6,26 6 4,81 "14,26 6 8,95*
"40 mV "4.41 6 3_79 "10,89 6 6,86*
"20 mV "2,72 6 3,08 "7,87 6 5,10*
0 mV "0,76 6 2,36 "4,84 6 3,39*
þ20 mV 1,39 6 2,74 "1,80 6 1,76*
þ40 mV 3,80 6 4,37 1,36 6 1,24
þ60 mV 6,46 6 7,06 4,57 6 3,01
þ80 mV 9,28 6 10,02 8,00 6 5,82
þ100 mV 12,89 6 15,09 10,48 6 7,76
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Apical Chloride Transport Is Diminished
in UC Patients
On the surface of the crypts, significantly lower Cl"/
HCO"3 exchange activity was observed in UC patients ver-
sus controls (Fig. 8A). mRNA levels of DRA were reduced
by )50% in UC patients compared to noninflamed controls
(Fig. 8B).
DISCUSSION
The absorption of water and ions (especially Naþ and
Cl") is an important function of colonic epithelial cells.
When the cells become unable to maintain normal levels of
absorption, different gastrointestinal symptoms such as di-
arrhea or constipation develop, which in severe forms can
be life-threatening. Therefore, understanding the physiology
and pathophysiology of absorption in the colon is crucially
important. In healthy humans '1.5 L of fluid flows into
the colon from the small intestine and 90% of this fluid is
absorbed.37 The main driving force of this large amount of
water reuptake is the Naþ absorption from the lumen
through the colonic crypts.37 In this study we show that the
activities of electroneutral (via NHE3) and electrogenic
Naþ absorption (via ENaC) are in inverse ratio to each
other in the proximal and distal colon. The segmental dif-
ferences of electrogenic Naþ absorption have been sug-
gested by Sandle et al.13,38 They found that electrogenic
Naþ transport is higher in the human descending colon ver-
sus the ascending colon in vitro.13,39 In addition, Sellin and
De Soignie39 showed that all segments of the human colon
actively absorb Naþ and Cl". Although ENaC was found
to be more active in the distal part of the colon, in vivo
studies revealed that water and Naþ absorption is greater in
the proximal versus the distal part of the colon.12,38,41
These data predict that electroneutral Naþ absorption must
be more dominant in the proximal colon. Consistent with
recently published data from rodent colon,11 we show here
that both the activity and the expression of NHE3, but not
NHE2, are decreasing from the proximal to distal colon in
human. In addition, the activity of NHE3 approximately
doubled in the cecum versus the rectum. These results are
in accordance with the data obtained in animal models. Al-
dosterone was found to stimulate intestinal Naþ absorption
FIGURE 5. Cl"/HCO"3 exchange (AE) activity and DRA expression in control colonic crypts. (A) Representative pHi trace of colo-
nic crypts isolated from patients with normal endoscopic findings. Removal of Cl" from the standard HCO"3 /CO2 solution
resulted in an alkalization of pHi. AE activity was the highest in the surface of the crypts. (B) Activity of the Cl
"/HCO"3 exchanger
in different parts of the colon. Significantly higher AE activity was measured in the distal versus the proximal part of the colon.
n ¼ 17–31 colonic crypts isolated from 4–10 patients. (C) Real-time PCR analysis of DRA mRNA expression in different parts of
colon in relation to villin (an epithelial marker). For each region, RNA was isolated from several biopsies of 3–5 controls. Data are
presented as means 6 SEM. *Significant difference (P < 0.05) between the different parts of the colon. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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and increase NHE3 expression by 3-fold in the proximal
colon but not in the distal colon.42 Notably, the expression
of NHE2 was unaffected. The prominent role of NHE3 in
Naþ absorption is suggested by mouse models as well. Di-
arrhea develops in NHE3-deficient, but not in NHE2-defi-
cient mice.43 Furthermore, the loss of NHE2 transporter
has no effect on the diarrheal state of NHE3-deficient
mice.44
Although NHE1 is not involved in the absorption of
Naþ (it is located in the basolateral membrane), it partici-
pates in the pHi regulation of colonic epithelial cells.
10,45
The importance of NHE1 was connected to inflammatory
disorders as well; therefore, we extended our study to
investigate both the activity and expression of NHE1.2
Contrary to NHE3, we could not find segmental differences
between the different parts of colon.
Colonic Cl"/HCO"3 exchange also plays an important
role in water and Naþ absorption from the large intestine.
The two main apical anion exchangers in the gastrointesti-
nal tract are the putative anion (PAT1 or SLC26A6) and
the downregulated in adenoma DRA or SLC26A3 trans-
porters.29,46 Notably, PAT1 is only expressed in the small
intestine, whereas DRA has a colon-predominant expres-
sion.45,46 The prominent role of DRA in the colon is also
suggested by the fact that DRA-deficient, but not PAT1-de-
ficient mice display dehydration due to severe diarrhea.47
Importantly, mutations of DRA cause congenital diarrhea
in humans.48 Our experiments demonstrate that Cl"/HCO"3
exchange is more active in the distal versus the proximal
colon. The basolateral anion exchanger 2 (AE2) has been
identified in the distal colon both in the surface and crypt
cells; however, DRA was localized only to the surface of
crypt cells.49,50 It is noteworthy that the differences
between the Cl"/HCO"3 exchange activities were detected
in the surface of the crypts, suggesting alterations of DRA
rather than other anion exchangers. This increased Cl"/
HCO"3 exchange rate in surface colonocytes was not paral-
leled by higher DRA mRNA expression levels. Since DRA
mRNA expression was standardized to villin expression,
which is expressed along the whole crypt length (albeit
FIGURE 6. Resting pHi and changes in the activity and expression of NHE1 and NHE3 in colonic crypts of UC patients. Biopsy
samples were collected from the distal part of the colon of the UC patients. Resting pHi was determined in UC in the same
way as in case of control colonic crypts. (A) No difference was detected in the resting pHi between active UC and control co-
lonic crypts. n ¼ 10 colonic crypts isolated from four patients. (B) The activity of NHE1 isoform was determined both in
active UC epithelial cells with the use of 1 and 50 mM HOE-642. Significantly higher NHE1 activity was detected in the base
and middle parts of the colonic crypts in active UC compared to the controls. (C) Activity of NHE3 was significantly
decreased in active UC throughout the crypt except for the base. n ¼ 18 colonic crypts isolated from seven patients. Real-
time PCRs were performed to determine for (D) NHE1 and (E) NHE3 mRNA expression in biopsies collected from the sigmoid
colon in relation to villin expression; results showed a significant and strong increase of NHE1 mRNA expression in UC com-
pared to noninflamed controls, whereas NHE3 mRNA levels were not significantly altered. For RNA isolation, several biopsies
from 7 control and 14 UC (mild to moderate inflammation of the sigmoid colon) patients were used. Data are presented as
means 6 SEM. *Significant difference (P < 0.05) between the different parts of the colon.
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more strongly towards to surface), whereas DRA is
expressed in a strongly surface-predominant fashion in the
human colon,36 and since crypt length increases towards
the distal colon, such expression studies may fail to reveal
a selective increase in surface cell expression.
Following the first, basic physiological part of the
study, we investigated the role of the same ion transport
mechanisms in UC in which diarrhea is one of the leading
symptoms. We found that the expression of NHE1 is
strongly upregulated in UC, which is in accordance with
elevation of functional activity. This is a very important
finding, since experiments in mice revealed that inhibition
of NHE1 activity with amiloride strongly decreased the
inflammatory processes in vivo in IBD mouse model.2 In
addition, there is other evidence showing that NHE1 may
be involved in the development of UC. NHE1 has been
shown to be an important regulator in many types of
immune response.51 NHE1 promotes TNF-a and IL-8 pro-
duction23,52 and activation of NHE1 promotes neutrophil
migration53 and myeloperoxidase activity and release.54
The 6-fold elevation in the mRNA expression of NHE1 in
UC and the above-described previous observations strongly
suggest that inhibition of NHE1 could be a potential thera-
peutic target.
Next we investigated the two major Naþ transport
mechanisms (NHE3 and ENaC) in patients suffering from
active UC. Our results clearly demonstrate that both mech-
anisms are functionally damaged. The loss of ENaC func-
tion is most probably due to transcriptional alterations. The
expression of the ENaC b subunit was shown to be down-
regulated in UC.18 In addition, Amasheh et al55 clearly
FIGURE 7. Differences in functional Naþ channel activity. (A) Average I/V plots obtained in cells derived from sigmoid colon/
rectum (n ¼ 12) of individuals with and without UC (n ¼ 5, respectively). Trypsin did not activate inward currents in colonic
crypts isolated from UC patients. (B) Trypsin caused a significant shift of the reversal potentials towards more positive values
in control but not in UC cells. Data are presented as means 6 SEM. *P < 0.05 significant differences versus the controls.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
TABLE 4. Whole cell current measurements in colonic
epithelial cells derived from sigmoid colon/rectum of
control individuals and patients with UC, prior and after
treatment with trypsin. Currents are shown as current
densities (pA/pF). Data represent mean 6 SE (*p < 0.05).
Number of cells is shown in parentheses.
UC sigmoid colon/rectum
(12) basal ENaC activities
UC sigmoid colon/rectum
(12) trypsin-induced ENaC
activities
"100 mV "8,94 6 4,35 "14,30 6 10,44
"80 mV "7,54 6 3,87 "11,86 6 8,67
"60 mV "5,77 6 2,98 "8,84 6 6,79
"40 mV "3,96 6 2,20 "6,45 6 5,30
"20 mV "1,92 6 1,07 "4,15 6 3,24
0 mV 0,15 6 0,75 "1,26 6 1,89
þ20 mV 2,45 6 2,07 2,28 6 3,69
þ40 mV 5,15 6 4,34 5,63 6 5,16
þ60 mV 6,91 6 6,35 7,12 6 6,59
þ80 mV 9,00 6 8,20 9,88 6 8,79
þ100 mV 10,31 6 7,55 12,37 6 10,42
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demonstrated that elevated proinflammatory cytokine levels
selectively impair b- and c-ENaC expression in UC. How-
ever, the loss of NHE3 function in UC is less clear.
Although Sullivan et al18 demonstrated that the expression
of NHE3 is decreased in colitis based on Western analysis
of colonic biopsies, we found no such significant differen-
ces between control and UC patients when the expression
levels of NHE3 were compared to those of a structural
brush border membrane protein with similar expression pat-
terns than NHE3.56 In addition, NHE3 immunostaining was
found to be normal in the brush border membrane of
inflamed colonocytes.56 Therefore, the molecular mecha-
nism of NHE3 functional damage still remains unsolved,
and may be due to changes in the regulatory proteins that
ensure NHE3 regulation and membrane retention.57
Finally, we provided evidence that both the activity
of anion exchange and the expression of the dominant
anion exchanger, namely, DRA, are significantly decreased.
Downregulated adenoma transporter is dominantly
expressed in the surface of the crypts, whereas the basolat-
eral anion exchangers are expressed in all parts of the
crypts.50 Our experiments on normal crypts showed that
the strongest activity of Cl"/HCO"3 exchange occurs on the
surface of the crypts. Importantly, anion exchange activity
decreased by '80% in UC, indicating that Cl" absorption
via DRA is seriously damaged. It has also been shown that
IL-1b reduces DRA mRNA expression in vitro by inhibi-
ting gene transcription.58 Furthermore, highly reactive oxy-
gen metabolites which are known to be involved in the
pathogenesis of UC59 inhibit Cl"/OH" exchange activity in
Caco-2 cells.60 These results suggest that gene transcription
by proinflammatory cytokines and/or functional changes of
Cl" absorption may play a crucial role in the pathogenesis
of diarrhea in colitis.
In conclusion, we have demonstrated in this com-
prehensive human study that 1) electroneutral (via
NHE3) and electrogenic Naþ absorption (via ENaC) are
in inverse ratio to each other in the proximal and distal
colon; 2) the anion exchanger DRA is more active in
the distal part of the colon; 3) both sodium and chloride
transport is damaged in UC; whereas, 4) NHE1, which
has been shown to promote immune response, is strongly
upregulated. These results open up new therapeutic tar-
gets in UC. Drug development and clinical studies are
crucially needed to determine whether selective inhibition
of NHE1 and/or stimulation of NHE3, ENaC, and DRA
would be beneficial in UC.
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Abstract Myofibroblasts play central roles in wound
healing, deposition of the extracellular matrix and epithelial
function. Their functions depend on migration and prolif-
eration within the subepithelial matrix, which results in
accelerated cellular metabolism. Upregulated metabolic
pathways generate protons which need to be excreted to
maintain intracellular pH (pHi). We isolated human gastric
myofibroblasts (HGMs) from surgical specimens of five
patients. Then we characterized, for the first time, the
expression and functional activities of the Na+/H+ exchanger
(NHE) isoforms 1, 2 and 3, and the functional activities of
the Na+/HCO3
− cotransporter (NBC) and the anion exchang-
er (AE) in cultured HGMs using microfluorimetry,
immunocytochemistry, reverse transcription polymerase
chain reaction and immunoblot analysis. We showed that
NHE1–3, NBC and AE activities are present in HGMs and
that NHE1 is the most active of the NHEs. In scratch wound
assays we also demonstrated (using the selective NHE
inhibitor HOE-642) that carbachol and insulin like growth
factor II (IGF-II) partly stimulate migration of HGMs in a
NHE1-dependent manner. EdU incorporation assays
revealed that IGF-II induces proliferation of HGMs which
is inhibited by HOE-642. The results indicate that NHE1
is necessary for IGF-II-induced proliferation response
of HGMs. Overall, we have characterized the pHi
regulatory mechanisms of HGMs. In addition, we demon-
strated that NHE1 activity contributes to both IGF-II- and
carbachol-stimulated migration and that it is obligatory for
IGF-II-induced proliferation of HGMs.
Keywords Fibroblast . Na+/H+ exchange . Gastrointestinal
tract . Human
Abbreviations
AE Anion exchanger
AMV Avian myeloblastosis virus
AMV-RT Avian myeloblastosis virus reverse
transcriptase
BCECF-AM 2,7-Biscarboxyethyl-5(6)-
carboxyfluorescein-acetoxymethylester
DAG Diacyl-glicerol
DAPI 4,6-Diamidino-2-phenylindole
DMEM Dulbecco’s Modified Eagle’s Medium
Specific author contributions György Lázár, Zsolt Simonka, Tibor
Wittmann and János Lonovics were involved in patient selection and
sample collection; Zoltán Rakonczay Jr., Viktória Venglovecz and
Péter Hegyi were involved in tissue culturing and microfluorometric
experiments; Andrea Varró, Rod Dimaline, Islay Steele, Nantaporn
Lertkowit, Andrea Schnúr, György Biczó and Andrea Geisz
performed molecular biology experiments and biological assay
experiments. Mátyás Czepán was involved in all of the above
mentioned experiments and drafted the manuscript. Péter Hegyi
designed and supervised the project, the experiments and the
manuscript. Mátyás Czepán spent 3 months in Liverpool as part of the
project funded by the NIH and NIHR.
M. Czepán : Z. Rakonczay Jr. : J. Lonovics :A. Schnúr :
G. Biczó :A. Geisz : T. Wittmann : P. Hegyi (*)
First Department of Medicine, University of Szeged,
6720 Korányi fasor 8-10,
Szeged, Hungary
e-mail: hegyi.peter@med.u-szeged.hu
G. Lázár : Z. Simonka
Department of Surgery, University of Szeged,
Szeged, Hungary
V. Venglovecz
Department of Pharmacology and Pharmacotherapy,
University of Szeged,
Szeged, Hungary
A. Varró : I. Steele : R. Dimaline :N. Lertkowit
Department of Physiology, University of Liverpool,
Liverpool, UK
Pflugers Arch - Eur J Physiol (2012) 463:459–475
DOI 10.1007/s00424-011-1059-6
DMSO Dimethyl sulfoxide
dNTP Deoxyribonucleotide-triphosphate
EDTA Ethylenediamine tetra-acetic acid
EdU 5-Ethynyl-2-deoxyuridine
ER Endoplasmic reticulum
FITC Fluorescein isothiocyanate
GAPDH Glyceraldehyde 3-phosphate
dehydrogenase
H2DIDS 4,4′-Diisothiocyanatodihydrostilbene-2,
2′-disulfonic acid
HaCaT cells Human adult low calcium temperature
keratinocytes
HEPES (4-(2-Hydroxyethyl)-1-piperazine-
ethanesulfonic acid
HGM Human gastric myofibroblast
HOE-642 4-Isopropyl-3-methylsulphonylbenzoyl-
guanidin methanesulphonate also known
as cariporide
IGF-II Insulin like growth factor II
IP3 Inositol 1,4,5-trisphosphate
J(B− ) Base flux
NBC Na+/HCO3
− cotransporter
NF-κB Nuclear factor kappa B
NHE Na+/H+ exchanger
NMDG N-metil D-glucamine
PBS Phosphate buffered saline
pHi Intracellular pH
PIP2 Phosphatidylinositol 4,5-bisphosphate
PKC Protein kinase C
PLC Phospholipase C
PP Proton pump
RPMI Roswell Park Memorial Institute
RT Room temperature
RT-PCR Reverse transcription polymerase
chain reaction
SEM Standard error of mean
SMA Smooth muscle actin
SR Sarcoplasmic reticulum
Introduction
Myofibroblasts, also known as activated fibroblasts, are
dynamic, spindle-like cells sharing the functional character-
istics of both fibrocytes and smooth muscle cells [24]. They
are crucial for the production of extracellular matrix and for
morphogenesis [42]; moreover, they take part in inflamma-
tory processes related to tissue repair and in the chronic
inflammation–adenoma–carcinoma sequence by secreting a
broad spectrum of cytokines thereby altering the microenvi-
ronment around epithelial cells [23, 41]. To accomplish their
functions, myofibroblasts migrate and proliferate in the
subepithelial compartment, generating acidic metabolites
and consequently protons in the cytosol [21]. Protons are
removed from cells mainly by acid/base transporters located
on the plasma membrane [7], thus maintaining isoionic
intracellular conditions.
Although many authors have investigated the regulation
of acid/base transporters and their role in migration and
proliferation of epithelial cells [16, 31, 39, 45] or fibroblasts
[10, 11, 48, 57], no information is available concerning the
effects of acid/base transporter activities on migration and
proliferation of gastric myofibroblasts.
One of the main proton extrusion mechanisms is sodium/
hydrogen exchange through the Na+/H+ exchangers (NHEs),
which are members of a transporter family comprising of ten
isoforms [32, 44]. It has been demonstrated that NHE1
functions not only as a cation exchanger, but also as a
modulator of intracellular signalling thereby regulating
motility in different animal species including mouse [53], rat
[14], dog [30], guinea pig [57] and human cells including
leukocytes [49], melanoma cells [55] and hepatoma cells [67].
NHE1 activity was found to be necessary for proliferation of
brain-derived pericytes [25], fibroblasts [26], lymphocytes
[60] and vascular smooth muscle cells [65]. Furthermore,
inhibition of NHE1 activity significantly reduces proliferation
rates in vascular smooth muscle cells [65].
It has been demonstrated that gastric epithelial cells
secrete matrix metalloproteinase-7 which cleaves
myofibroblast-produced insulin-like growth factor binding
protein-5 thereby releasing insulin-like growth factor-II
(IGF-II). IGF-II acts as a potent stimulant of both epithelial
and myofibroblast proliferation [36]. The muscarinic
acetylcholine receptor type 3 (M3) agonist carbachol has
been shown to increase NHE activity in rabbit parietal cells
[3] and in guinea pig pancreatic ductal epithelial cells [59].
Many inhibitors of NHE activity have been described as a
consequence of intensive research on amiloride derivatives
to develop isoform-specific NHE inhibitors for use in
cardiovascular care. 4-Isopropyl-3-methylsulphonylbenzoyl-
guanidin methanesulphonate (HOE-642), also known as
cariporide, is one of the most effective compounds, which
can dose-dependently inhibit specific NHE isoforms [47].
The aim of this study was to characterize the acid/base
transporters of human gastric myofibroblasts (HGMs), focus-
ing on the possible roles of NHE1 in cell migration and
proliferation.
Materials and methods
Chemicals and solutions
Chemicals and solutions used for cell culture were purchased
from Sigma-Aldrich (Budapest, Hungary). All reagents for
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immunocytochemistry, unless indicated otherwise, were
purchased from Jackson ImmunoResearch Laboratories (West
Grove, PA, USA). Chemicals and reagents for polymerase
chain reaction (PCR), unless indicated otherwise, were
obtained from Promega (Southampton, UK). All primers
were purchased from Eurogentec (Southampton, UK).
HOE-642 (cariporide) was kindly donated by Sanofi-
Aventis (Frankfurt, Germany). 2,7-Biscarboxyethyl-5(6)-
carboxyfluorescein-acetoxymethylester (BCECF-AM) and
HOE-642 were dissolved in dimethyl sulfoxide. The compo-
sition of solutions used for the measurements of intracellular
pH (pHi) is given in Table 1. 4-(2-Hydroxyethyl)-1-piperazine-
ethanesulfonic acid (HEPES) solutions were titrated to pH 7.4
at 37°C using either NaOH or HCl. HCO3
−-buffered solutions
were gassed with 95% O2 and 5% CO2 at 37°C.
Ethics
The study was approved by the Ethics Committee of the
University of Szeged, Hungary. All surgical patients gave
informed consent.
Patients, isolation and culture of HGMs
Tissue specimens from patients undergoing gastric tumour
resection in the Department of Surgery, University of Szeged,
Hungary were obtained intraoperatively at least 3–4 cm away
from the tumour and were transported immediately to the
laboratory in ice-cold media for culturing (n=3). Two other
specimens from multiple organ cadaver donors were
obtained similarly. Patient details can be found in Table 2.
Histopathology confirmed that all specimens were normal
gastric tissue samples. The isolation of HGMs was performed
using a previously described method [27]. Briefly, the speci-
mens were washed and chopped into very small pieces and
were then bathed in a shaking water bath at 37°C for 15 min
with 1 mM dithiothreitol. After washing, the specimens were
incubated for 30 min at 37°C with 1 mM ethylenediamine
tetra-acetic acid (EDTA) four times. Specimens were cultured
for 1–2 weeks in Roswell Park Memorial Institute (RPMI)
medium supplemented with 10% fetal bovine serum, 1%
penicillin–streptomycin and 2% antibiotic–antimycotic solu-
tion. After the cells became confluent, they were trypsinized
with 0.25% trypsin-EDTA and were transferred into Dulbec-
co’s Modified Eagle’s Medium (DMEM) with 4 mM L-
glutamine containing 10% fetal bovine serum, 1% amino
acid solution, 1% penicillin–streptomycin and 2% antibiotic–
antimycotic solution. The medium was replaced every 48 h
and the cells were passaged after reaching confluency up to
Table 1 Composition of solutions. Values are in millimolar concentrations
HEPES HCO3
− NH4Cl
HEPES
NH4Cl
HCO3
−
Cl−-free
HEPES
Cl−-free
HCO3
−
Cl−-free
NH4Cl/
HEPES
Cl−-free
NH4Cl/
HCO3
−
Na+-free
HEPES
Na+-free
HCO3
−
Na+-free
NH4Cl/
HEPES
Na+-free
NH4Cl/
HCO3
−
High K+-
HEPES
NaCl 130 115 110 95 5
KCl 5 5 5 5 5 5 5 5 130
Na-HEPES 10 25 10 10
CaCl2 1 1 1 1 1 1 1 1 1
MgCl2 1 1 1 1 1 1 1 1 1
Glucose 10 10 10 10 10 10 10 10 10 10 10 10 10
NH4Cl 20 20 20 20
NaHCO3 25 25
HEPES 10 10 10 10
Na-gluconate 140 115 120 95
K2-sulfate 2.5 2.5 2.5 2.5
Ca-gluconate 6 6 6 6
Mg-gluconate 1 1 1 1
NH4-sulfate 20 20
NMDG 140 115 120 95
Atropine 0.01 0.01 0.01
Choline-HCO3 25 25 25
Table 2 Patients’ details
Patient no. Gender Age Diagnosis
1 Female 71 Gastric cancer
2 Male 76 Gastric cancer
3 Male 66 Gastric cancer
4 Female 42 Subarachnoidal haemorrhage
5 Male 49 Traumatic head injury
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passage 10. Cell cultures were continually incubated at 37°C
in a mixture of 5% CO2 and 95% air.
Immunocytochemistry
Twelve thousand HGMs were seeded onto chamber slides
and were allowed to adhere overnight. Cells were fixed
using 4% paraformaldehyde for 30 min and were washed
twice with phosphate buffered saline (PBS, Invitrogen,
Paisley, UK). Permeabilization was performed by incuba-
tion with a filtered, PBS-based solution containing 0.2%
Triton X-100 and 0.3% protease-free bovine serum albumin
for 30 min. Cells were then incubated with 10% donkey
serum in PBS for 30 min. After washing twice with PBS,
primary antibodies were added to the chambers and the slides
were incubated in moist atmosphere at 4°C, overnight. The
following primary antibodies were used: anti-α-smooth
muscle actin (α-SMA) antibody raised in guinea pig (1:400),
anti-vimentin antibody raised in mouse (1:400), anti-
cytokeratin antibody raised in mouse (1:400), anti-desmin
antibody raised in mouse (1:400, all four antibodies from
Dako, Denmark) and anti-NHE1, -NHE2 and -NHE3
antibodies raised in goat (1:50, purchased from Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Primary
antibodies were removed by a sequence of washes for
10 min each with 0.14, 0.5 and 0.14 M NaCl dissolved in
PBS, respectively. Slides were then incubated with
secondary antibodies for 60 min in dark and moist conditions.
The following secondary antibodies were used: fluorescein
isothiocyanate (FITC)-conjugated anti-guinea pig secondary
antibody [1:400, diluted in 10 mM HEPES, pH 7.5], Texas
Red- and FITC-conjugated anti-mouse antibody (1:400) and
FITC-conjugated anti-goat secondary antibody (1:400). After
hybridization, slides were washed three times with PBS and
were covered with 4,6-diamidino-2-phenylindole (DAPI)
containing Vectashield mounting medium (Vector Labora-
tories, Peterborough, UK), then cover slipped.
Intracellular pH measurement
One hundred thousand HGMs were seeded onto 24-mm-
diameter round glass coverslips in full media. They were
allowed to recover for 24 h before experiments. Coverslips
were then transferred into a perfusion chamber and
mounted on an inverted microscope (Olympus, Budapest,
Hungary). Cells were bathed in HEPES solution at 37°C
and were loaded with 2 μM pH-sensitive fluorescent dye
BCECF-AM (Invitrogen, Paisley, UK) for 20 to 30 min.
Thereafter, myofibroblasts were continuously perfused with
solutions at a rate of 5 to 6 ml/min and pHi was measured
by using an imaging system (CellR; Olympus, Budapest,
Hungary). Cells were excited at wavelengths of 490 nm and
440 nm, and the 490/440 fluorescence emission ratio was
measured at 535 nm. One pHi measurement was recorded
per second.
In situ calibration of the fluorescence signal was performed
using the high K+-nigericin technique as previously described
[22, 58]. The pH of high K+–HEPES solution supplemented
with 10 μM nigericin was set to 6.8 or 7.4 at 37°C, then cells
loaded with BCECF were superfused by these solutions and
the 490/440 fluorescence ratio was recorded. Multiple-point
calibrations, i.e. sequential BCECF pH measurements (with
high K+–HEPES–nigericin solutions ranging pH from 6.2 by
0.4 step to 8.2) were performed to confirm data accuracy.
Linear projections were made from the steady-state fluores-
cence pH data during high K+-nigericin superfusion with
known pH. Adaptation of projections to the resting fluores-
cence data of unknown pHi in standard HEPES solution
results in accurate resting pHi.
In order to characterize the acid/base transporters, we
used ion-withdrawal technique, and ammonium pulse
technique in HEPES- and HCO3
−/CO2-buffered solutions.
Initial rates (first 30–60 s) of recovery from acidosis were
calculated by linear regression.
Determination of buffering capacity and calculation of base
fluxes
The intrinsic buffering capacity (βi) of HGMs was estimated
by the NH4
+ pre-pulse technique [62]. βi refers to the ability
of intrinsic cellular components (excluding the bicarbonate
buffer system) to buffer changes of pHi. Briefly, HGMs were
exposed to various concentrations of NH4Cl while Na
+ and
HCO3
− were omitted from the solution to block the Na+-
dependent pH regulatory mechanisms. βi was estimated by
the Henderson–Hasselbalch equation. The total buffering
capacity (βtotal) was calculated as βtotal=βi+βHCO3
−=βi+
2.3×[HCO3
−]i, where βHCO3
− is the buffering capacity of the
HCO3
−/CO2 system and [HCO3]i is the intracellular concen-
tration of HCO3
−. Transmembrane base flux [J(B−)] was
calculated by using the equation J(B−)=dpH/dt×βtotal. The
βtotal value used in the calculation of J(B
−) was obtained
from Fig. 2b by using the pHi value at the start of the 30-s
period over which dpH/dt was measured.
Reverse transcription polymerase chain reaction
RNA was isolated from myofibroblast cultures using a
Qiagen RNEasy Mini Kit (Qiagen House, Crawly, UK)
according to the manufacturer’s instructions; human kidney
RNAwas isolated from whole tissue from surgical specimens
utilizing TRIzol reagent. RNA was reverse transcribed to
cDNA and RNA/primer annealing was performed with 0.5 μg
oligo-dT primer at 65°C for 5 min. After cooling, samples
were reverse transcribed in a final reaction volume of 30 μl
containing the annealed RNA/primer set, 5× AMV (avian
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myeloblastosis virus) buffer, 1.25 mM dNTP (deoxyribonu-
cleotide-triphosphates) mix, 20 unit RNAse inhibitor and 15
unit AMV-RT (AMV-reverse transcriptase). Reactions were
incubated at 42°C for 1 h; enzymes were inactivated at 85°C
for 5 min. cDNA (1 μl) was used as template for each PCR in
a final volume of 25 μl, containing 10× master mix
Taq-buffer, 10 nM dNTPs, 2.5 unit Taq-polymerase and
1 μM NHE primer sets. The sequence of NHE primers
is given in Table 3. PCR settings were as follows:
denaturation at 95°C for 15 s, annealing at 60°C for 15 s,
extension at 72°C for 45 s, 30 cycles. PCR products and
DNA HyperLadderPlus (BioLine, Taunton, USA) were
run on a 0.8% agarose gel containing 0.005% ethidium
bromide in Tris-buffered EDTA solution at 80 V, then the
gel was illuminated in a BioRad UV (ultraviolet) chamber
and photographs were taken.
Immunoblot analysis
Confluent cells (3,000,000 cells at least) were washed with
PBS after removing the media and were then incubated
with 100 mM EDTA for 15 min. After centrifugation
(500×g, 8 min), the supernatant was gently removed and
was lysed with RIPA (radio-immuno precipitation assay)
buffer supplemented with 1% protease inhibitor cocktail
(Calbiochem-Merck Chemicals, Darmstadt, Germany).
Samples were vortexed and frozen in liquid nitrogen for a
few seconds then centrifuged at 11,000×g for 10 min at
4°C. The protein concentrations of supernatants containing
whole cell protein lysates were determined by using
Bradford’s reagent. Samples were heat treated at 30°C for
30 min and 100 μg protein was electrophoresed on 8%
sodium dodecylsulfate-polyacrylamide gels according to
the method of Laemmli using a Hoefer Mighty Small II
instrument (Harvard Bioscience Inc., Massachusetts, USA).
After separation, proteins were blotted to matching-sized
nitrocellulose membrane for 60 min at 100 V. Membranes
were blocked in 5% nonfat dry milk for 1 h and were
incubated with primary antibodies (1:100 for NHE)
overnight at 4°C on a rocker. The same NHE primary
antibodies were used as for immunocytochemistry. Primary
antibodies were removed by washing with TBST for 3×
10 min. HRP-conjugated secondary antibodies (Dako,
Denmark) were applied for 60 min at RT on a rocker. After
3×10 min TBST wash, the immunoreactive protein was
visualized by enhanced chemiluminescence. Remaining
antibodies were removed by washing with TBST, then
anti-glyceraldehyde 3-phosphate dehydrogenase antibody
(Dako, Denmark) was added to the membrane for 60 min at
RT. Secondary antibody (1:10,000) was also applied for
60 min at RT then signals were recorded as described
earlier.
Migration assays
HGMs (125,000 cells) were seeded onto six-well plates and
allowed to adhere overnight in full media. On the following
day, the confluent monolayer was gently scratched using a P2
tip. Only the wells containing even-sided and sharp-edged
wounds were used for experiments. After gentle washing for
three times with serum-free media, wounds were measured
and photographed under inverted light microscope. Reagents
were then added to the wells in serum-free media in all of the
experiments and plates were incubated in CO2 incubator at
37°C for 24 h. Migration was evaluated by counting the cells
in the same area of the wound after 12 and 24 h as reported
earlier [43].
Proliferation assays
Myofibroblasts (50,000 cells) were seeded onto cover
glasses. After overnight incubation, HGMs were synchro-
nized by incubation for 30 h in serum-free media.
Thereafter, 10 μM 5-ethynyl-2-deoxyuridine (EdU; Alexa
Fluor 488 Imaging Kit, Invitrogen, Oregon, USA; for
further details, see reference [50]) was added to the cells for
overnight incubation with or without treatment. After
incubation, the manufacturer’s protocol was applied to fix
and permeabilize the cells and to detect EdU incorporation.
We used DAPI to detect nuclear staining. The proliferation
rate was calculated by normalizing the number of EdU
positive cells to the DAPI-stained cells in 10 fields at 20x
magnification.
Statistical analysis
Values are expressed as means±standard error of mean
(SEM). Statistical analyses were performed using non-
parametric Kruskal–Wallis tests with post-hoc Wilcoxon
tests for pairwise comparisons and Bonferroni correc-
tion to test post-hoc significance. p<0.05 was accepted
as significant. n numbers are given as follows: n =
number of patients/number of independent experiments
per patient.
Table 3 NHE primer sequences
Primer name Sequence (5' - 3')
NHE1 forward CCT-CTC-TGG-GTG-GAG-AAG-CT
NHE1 reverse CCC-AGG-AAC-GAC-ACA-GAA-AG
NHE2 forward CCA-TGG-AAC-CAC-TGG-GCA-AC
NHE2 reverse TGC-AGG-GGG-AGA-CTT-CTC-AT
NHE3 forward TCC-AAG-TCG-ACC-AAG-CTG-GG
NHE3 reverse AAG-GCC-TCG-TCC-GGA-GAA-AA
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Results
Identification of myofibroblasts
Cells showed positive staining for α-SMA and vimentin but
not for cytokeratin and desmin, which are characteristics of
myofibroblasts (Fig. 1). The purity of the HGM cell cultures
was ∼100%. As positive controls for cytokeratin and desmin
antibodies, we used CAPAN-1 (human pancreatic adenocar-
cinoma cell line) cells and cultured human high grade
pancreatic neuroendocrine carcinoma cells, respectively. In
both cases, appropriate localisation was demonstrated
(Fig. 1).
Determination of the resting pHi of HGMs
The multiple-point calibration technique utilizing high
K+–HEPES/nigericin solution was used to determine the
resting pHi of HGMs. Our experiments showed that the
resting pHi of HGMs in HEPES solution was 7.09±0.02
(Fig. 2).
Characterization of the acid/base transporters of HGMs
Next we tried to identify the functionally active acid/base
transporters expressed on the plasma membrane of
HGMs. Na+ withdrawal from the standard HEPES solution
Fig. 1 Immunocytochemical identification of cell cultures. Cells
isolated from human gastric samples were grown on chamber slides
and were subjected to immunocytochemical analysis of vimentin and
α-smooth muscle actin (α-SMA) expression as specific markers of
myofibroblasts. Cytokeratin and desmin antibodies were used for
detecting epithelial and muscle cells, respectively. Nuclei were
counterstained with DAPI (blue). Vimentin (red) and α-SMA (green)
verified the presence of myofibroblasts, whereas no epithelial or
smooth muscle cells were detected (n=5/1–2). Control stainings were
performed to test the desmin and cytokeratin antibodies. Cultured
cancer cells (from human high grade pancreatic neuroendocrine
carcinoma) were used as positive controls for desmin (green staining,
n=1). To test the cytokeratin antibody, control staining was performed
on CAPAN-1 (human pancreatic adenocarcinoma cell line) cells.
Green staining shows cytokeratin; blue staining shows DAPI (n=1)
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Fig. 2 The resting pHi of gas-
tric myofibroblasts and mea-
surement of buffering capacity.
A Human gastric myofibroblasts
(HGMs, 100,000) were seeded
onto cover glass to form mono-
layers. Cells were allowed to
recover for 24 h. a Phase
contrast image of myofibroblasts
is shown. Four to seven cells
as regions of interests (ROIs)
were marked. b Thermal-
adjusted image is shown to
demonstrate homogenous
BCECF dye distribution. Color
coding shows the pHi; c 490
and d 440 nm fluorescent
images are also shown. e Cells
were excited at wavelengths of
490 and 440 nm after loading
the cells with the pH-sensitive
fluorescent dye 2 μM
BCECF-AM, and the 490:440
fluorescence emission ratio was
measured at 535 nm. Cells
were exposed to continuous
perfusion with nigericin/high
K+–HEPES solutions of pH 6.80
and 7.40. The resting pHi was
calculated by multiple-point
calibration (n=5/5–6). The
figure shows a representative
calibration curve; the mean
resting pHi in standard HEPES
solution was 7.09±0.02. B
The buffering capacity of HGMs
was determined by exposing
the cells to various concentra-
tions of NH4Cl while Na
+ and
HCO3
− were omitted from the
solution to block Na+-dependent
pH regulatory mechanisms.
The intrinsic buffering capacity
(βi) at different pHi (black
circle, n=85) was estimated by
the Henderson–Hasselbalch
equation. Regression analysis
was performed using the
curve-fitting protocol in Excel.
The total buffering capacity
(βtotal) was calculated as βtotal
=βi+βHCO3
−=βi+2.3×
[HCO3
−]i, where βHCO3
− is the
buffering capacity of the
HCO3
−/CO2 system and [HCO3]i
is the intracellular
concentration of HCO3
−
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caused strong reversible acidification suggesting the
presence of an active Na+-dependent H+ efflux mechanism
(Fig. 3a).
Switching the standard HEPES solution to standard
HCO3
−/CO2 solution caused rapid intracellular acidification,
most probably due to CO2 diffusion into the cells. Thereafter,
a small pHi recovery was observed suggesting a HCO3
−
influx and/or H+ efflux mechanism (Fig. 3b). In order to
determine the Na+ dependency of this HCO3
− influx/H+
efflux mechanism, the same experiment was performed in
Na+-free conditions (Fig. 3c). Since no recovery was found
in the presence of HCO3
−/CO2 in Na
+-free solution, we can
assume that the HCO3
− influx/H+ efflux mechanism in
HGMs is Na+-dependent. These results indicate that HGMs
express functionally active NHE and/or NBC.
Next we tested whether HGMs contain functionally active
anion exchangers (AE). Cl− removal from the standard
HCO3
−/CO2 solution caused reversible alkalization suggesting
the presence of a Cl−-dependent HCO3
− efflux mechanism
(Fig. 3d). Importantly, omitting HCO3
− from the extracellular
solution in combination with Cl− removal resulted in no
significant change in pHi (Fig. 3e). This indicates that HGMs
express functionally active AE.
To confirm these findings, the activities of acid/base
transporters were also investigated by the ammonium pulse
technique. Exposure of HGMs to 20 mM NH4Cl induced
an immediate rise in pHi due to the rapid entry of the
lipophilic base, NH3, into the cells, which binds intracellu-
lar protons generating NH4
+ and causing alkalization. The
recovery from this alkali load is promoted by AEs in the
Fig. 3 Na+-dependent HCO3
− influx and Cl−-dependent HCO3
−
efflux mechanisms are present in HGMs. Representative pHi curves
of HGMs are shown. a The sudden removal of extracellular Na+ from
the standard HEPES solution caused rapid acidification, which was
reversed by the re-addition of the ion. b Administration of HCO3
−/
CO2-buffered solution after standard HEPES solution caused acidifi-
cation of pHi followed by alkalization (HCO3
− influx). c Switching
from Na+-free HEPES solution to Na+-free HCO3
−/CO2-buffered
solution caused acidification, but no pHi recovery was seen. d In
HCO3
−/CO2-buffered solution, Cl
− removal resulted in alkalization of
pHi followed by a complete recovery after re-addition of Cl
−. e Cl−
removal from the standard HEPES solution did not alter significantly
the pHi, and it reached again the resting value before re-addition of
Cl− (n=5/5–6)
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presence of HCO3
− and Cl− in the extracellular solution. In
support of this, the recovery from alkali load was much
steeper in the presence of HCO3
−/CO2 (Fig. 4c, d)
compared with the absence (Fig. 4a, b) of HCO3
−/CO2. It
is worth mentioning that the slow uptake of NH4
+ is also a
prerequisite for the acid loading. After the removal of
NH4Cl, NH3 diffuses out of the cell, therefore facilitating
the dissociation of intracellular NH4
+ to H+ and NH3, which
rapidly decreases pHi. Thereafter, the pHi starts to recover
after this acidification owing to activation of pHi regulatory
mechanisms namely the NHE, NBC and proton pumps (PP;
Fig. 4c). In the absence of extracellular HCO3
− and in the
presence of Na+, the recovery from acidosis reflects the
activity of NHE and PP (Fig. 4a). However, the lack of
recovery in the absence of Na+ excludes functionally active
PP in HGMs (Fig. 4b). The addition of HCO3
− to the
extracellular solution strongly increases the pHi recovery
from acidosis (Fig. 4c). Since there is no pHi recovery
from acidosis in Na+- and HCO3
−-free solution (Fig. 4d),
it is assumed that the HCO3
− influx mechanism is most
probably accomplished by the Na+-dependent NBC.
Therefore, we tested the effects of the NBC inhibitor
H2DIDS in 0.5 mM concentration and the NHE1 and
NHE2 inhibitor HOE-642 at 50 μM on the recovery rates
during and following an acid load in HCO3
−/CO2-buffered
solution (Fig. 4). We calculated J(B−) from these and from
the above experiments (Fig. 4) and found that NBC
inhibition greatly reduced pHi recovery after acid load
Fig. 4 Na+-dependent H+ efflux and Na+-dependent HCO3
− influx
were detected in HGMs a Representative pHi curves of HGMs are
shown. Cells were exposed to 20 mM NH4Cl pulse in HEPES-
buffered solution for 3 min. After the acid load, recovery of pHi could
be observed. However, the administration of Na+-free HEPES solution
after the ammonium pulse inhibited pHi recovery after the acid load. The
same technique was applied in HCO3
−/CO2-buffered solution. Note that
the initial phase of the pHi recovery during the ammonium pulse is
quicker than in HEPES solution and the recovery phase after the acid
load is much steeper. Also in Na+-free HCO3
−/CO2-buffered solution, no
recovery could be seen after the ammonium pulse. b The bar chart
shows the summary data of base fluxes after recoveries from acid load.
Values are shown as means±SEM (n=5/10–12). *p<0.05 vs. 25 mM
HCO3
−. c Inhibition of Na+/HCO3
− co-transporter (NBC) with 0.5 mM
H2DIDS and/or inhibition of NHE1–2 with 50 μMHOE-642 during acid
load in HCO3
−/CO2-buffered solution is shown. d The rates of recovery
from acid load were determined and base fluxes were calculated from the
experiments shown above. Absolute values are displayed for comparison
(n=5/1–2); values are shown as means±SEM. *p<0.05 vs. 140 mM
Na+, 25 mM HCO3
−; a p<0.05 vs. 25 mM HCO3
−+0.5 mM H2DIDS; b
p<0.05 vs. 25 mM HCO3
−+50 μM HOE-642
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(20.54±1.76 vs. 7.99±0.39 mM B−/min) revealing high
transporter activity. 50 μM HOE-642 further decreased the
recovery rate from acidosis (7.99±0.39 vs. 3.91±0.41 mM
B−/min) indicating high NHE1 and NHE2 activities.
Simultaneous administration of the two inhibitors resulted
in very slow recovery (0.98±0.09 mM B−/min). Without
HCO3
−/CO2 buffering in standard HEPES solution, cells
showed much slower recovery than with bicarbonate
buffering (13.36±0.41 vs. 20.54±1.76 mM B−/min). As
seen on Fig. 4b, d, eliminating Na+ from the extracellular
solution inhibited the cells to recover from an acid load in
both HCO3
−/CO2-buffered solution and in standard
HEPES solution.
Next, we focused our attention on characterizing the
NHE isoforms expressed on the plasma membrane of
HGMs. The HGMs were acid-loaded by exposure to a
3-min pulse of 20 mM NH4Cl in HEPES solution followed
by a 5-min exposure to Na+-free HEPES solution (Fig. 5a).
Since neither Na+ nor HCO3
− was present in the extracel-
lular solution, acid/base transporters were inhibited and the
pHi was adjusted to a stable acidic level. NHE activity was
induced by the re-addition of extracellular Na+ and the
activity of NHEs was determined by measuring the initial
rates of pHi recovery over the first 60 s (60 data points).
The activities of the different NHE isoforms were
determined by using the isoform selective NHE inhibitor
HOE-642 (cariporide). At 1 μM HOE642 inhibits NHE1
whereas at 50 μM it inhibits both NHE1 and NHE2,
but not NHE3 [69].
Our data indicate that NHE1 is responsible for about
85% of the Na+/H+ exchange activity, whereas NHE2
activity is around 10% and the remaining NHE activity is
approximately 5% (Fig. 5b). Of course, we cannot exclude
the possibility of the involvement of other NHEs. However,
even if they were expressed, they would only have marginal
influence on H+ efflux.
mRNA and protein expression of NHE1-3 in HGMs
Based on results of the functional measurements, we
investigated the presence of NHE transporters at the mRNA
and protein levels. Reverse transcription polymerase chain
reaction confirmed the expression of NHE1, NHE2 and
NHE3 (Fig. 5c). We also analysed the expression of NHE
isoforms in HGMs by Western blot. We found that NHE1 is
present in HGMs, but we were unable to show NHE2 and
NHE3 expression. Positive controls (human kidney) con-
firmed that the antibodies used for these studies were fit for
purpose (Fig. 5d). We speculate that NHE2 and NHE3
protein abundance is low in our lysates so below the limit
of detection. Using immunocytochemistry, we demonstrat-
ed NHE1-3 localisation to the plasma membrane of HGMs
(Fig. 5e).
IGF-II and carbachol increases NHE activity
We then investigated the effects of IGF-II and carbachol on
the activities of NHEs. Importantly, both IGF-II and carbachol
dose-dependently stimulated NHE activity. Carbachol con-
centrations were tested in range of 1–1,000 μM. Carbachol
(10 μM) had the greatest effect on NHE activity. 100 ng/ml
IGF-II was more effective than 10 ng/ml in increasing NHE
activity (Fig. 6).
Migration of HGMs is stimulated by carbachol and IGF-II
Next, we investigated the effects of carbachol and IGF-II on
cell migration and the role of NHE1 in migration of HGMs
using scratch wound assay. We found that both 100 ng/ml
IGF-II and 10 μM carbachol stimulate the migration of
HGMs (Fig. 7). Inhibition of NHE1 by HOE-642 had no
effect on unstimulated cell migration, but it significantly
inhibited both carbachol- and IGF-II-stimulated migration
(by 29±7% and 33±8%, respectively).
IGF-II increases proliferation in an NHE1-dependent
manner
Finally, we tested the effects of HOE-642, IGF-II and
carbachol on HGM proliferation. EdU incorporation assays
showed that 100 ng/ml IGF-II increased cell proliferation
over two-fold. Carbachol and/or HOE-642 did not affect
proliferation. However, NHE1 inhibition by 1 μM HOE-642
completely blocked the stimulatory effect of IGF-II on cell
proliferation (Fig. 8).
Discussion
In this study, we have characterized the pHi regulatory
mechanisms of HGMs for the first time. The data demonstrate
that NHE1 activity contributes to IGF-II- and carbachol-
stimulated migration and that it is obligatory for IGF-II-
induced proliferation of HGMs.
The resting pHi of HGMs, 7.09±0.02, is similar to that
in fibroblasts [12, 28, 46] and smooth muscle cells [64].
Myofibroblasts displayed three main acid/base transporters,
namely NBC, AE and NHE. These are also the main
mechanisms regulating pHi in fibroblasts [2, 12, 29] and in
smooth muscle cells [15]. Thus, AE decreases, whereas,
NBC and NHE increase pHi. J(B
−) calculations revealed
high NBC and high NHE activities which are the main
transporters aiding recovery from an acid load in HGMs. In
the present study we chose to focus on the roles of NHEs.
Carbachol (10 μM) strongly stimulated NHE activity of
HGMs. It has been shown that carbachol also increases NHE
(and AE) activity in lacrimal gland epithelia [59] and in rabbit
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parietal cells [3]. In the latter study, carbachol strongly
increased NHE activity and its effect was completely blocked
by 1 μM HOE-642 suggesting the involvement of NHE1.
Atropine or intracellular Ca2+ chelation inhibited the activa-
tion of NHE indicating a typical muscarinic receptor effect
with a Ca2+-dependent signalling pathway [4, 59]. In the
Fig. 5 Identification of NHE
isoforms. a Representative pHi
curves of HGMs are shown.
Cells were loaded with acid by
using the ammonium pulse
technique. After Na+
withdrawal, the isoform-
selective NHE inhibitor
HOE-642 was administered in
1 μM (inhibits NHE1) or 50 μM
(inhibits NHE1 and NHE2)
concentration, together with
re-addition of Na+. The initial
rates of the pHi recovery during
HOE-642 administration
were calculated by linear
regression analysis to determine
the activity of NHE isoforms.
b The bar chart demonstrates
that NHE1 is responsible for 83
±5%, NHE2 for 11±1% and
other isoforms for 4.5±0.8% of
all Na+/H+ exchange activity.
Data are shown as means±SEM
(n=5/5–6). c Reverse
transcription PCR confirmed the
expression of NHE1–3
isoforms (n=3/6–7). Expected
PCR product sizes are as
follows: NHE1, 341 bp; NHE2,
407 bp; NHE3, 299 bp. In
water blind, we used water as
template. d Immunoblot analysis
showing different NHE isoforms
in HGMs and human kidney
controls. Protein sizes are as
follows: NHE1, 95 kDa; NHE2,
85 kDa; NHE3, 75 kDa;
GAPDH, 36 kDa (n=4–5/3–10).
e NHE1, NHE2 and NHE3
were identified by immunocyto-
chemistry in the plasma
membrane of HGMs. Nuclei
were counterstained with DAPI
(blue staining). No specific
staining was detected when the
primary antibody was omitted
(n=3/1–2)
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Fig. 6 The effects of carbachol and IGF-II on NHE activity. a
Representative pHi curves of HGMs are shown. We tested different
carbachol and IGF-II concentrations on NHE activity using the
ammonium pulse technique. The figure shows the effects of 10 μM
carbachol and 100 ng/ml IGF-II treatment. Note that the changes in
the rates of pHi recovery from acidosis during treatment are much
higher compared with the recovery rates without IGF-II or carbachol
treatment. b The bar diagram shows the summary data obtained from
the above mentioned experiments. Administration of 10 μM carbachol
and 100 ng/ml IGF-II significantly increased NHE activity. Values are
normalized to the basal NHE activity. Data are shown as means±SEM
(n=5/5–6). *p<0.05 vs. 0 μM or 0 ng/ml
Fig. 5 (continued)
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latter publications, the authors suggested that Ca2+-dependent
stimulation causes a selective activation of NHE1, whereas
cAMP-dependent stimulation with forskolin-activated NHE1,
NHE2 and more strongly NHE4. In HCO3
−-containing
solution, pHi did not change indicating that activation of
NHE and AE is primarily volume regulatory mechanisms,
and they speculated that the physiological significance of
secretagogue-induced NHE activity may be related to volume
and not to pHi regulation during acid secretion of rabbit
parietal cells [3].
IGF-II, which has been shown to stimulate migration and
proliferation of many cell types including myofibroblasts
Fig. 7 Carbachol and IGF-II treatment increased migration rates of
HGMs in a NHE1-dependent manner. a HGMs (100,000) were
cultured in six-well plates. After reaching confluency, the monolayer
was wounded by a P2 tip along an oriented line in the middle of the
well and detached cells were removed by washing with serum-free
media. Only wounds with sharp and even edges were used for
experiments. Reagents were added to the wells in serum-free media
and the plate was incubated for 24 h at 37°C, 5% CO2. Images were
taken at 0, 12 and 24 h from representative areas. Cells were treated
with or without 10 μM carbachol or 100 ng/ml IGF-II, and/or 1 μM
HOE-642 and cells which migrated into the wound were counted at 12
and 24 h. The scale bar on the first picture represents 100 μm. b The
bar chart shows the migration rates normalized to the basal rate at 24 h.
Values are shown as means±SEM, n=5/1–3; *p<0.05 vs. no treatment,
a p<0.05 vs 100 ng/ml IGF-II, b p<0.05 vs 100 ng/ml IGF-II and 1 µM
HOE-642, c p<0.05 vs 10 µM carbachol
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[36, 52], also stimulated NHE activity. It is known that
IGF-II exerts its effects through the tyrosine kinase receptor
IGF-IR and it is also well known that NHE1 is mainly
regulated by phosphorylation. Meima et al. reported that
IGF-IR activates Ser/Thr kinases in the Akt signalling
pathway and increases myofibroblast migration, growth and
NHE activity by phosphorylating intracellular NHE regula-
tory domains thus enhancing transporter activity [37]. The
distal region of the cytoplasmic tail of NHE corresponding to
amino acids 700–815, is enriched in serine and threonin
residues that are phosphorylated by different protein kinases
in response to hormones and/or growth factors [51]. It has
also been suggested that Ser/Thr kinases not only stimulate
NHE1 activity, but also increase NHE1 promoter transcription
[5]. ERK1/2 regulates gene expression via the MAPK
cascade [40] after NHE1 phosphorylation/activation through
p90RSK (a downstream substrate of ERK1/2) [56]. p90RSK
directly phosphorylates NHE1 at position 703(Ser) in vascular
Fig. 8 IGF-II stimulates the proliferation of HGMs in a NHE1-
dependent manner. a Representative images showing EdU localisation
after treatment with 1 μM HOE-642, 100 ng/ml IGF-II and/or 10 μM
carbachol compared to control. HOE-642 (1 μM) did not affect
proliferation either on its own, or in a combination with 10μMcarbachol.
IGF-II (100 ng/ml) increased the rate of proliferation. Furthermore, the
inhibition of NHE1 suppressed the IGF-II stimulatory response. Nuclei
were counterstainedwith DAPI (blue staining). The scale bar on the first
picture represents 50 μm. b The bar chart shows the proliferation rates
of a normalized to the basal proliferation rate; *p<0.05, a p<0.05 vs
100 ng/ml IGF-II (n=5/1–2)
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smooth muscle cells after growth hormone treatment and the
exchanger activity was found to be increased [56]. Another
important factor in the regulation of NHE is protein 14-3-3,
which binds to position 703(Ser) after its phosphorylation
and limits dephosphorylation by protein phosphatases [33].
Additional Ser/Thr phosphorylation sites have been recently
identified in the ERK pathway, but their importance must be
confirmed [35].
Our experiments demonstrate that reagents increasing NHE
activity also increase HGM migration and proliferation, so the
question arises whether in turn NHE inhibition may inhibit cell
migration and proliferation. The effects of parasympathomi-
metics on cell migration are conflicting, though they are
thought to stimulate NHE activity in general. In HaCaT cells,
carbachol did not alter single random cell locomotion
compared to non-treated cultures [38]. Epidermal keratino-
cytes showed enhanced migration after long-term muscarinic
stimulation with acetylcholine in an agarose gel outgrowth
system [18], whereas carbachol treatment arrested wound
healing in epidermal keratinocytes [9]. Besides the differences
between species and tissues, it seems that various muscarinic
receptors can mediate different migration responses even in
the same cell [63]. Our experiments clearly showed that
10 μM carbachol stimulated migration of HGMs, at least
partly in a NHE1-dependent manner, but higher or lower
doses had no further effect on migration (data not shown). It
is known that protein kinase C (PKC) might mediate M3
receptor signals causing PLC to cleave membrane phospho-
lipids. PIP2 is cleaved into diacyl glycerol and IP3 which is
released into the cytosol and binds to IP3 receptors localised
at the ER (or SR) causing consequent increase of the
cytosolic calcium concentration and a cascade of activity
including locomotion of contractile cells [1]. M3 receptors,
through PLC, may also activate PI3K/Akt cascade. In the
context of gastric cancer, it is worth mentioning that apoptosis
can be suppressed through the PI3K/Akt/mTOR pathway
allowing vigorous proliferation and better survival [68]. PKC
modulates gene regulation via NF-κB and by joining Raf/
MAPK cascade. It has been shown recently that PKC may
phosphorylate the potent activation transcription factor-2,
which controls c-Jun-mediated activation of transcription
[66]. The observed increase in migration in our studies
suggests, however, a permissive or supporting role of NHE1
in enabling migratory mechanisms to take effect in response
to bioactive compounds. Others have found that not only
NHE1 activity, but also intact NHE1 protein structure is
required for locomotion, since mutations/modifications of
protein structure or inhibition of the exchanger activity also
inhibits migration [30]. Notably, NHE1 is a scaffolding-
organizing protein functioning as a transmembrane signal
transducer for various agents modulating cell volume, cell
migration and growth through NHE1 activity [27]. Muscarinic
agonists have also been shown to evoke differential effects on
proliferation depending on the type of the muscarinic receptor
[63]. We found that the M3 agonist carbachol does not induce
proliferation of HGMs.
IGF-II stimulates the proliferation of many cell types,
including myofibroblasts [19, 36]. NHE1 may act as an
organizer of different cell growth inducing signals through
modulation of transporter activity via receptor tyrosine
kinases and joint pathways. Denker et al. reported that
NHE1 protein contains an intracellular esrin/radixin/moesin
(ERM) motif close to the plasma membrane, which anchors
the protein to the subcortical actin filament network and
serves as a host to actin polymerization [14]. In a wound
healing assay, migration was impaired when mutations
disrupted the ERM site. Not only ERM site mutations,
but also mutations of the transporter sequence (resulting
in diminished NHE1 activity), impair de-adhesion
resulting in failure to retract lamellipodia. Besides this
membrane anchoring, NHE1 is important in regulating
cell volume and local pH at changing membrane sites of
a moving cell; it is known that in fibroblasts NHE1 is most
abundant at the rear and front pole of a spatially polarized
migrating cell [14].
We showed that inhibition of NHE1 blocks migration
and proliferation of HGMs. Since stromal cells play an
important role in cancer initiation and progression [6, 13,
31], our results may have both physiological and therapeu-
tic relevance. It is well documented that proliferation is
reduced by NHE1 inhibition in human cancer cells [20, 49].
However, it is also possible that intracellular alkalization
simply promotes or permits proliferative responses, because
as the pHi becomes more alkaline, cellular metabolism
becomes more rapid mainly due to the more effective energy
producing mechanisms [20]. For example, in tumour cells,
acid/base conditions are of particular importance, because
cancer cells share an aberrant intracellular alkalization
facilitating their malignant behavior, whereas the microenvi-
ronment becomes more acidic [8]. Nevertheless, as mentioned
before, NHE1 is highly regulated by phosphorylation and Akt
kinases that phosphorylate NHE1 increasing its activity also
stimulate proliferation at the same time [17, 34, 54].
In conclusion, we have demonstrated that HGMs express
functionally active NHE, NBC and AE transporters which
regulate pHi. Furthermore, we have shown that NHE1
contributes to IGF-II- and carbachol-stimulated migration,
and that it is obligatory for IGF-II-induced proliferation.
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A humán kationos tripszinogén és mutációinak szerepe pancreatitisben 
Tézis kivonat 
BEVEZETÉS 
A pancreatitis a hasnyálmirigy gyulladásos megbetegedése, kialakulásának hátterében a 
pancreasban kórosan megnövekedett tripszinaktivitása áll. A korai tripszin aktiválódás ellen 
többek között a pancreas vezeték sejtek által termelt, bikarbonátban gazdag, alkalikus folyadék 
folyamatos szekréciója véd. A folyadék folyamatos termelése biztosítja a zimogének 
vékonybélbe jutását. A szekréció csökkenése az emésztőenzimek kijutási időtartamának 
megnövekedése mellett az intraduktális pH savanyodását eredményezi. Ez felveti annak 
lehetőségét, hogy az intraduktális pH csökkenése szerepet játszik a betegség kialakulásában. 
A hasnyálmirigy-gyulladás örökletes formája a herediter pancreatitis, dominánsan 
öröklődő autoszomális betegség, hátterében a legtöbb esetben a kationos tripszinogént kódoló 
szerin proteáz 1 (PRSS1) gén pontmutációi állnak. Az a felismerés, hogy a PRSS1 mutációk 
betegséget okoznak, igazolta a tripszin pancreatitisben betöltött kulcsfontosságú szerepét. A 
betegekben előforduló gyakoribb PRSS1 mutációk (p.R122H, p.N29I) megváltoztatják a fehérje 
biokémiai tulajdonságait oly módon, hogy fokozzák a spontán tripszin képződést 
(autoaktivációt). Mindezt az autoaktiváció és lebontás kimotipszin C (CTRC) általi 
szabályozásának a megváltoztatása révén érik el. A mutáció a tripszinogén fehérje hibás 
feltekeredését és emiatt a sejtből történő csökkent szekrécióját is okozhatja. A hibás 
feltekeredésből fakadó endoplazmatikus retikulum (ER) stressz a tripszin aktivitástól független 
mechanizmussal okozhat betegséget. A betegséget okozó PRSS1 mutációk mellett számos 
ritkábban előforduló pontmutációt is leírtak idiopátiás pancreatitises betegekben. Ezen ritka 
mutációk szerepe a betegség kialakulásában nem bizonyított, de sok szerző szerint feltételezhető 
a betegséget okozó mutációk analógiájára. 
CÉLKITŰZÉSEK 
Kísérleteinkben célul tűztük ki a pH változás hatásának vizsgálatát a kationos 
tripszinogén autoaktivációjára. Célunk volt továbbá idiopátiás sporadikus pancreatitises 
betegekben talált 13 ritka tripszinogén variáns biokémiai jellemzése és sejtes szekréciójának 
vizsgálata, illetve a variánsok betegség okozó szerepének megállapítása a kapott eredmények 
alapján. 
ANYAGOK ÉS MÓDSZEREK 
PRSS1 génvariánsok elkészítése 
A humán PRSS1 és CTRC kódoló DNS-ét tartalmazó pcDNA3.1(-) eukarióta és pTrapT7 
prokarióta expressziós plazmidok a laboratóriumban rendelkezésre álltak. APRSS1 génvariánsokat 
PCR-mutagenezissel állítottuk elő. A mutagenezis sikerességét minden esetben DNS-
szekvenálással ellenőriztük. 
Az emésztő proenzimek termelése és tiszítása 
A vad típusú és mutáns humán kationos tripszinogén fehérjét aminopeptidáz P-hiányos E. 
coli törzsben (LG-3) termeltettük. A zárványtestekben felhalmozódott fehérjét ultrahang kezelés 
segítségével izoláltuk, melyet in vitro renaturálás követett. CTRC előállítása humán embrionális 
vese sejtek (HEK 293T) tranziens transzfekciója segítségével történt.  
A vad típusú és mutáns tripszinogéneket ekotin- míg a CTRC-t nikkel affinitás 
kromatográfia segítségével tisztítottuk meg. A fehérje preparátumok koncentrációit a 280 nm-en 
mért fényelnyelésből számítottuk ki a fehérje moláris extinkciós koefficiensének 
felhasználásával. 
A proteázok aktivitásának meghatározása 
Az enzimaktivitást szintetikus peptid szubsztráton mértük. A proteolitikus hasítás 
eredményeképpen sárga p-nitroanilin keletkezett, amelynek felszaporodását spektrofotométer 
segítségével követtük. 
 
 
A tripszinogén variánsoksejtes szekréciójának vizsgálata  
A szekréciós kísérletekhez HEK293T sejtvonalat használtunk. A sejtek transzfekciója 
után 48 órával vizsgáltuk a tápfolyadékba kiválasztott tripszinogén mennyiségét. A termelt 
fehérje mennyiség megállapításához enzim aktivitás mérést, poliakrilamid-gélelektroforézist, 
valamint Western blot technikákat alkalmaztunk. 
EREDMÉNYEK 
I. Vizsgáltuk a humán kationos tripszinogén autoaktivációjának pH-függését 
1. Kimutattuk, hogy a pH 8,5-ről 7-re csökkenésével a humán kationos tripszinogén 
autoaktivációjának sebessége fokozódik, azonban a pH további csökkenésével (7-ről 
6-ra) csak kis eltérés volt megfigyelhető. 
II. Funkcionálisan jellemeztünk idiopátiás pancreatitises betegben talált 13 humán 
kationos tripszin variánst 
1. A 13 mutációból csak 1 (p.D100H) variáns mutatott fokozott autoaktivációt, amely 
hasonlított a betegséget okozó mutációk fenotípusához. Ezt a variáns azonban 
csökkent szekréció is jellemezte, így a növekedett intrapancreatikus tripszin aktivitás 
nem valószínűsíthető.  
2. Érdekes módon, öt tripszinogén mutáns (p.P36R, p.G83E,p.I88N, p.V123M) 
kimotripszin C általi gyorsabb lebomlást tanúsított, ami ellentétben áll a patogén 
mutációk fenotipusával.  
3. A szekréciós vizsgálatok azt mutatták, hogy két variánsnak a kiválasztása 
(p.I88N, p.K170E) növekedett, ezzel szemben ötnek nagyobb (p.D100H, p.C139F), 
illetve kisebb (p.K92N, p.S124F, p.G208A) mértékben csökkent a vad típushoz 
képest. Mivel a p.I88N variáns lebomlása fokozott volt, az emelkedett tripszin 
aktivitás ebben az esetben sem valószínű.  
4. Három mutáns (p.Q98K, p.T137M, p.S181G), nem mutatott eltérést a vad 
típushoz képest. 
 KÖVETKEZTETÉSEK 
Munkánk során kimutattuk, hogy a humán kationos tripszinogén autoaktivációja pH 
függő, a pH savanyodásával az autoaktiváció sebessége fokozódik. Ez arra enged következtetni, 
hogy a csökkent folyadék szekrécióval járó intraduktális pH esése elősegíti a korai tripszin 
aktivációt és ezáltal hozzájárul a pancreatitis kialakulásához.  
A sporadikus krónikus pancreatitises betegekben talált ritka PRSS1 variánsok nem 
mutatták a klasszikus betegséget okozó fenotípust, viszont a gyors degradáció, illetve csökkent 
szekréció gyakran megfigyelhető volt. A szekréciós defektussal rendelkező variánsok (p.D100H, 
p.C139F) patogenitása a következményes ER stressz miatt, a fokozott szekréciót mutató variánsé 
(p.K170E) pedig az emelkedett tripszinaktivitás miatt valószínűsíthető. 
 
